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SUM M ARY.
BCR-ligation in B lymphocytes results in differential biological responses 
according to the maturational stage of the cell. Thus, while mature B lymphocytes 
become activated and proliferate in response to antigen receptor crosslinking, immature 
B lymphocytes become unresponsive or undergo apoptosis. Although these biological 
responses to antigen are well reported, the signalling pathways activated in each 
scenario are still poorly defined. In particular, the signalling cascades that result in the 
apoptosis of immature B lymphocytes which recognise self-antigen are still unclear.
Recent studies within our group have highlighted the phospholipase, cPLA^, as 
a possible transducer of apoptotic signals following BCR-ligation (53) in WEHI-231 
cells. Additionally, CD40 co-stimulation has been shown to rescue immature B 
lymphocyte from BCR-mediated apoptosis. We were therefore interested in 
investigating the signalling pathways linking the BCR to cPLA^ activation and the 
mechanisms utilised by CD40 co-stimulation in the reversal of BCR-mediated 
apoptosis.
Initial studies examined the activation of the MAPKinase family of enzymes as 
these protein kinases, along with Ca^ "^ , have been implicated in the activation of cPLA^. 
Our studies indicated that BCR-ligation induced the activation of a short, transient, 
ERK-MAPKinase signal, but not p38 MAPKinase or INK. Additional studies have 
shown that inhibition of this ERK-MAPKinase signal by pharmacological means 
reduces BCR-induced apoptosis and cPLAj activation. Interestingly, CD40 co­
stimulation was shown to uncouple the BCR from ERK-MAPKinase activation, 
suggesting the prevention of cPLA^ activation may account for the anti-apoptotic 
properties of CD40 co-stimulation.
BCR-induced apoptosis of WEHI-231 cells is known to occur approximately 
24-48 hours post receptor ligation. We therefore examined the activity of ERK- 
MAPKinase over these time periods. Interestingly, untreated WEHI-231 cells were 
shown to exhibit a basal cycling, ERK-MAPKinase activity, suggesting this protein 
was involved in the normal proliferation of these cells. BCR-ligation was shown to 
abolish this signal after approximately 2-^suggesting that BCR-induced growth arrest 
involves the down-regulation of this cyclic ERK-MAPKinase activity. Additionally, 
CD40 co-stimulation was shown to restore this proliferative ERK-MAPKinase signal. 
Inhibitor studies corroborated this proposal that these late, cycling ERK-MAPKinase 
signals contribute to basal and CD40-rescued growth and proliferation of WEHI-231 
cells. In summary, these results suggest differential roles for ERK-MAPKinase in 
regulating WEHI-231 cell fate. Firstly, an early, BCR-stimulated apoptotic signal, and 
secondly, a long-term proliferative signal. They also suggest that the induction of
X V lll
growth arrest and apoptosis in WEHI-231 cells result from the activation of distinct 
signalling pathways.
We therefore investigated possible mechanisms involved in both the 
suppression, and re-establishment, of proliferative ERK-MAPKinase activity by BCR- 
ligation and CD40 co-stimulation respectively. Firstly, we examined the role of PI(3)K 
which is known to be involved in the induction of survival signals and ERK- 
MAPKinase activation in other cell systems. Our results suggested that PI(3)K 
mediated PtdIns(3,4,5)P3 generation does not play a role in CD40-mediated rescue from 
BCR-induced growth arrest. These results were corroborated by the inability to detect 
activity of the anti-apoptotic protein, Akt, following CD40 co-stimulation. Inhibitor 
studies did however indicate that PI(3)K activity plays a role in the basal proliferation of 
WEHI-231 cells. However, PtdIns(3,4,5)P3 generation, unlike basal ERK- 
MAPKinase, was not found to be cyclic in nature. These findings do not rule out a role 
for the involvement of other phosphatidylinositol species generated by PI(3)K activity, 
including PtdIns(3,4)P2 which is known to activate ERK-MAPKinase. Additionally, 
our results also indicated that BCR-induced PtdIns(3,4,5)P3 generation, whilst not 
essential for BCR-induced apoptosis may play role in coupling the BCR to apoptotic, 
ERK-MAPKinase dependent signals.
Our results also described the coupling of the BCR in both immature and mature 
B lymphocytes to sphingosine kinase, a lipid kinase whose activity has not previously 
been shown in B lymphocytes, but is known to activate survival signals in other cell 
types. Although the BCRs of both immature and mature B lymphocytes were shown to 
be coupled to this kinase, the kinetics of activation were shown to differ slightly. BCR- 
ligation of both mature and immature B cells induced a short, transient, activation of 
sphingosine kinase, perhaps suggesting that sphingosine kinase activation may induce a 
activation/proliferative signal, which requires additional co-stimulation for its sustained 
activation and proliferative effects. Accordingly, CD40 co-stimulation of WEHI-231 
cells was shown to enhance and prolong sphingosine kinase activation.
Our results also indicated that BCR-ligation down-regulates ERK-MAPKinase, 
but not Ras activity. We have therefore investigated the role of Rapl and RKIP, 
molecules known to competitively compete with Ras for Raf activity. Initial studies 
have suggested that Rapl is not involved in this process, whilst results examining the 
role of RKIP are still inconclusive. Future aims are therefore to further characterise the 
mechanisms employed by BCR-ligation in WEHI-231 cells in the downregulation of the 
prolifeartive ERK-MAPKinase signals and how these are restored by CD40 co­
stimulation.
XIX
CHAPTER 1 - B Lymphocytes.
1.1 The immune system.
The immune system has evolved to protect the host from pathogens such as 
parasites, viruses or bacteria. The cells that mediate this immune response include 
phagocytes, antigen-presenting cells including dendritic cells and lymphocytes which 
work together in a specific, yet complex, manner. Phagocytic cells can be divided into 
two families, monocytes/macrophages and granulocytes, the latter including neutrophils, 
basophils/mast cells and eosinophils. These cells can internalise microorganisms before 
exposing them to an array of killing mechanisms. These may include the generation of 
reactive oxygen intermediates such as superoxide anions («O^'), nitric oxide formation, 
proteolytic enzymes such as lysozyme and acid hydrolyases, cationic proteins or 
intracellular pH changes. These cells form the basis of the innate immune response 
which is the first line of defence against infection but is non-specific in nature. 
Lymphocytes also play an important role in the immune response, but unlike phagocytic 
cells, lymphocytes specifically recognise individual gens and form part of the 
adaptive immune response. Lymphocytes can be divided into two categories - T 
lymphocytes and B lymphocytes. B lymphocytes fight extracellular pathogens by the 
releasing antibody, a molecule that recognises and binds to a specific target molecule 
termed the antigen. T lymphocytes are involved in a wider range of activities. These 
include the control of B lymphocyte development and proliferation, interacting with 
phagocytes to aid in the destruction of their internalised pathogens and the direct 
destruction of host cells that have become infected by viruses or other pathogens. The 
latter function is mediated by cytotoxic (Tc) CD8^ T lymphocytes whilst the other 
described functions are attributable to helper (Th) CD4^ T lymphocytes. One interesting 
feature of the adaptive immune response is that, unlike the innate immune response, it 
improves with each successive encounter with the same pathogen. The adaptive immune 
response is therefore important for the generation of long-life immunity to a particular 
infection.
During the induction of an immune response there is considerable interaction 
between both the innate and adaptive immune responses. For example, some 
phagocytes, such as tissue macrophages, can internalise antigen and present them to T 
lymphocytes in a form they can recognise in a process called antigen presentation. As a 
consequence the activated T lymphocyte can release an array of cytokines to aid in 
phagocyte activation and the consequent destruction of its internalised pathogen. In 
addition some phagocytes use antibodies released by B lymphocytes to allow them to 
recognise pathogens more effectively. For example, if an antibody binds to a pathogen, 
it can link to a phagocyte via the Fc portion of the antibody. This allows the pathogen
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to be internalised and destroyed by the phagocyte, with the antibody acting as an 
opsonin.
Both T and B cells have become major targets of biomedical research. This has 
generated a wealth of literature in both the development, and effector functions of these 
cell types. However, it is clear that much work still has to be done in these fields. One 
particular area that is attracting much interest is the molecular and biochemical 
mechanisms underlying B cell development/differentiation and particularly maturation- 
state dependent cellular responses. This is of particular relevance in the latter stages of 
B lymphocyte development because the signals transduced following antigen encounter 
are mediated by the same receptor, but result in differential biological responses. The 
study of these differential responses will further our knowledge not only of B 
lymphocyte development, but also the role of B lymphocyte dysfunction in a number of 
disease states including autoimmune disease.
1.2 B cell development.
The B cell has a major role in the humoral immune response to infection by 
producing antigen specific antibodies. Unlike birds, in which primary B-cell 
lymphopoiesis occurs in the lymphoepithelial organ, the bursa of Fabricius, mammals 
do not have a specific organ for B-cell lymphopoiesis. Consequently, B cells develop 
from pluripotent stem cells in the fetal liver from 8-9 weeks of gestation in humans and 
by about 14 days in the mouse (1). In later embryonic stages, the site of B-cell 
production moves to the bone marrow where it continues into adult life. In terms of
kinetics, studies have shown that approximately murine B cells are produced
each day. However, since the murine spleen only contains 7.5 x 10  ^cells, it is clear 
that a large percentage of these developing cells must die. Like thymocytes developing 
in the thymus, the majority (75%) of B cells maturing in the bone marrow undergo a 
process of negative selection. This allows for the development of B lymphocytes that 
can interact with foreign antigen, whilst at the same time avoiding the generation of B 
cells that bind self-antigen. After leaving the bone marrow, B cells enter the periphery, 
passing through the blood into the secondary lymphoid organs - spleen, lymphocyte 
nodes and mucosal-associated lymphoid tissues. Within these secondary lymphoid 
organs, B lymphocytes localise into discrete clusters or follicles in association with 
follicular dendritic cells and specialised stromal cells. This microenvironment provides 
essential survival signals required for the survival of these peripheral B lymphocytes.
During their normal development, B lymphocytes progress through orderly 
stages of differentiation from initial lineage commitment in the bone marrow to the 
formation of fully mature immunocompetent B cells in the periphery (figure 1). The
starting point of B lymphocyte development is the haematopoietic stem cell (HSC) 
found in the fetal liver and after birth, and into adult life, in the bone marrow. In 
addition to generating both T and B lymphocytes these cells can differentiate into 
eiythroid or myeloid cells (2). Commitment of HSCs to the B lymphocyte lineage has 
been shown to be dependent on the expression of the paired box transcription factor 
Pax5 (2). Indeed, studies have shown that when a mixed population of wild-type and 
Pax5-/- HSCs are starved of IL-7, the wild-type cells differentiate into B lymphocytes, 
whilst the Pax5-/- cells survive and obtain a myeloid cell phenotype. Thus, present 
models suggest that Pax5, whilst promoting the expression of B lymphocyte specific 
genes also acts to suppress promiscuous transcription of genes from other 
haematopoietic lineages.
Following commitment to the B lymphocyte lineage, each precursor cell passes 
through a number of developmental "compartments" in which they lose or gain specific 
surface molecules depending on their maturational stage which, phenotypically, can be 
used to define discrete stages of development (3) (figure 2). The stages of B 
lymphocyte differentiation can also be divided into two quite distinct stages; antigen- 
independent and antigen-dependent phases (4) (figure 1).
Antigen-independent differentiation occurs in the bone marrow and ultimately 
leads to the production of immature B cells with surface membrane immunoglobulin, 
that is both functional and specific, coupled to di-sulphide linked Iga (CD79a)-Igp 
(CD79b) heterodimers which act as signalling elements. The processes involved in the 
expression of this “mature” receptor complex, or B-cell receptor (BCR), are initiated 
early in B lineage commitment (figure 3) and have been extensively studied 
in murine models.
The differentiation of HSCs to immature B lymphocytes begins with the 
production of an early pro-B cell and is accompanied by the ordered expression of 
surrogate, and finally, mature BCRs (figure 4) by following a defined pattern of 
immunoglobulin heavy and light chain rearrangements under the control of the 
recombination-activating genes, RAGl and RAG2, which are highly expressed at the 
pro- and pre- B cell stages of differentiation (5). Thus, RAG activity ultimately leads to 
the production and cell surface expression of functional immunoglobulin.
The immunoglobulin heavy chain variable region is encoded by V and J gene 
segments with additional diversity provided by the D gene segment. Rearrangement of 
the immunoglobulin heavy gene begins at the early pro-B cell stage with the 
rearrangement of D gene segments to J gene segments (D^J^) producing late pro-B 
cells. Although no functional immunoglobulin protein is expressed in late pro-B cells, 
these cells do express components of the mature BCR on their cell surface. Recent 
studies (6) have shown the expression of Iga-Igp heterodimers on the surface of late
pro-B cells in association with calnexin. Further rearrangement to the immunoglobulin 
gene occurs at the late pro-B cell stage with the joining of the gene to the already 
rearranged gene segments. If this rearrangement produces a productive heavy 
chain rearrangement, these cells are thought to divide several times before reaching the 
pre-B cell stage. The use of Ig|3-/- mice has shown that expression of this molecule on 
the cell surface of pro-B cells is essential for the continuing development of these cells. 
Studies have shown that mice deficient in Ig(3 exhibit a complete block in B cell 
development before to rearrangement. It has therefore been suggested that 
signalling through the Igo/Ig(3-calnexin receptor on pro-B cells may be required for 
successful initiation of to gene rearrangement (7). Further evidence to support 
this comes from recent observations investigating the potential signalling qualities of 
Iga-Igp molecules expressed on pro-B cells from RAG-2-/- mice. Ligation of IgP on 
these cells was shown to mimic pre-BCR like signals which induce early B cell 
differentiation (6). These studies showed that developmentally arrested pro B cells 
from RAG-2-deficient mice could be induced to differentiate to the preB cell stage when 
treated with anti-Igp antibody. These results suggest that crosslinking of Igp on pro-B 
cells activates differentiation signals similar to those initiated by the preB cell receptor 
during normal development. As RAG-2-/- pro-B cells express all the necessary 
machinery for signal transduction, except the expression of \x heavy chain, and 
observations that Igp-deficient mice have a developmental block at the pro-B cell stage, 
these results suggest an essential role for Iga-Igp molecules as signal transducers of the 
pre-BCR and that signals delivered by Iga-Igp molecules in pro-B cells can drive B cell 
differentiation to the pre-B cell stage (6).
As previously mentioned, progression to the pre-B cell stage results in the 
surface expression of |i chain. This process is known to be dependent on the cell 
surface association of the | L i  heavy chain with the light chain surrogate proteins VpreB 
and X5 (8) along with Iga-Igp molecules. The expression of these molecules, termed 
the “pre-B cell receptor” has shed new light on the developmental progression of pre-B 
cells. Genetic studies, creating mice deficient in either the membrane form of | L i  heavy 
chain or the ^5 protein, showed that B lymphocyte development was blocked at the pre- 
B cell stage (9). Surface expression of this pre-BCR has been shown to be important 
for allelic exclusion at the heavy chain locus (10). This is because this receptor 
instructs the cell to stop further gene rearrangements (11). Furthermore, studies 
using a membrane |i-chain mutant have shown that expression of this mutant prevents 
the association of Iga/Igp with this molecule, whilst also preventing allelic exclusion 
and developmental progression to the pre-B cell stage (7).
Maturation of pre-B cells to immature B cells involves further gene 
rearrangements to the immunoglobulin light chain to generate conventional light chains 
( k  or X), with appropriate constant and variable regions, which associate with the 
already expressed heavy chain (10). This leads to the expression of a BCR consisting 
of | L i  heavy chain, conventional light chains and also the associated, intracellular Ig- 
(x/Ig-P molecules, and is the first BCR to exhibit antigen specificity and also expresses 
a more diverse repertoire of specificity than the pre-BCR (10, 12).
Following the stable expression of IgM on the B cell surface, immature B cells 
enter into the antigen-dependent phase of development where they can respond to 
specific antigens due to the expression of mature mIgM on their cell surface.
Therefore, up until this point, no selective processes have been employed to prevent 
the maturation of B cells with BCRs capable of recognising self-antigen. Immature B 
cells consequently go through a number of complex checkpoints mediated by the 
antigen specificity of their BCR and involves both positive and negative signals 
regulating both survival, death and also the reactivation of the immunoglobulin V(D)J 
gene recombinase system. The reactivation of the RAG gene system is believed to 
allow further light-chain rearrangements in immature B cells that recognise self-antigen 
whilst in the bone marrow, thus allowing them to alter their antigen specificity (13). 
This forms part of clonal selection allowing for the removal of immature B cells that 
possess self antigen receptors and would therefore mount an auto-immune response if 
they were allowed to escape to the periphery, however, clonal selection and the 
phenomenon of allelic exclusion specifically result in the generation of antigen 
monospecificity, that is, one B lymphocyte is specific for one antigen.
The process of negative selection of B lymphocytes is still an area under intense 
investigation but is believed to occur by three distinct, yet inter-linked, molecular 
mechanisms, deletion, anergy and receptor-editing (14). Recent reports have indicated 
that immature B cells isolated from the bone-marrow undergo programmed cell death, 
or apoptosis, within 16 hours when cultured in vitro with anti-BCR antibodies (14). 
However, although BCR-ligation of immature B cells in vitro undoubtedly initiates an 
apoptotic mechanism, the in vivo response to self-antigen presented in the bone 
marrow may be very different. Initial studies trying to address these areas suggested 
that highly purified immature B cells initiate an apoptotic programme upon BCR- 
ligation. In contrast, unfractionated bone-marrow B cell cultures induced receptor 
editing instead of apoptosis (14). This suggested that the environment of the cell, in 
this case the bone-marrow, provides signals blocking apoptosis and inducing RAG 
activation. The process of receptor editing during negative selection allows potentially 
self-reactive immature B cells to rearrange their light chains and subsequent antigen 
specificity (13). However, these cells are not always rescued from apoptosis and many
undergo unsuccessful receptor editing and fail to produce a functional BCR and 
subsequently die by apoptotic mechanisms (10).
Recent studies by Sandel et. a l, 1999 (14) have confirmed a role for the cells 
microenvironment in determining the response to antigen encounter. By labelling 
transitional B cells (immature B cells that have just entered the periphery from the bone 
marrow) using carboxy-fluorescein diacetate succinimidyl ester (CFSE) in conjunction 
with propidium iodide staining, the authors were able to monitor the fate of these 
transitional cells when mixed with bone marrow or disassociated spleen following 
receptor ligation. Interestingly, labelled transitional cells co-cultured with bone marrow 
did not undergo apoptosis, but rather induced RAG expression following BCR-ligation 
which would allow for further light chain rearrangement and hence alter the specificity 
of the cells BCR. In contrast, labelled cells co-cultured with dissociated spleen undergo 
apoptosis. This suggests that the bone marrow microenvironment provides signals that 
block BCR-induced apoptosis and promote receptor editing due to RAG induction. 
However, in the periphery, transitional B cells do not receive these signals and undergo 
apoptosis as a default programme. The authors suggest that the protective effect 
mediated by co-culture with the bone marrow environment may be due to the presence, 
and cell-cell contact, with as yet unidentified Thy-1.2 expressing bone marrow stromal 
cells. Subsequently, the authors suggest that these cells may be capable of altering 
BCR signals in favour of receptor editing rather than apoptosis, or to allow self-reactive 
immature B lymphocytes to survive long enough in the bone marrow to produce a non- 
autoreactive BCR. Additional work by the same authors (8) has suggested that 
immature B lymphocytes undergo a “window of opportunity for re-direction” following 
BCR-ligation. In summary, the author suggests that following the induction of an 
apoptotic programme after just 10-20 minutes of BCR-ligation, the cells undergo a 10- 
12 hour window in which their fate can be re-directed. For example, in the bone 
marrow this may result in RAG expression and hence receptor editing. If no additional 
signals are initiated within this 10-12 hour window then these cells irreversibly undergo 
apoptosis.
Additionally, treatment of immature B cells with anti-IgM results in the loss of 
surface IgM by capping and endocytosis and may also play a role by which self-reactive 
B cells are rendered tolerant, or anergic, during development. This mechanism allows 
self-reactive cells to initiate receptor-editing. Here, cells that have not been deleted are 
rendered anergic due to BCR internalisation and are believed to re-enter the pre-B cell 
compartment where they undergo a second round of light chain rearrangement (8). 
Therefore, this process is thought to break allelic exclusion and allow the cell to 
undergo immunoglobulin gene rearrangement and subsequently express a completely 
new immunoglobulin receptor.
As an environment, the bone marrow does not allow immature B cells to 
encounter all self-antigens. Therefore, B cells maintain an immature B cell phenotype 
for a number of days after leaving the bone marrow for the periphery. These 
“transitional-immature” B cells therefore remain sensitive to deletion if they encounter 
antigen (8). Surviving cells then enter the periphery as transitional (Tl) cells expressing 
low levels of IgD (IgM*^ ®’'IgD’°'^ ). It has been suggested that the temporary maintenance 
of high-level mIgM expression retains the transitional cells sensitivity to antigen and 
thus deletion by apoptosis if it recognises self antigen present only in the periphery 
(10). Therefore, because the default programme for these cells following antigen 
exposure is apoptosis, these cells require T cell-dependent survival signals if they are to 
survive
Following their exit from the bone marrow into the periphery, B lymphocytes 
that have successfully traversed the immature-transitional (Tl) stage of development 
migrate to the spleen, arriving at the marginal zone sinusoids before moving into the 
outer zones of the periarteriolar lymphoid sheath (PALS). Few of these T IB  cells will 
develop into fully mature B cells. Typically, of the 2x10^ IgM+ B cells that develop 
daily in murine bone marrow only 10% will reach the spleen and only 1-3% will 
survive and enter the mature B cell pool (15). The precise mechanisms leading to the 
selection of T 1 cells destined for the mature B cell pool are still unclear. However, 
recent studies have suggested that cells at this stage of development require constant 
BCR-derived signals to progress to the next stage of development (11, 16). These 
BCR-derived signals almost certainly provide a positive signal and a number of studies 
provide evidence suggesting that lack of these signals, or excessively strong BCR- 
derived signals, leads to apoptosis within 3-4 days (17, 18). In addition, stimulation of 
these T IB  cells by cytokine or co-receptor ligation is thought to help shape the level of 
BCR stimulation which will in turn decide the fate of the cell (17). B lymphocytes 
which survive this passage develop into transitional (T2) cells with a characteristic 
IgM^ '^ '^ IgD'"'^  ^phenotype (15, 16). These cells then migrate to the primary follicles of 
the spleen where they become mature IgM*“'^IgD‘’*®’’ B lymphocytes
In contrast to what occurs with immature B lymphocytes, BCR-ligation leads to 
the activation of mature B lymphocytes and if the appropriate accessory signals are 
present, an immune response. Subsequently, BCR-ligation and hence cellular 
activation by antigen, initiates one of two responses in mature B lymphocytes. Firstly, 
following antigen stimulation these cells may become IgM or IgG antibody-secreting 
plasma cells, devoted to antibody production in the primary immune response. 
Secondly, mature B cells primed with antigen may undergo isotype switching, V region 
somatic mutation and affinity maturation to become memory B cells which can in turn 
become IgG secreting plasma cells (4). Memory B cell formation is crucial for the
induction of the secondary immune response, and the ability to generate these cells 
forms the basis of vaccination.
The formation of memory B cells occurs in germinal centres (GCs) which are 
formed during primary immune responses to T cell-dependent antigens in lymphoid 
follicles (figure 5). The initial stages of germinal centre formation involve the 
exponential growth of B cell blasts activated by T-cell-dependent antigens in areas rich 
in follicular dendritic cells (FDCs). As well as acting as antigen-presenting cells 
(APCs) to CD4^ T cells (17), FDCs also maintain the expression of unprocessed 
antigen on their cell surface, which is later recognised by newly-formed memory B 
lymphocytes (4). Following their expansion the B cell blast population migrates from 
the centre of the follicle to form the dark zone of the GC. Here, the B-cell blasts 
continue to proliferate, lose membrane-Ig expression and are now termed centroblasts. 
The dividing centroblasts are then thought to activate a hypermutation programme and 
give rise to daughter centrocytes which are non-dividing. These centrocytes then 
migrate to the light zone of the GC which is rich in FDCs. The level of B cell apoptosis 
in the light zone of the GC is very high because the centrocytes present in the light zone 
are intrinsically hard-wired to undergo apoptosis unless they are rescued. Rescue of 
centrocytes from apoptosis in the light zone has been shown to occur by two 
mechanisms. Firstly, centrocytes which express high-affinity receptors for Ag 
expressed on FDCs are positively selected. Secondly, CD40 ligation on the surface of 
centrocytes has also been shown to rescue these cells from apoptosis, suggesting a role 
for helper T-cell interactions (4, 17). Positively selected centrocytes then go on to 
establish the memory B-cell pool, providing the precursors for plasma cells with 
improved antibody affinity (19).
1.3 Positive versus negative signalling via the BCR.
Ligation of the BCR with antigen plays a crucial role in determining the fate of 
B lymphocytes according to their maturational state. Hence, immature B lymphocytes 
have been shown to be clonally deleted following BCR-ligation, whilst mature B 
lymphocytes become activated by the same receptor at the intracellular level. Although 
many of the signalling events regulating cell cycle progression and commitment to 
apoptosis or cell survival and proliferation appear to be similar to those described in 
other systems, the precise combination of early BCR-coupled signalling events 
integrated to dictate a particular response are yet poorly defined. Therefore in recent 
years research into dissecting the signalling events involved in both positive and 
negative BCR signalling has been intense. These studies have aimed to address key 
differences in transcriptional events following BCR-ligation, but have also addressed 
areas such as the quality and quantity of BCR-ligation as possible modulators of cell
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fate. This section aims to summarise the main signalling events activated by BCR- 
ligation and also discuss current concepts behind differential signalling by the BCR in 
both negative and positive responses. Firstly however, I shall describe the current 
models of regulation of cell progression and apoptosis.
1.4 Cell cycle.
Under normal physiological conditions, cell growth is regulated by a number of 
cell cycle checkpoints to prevent abnormal cell cycle entry. These checkpoints ensure 
that aberrant cell cycle progression under conditions of cell damage results in the 
induction of apoptotic programmes aimed at deleting these cells. Cell 
growth/proliferation is therefore a balance of appropriate signals between growth 
promoting, and growth inhibitory pathways.
Cell cycle progression is tightly regulated at two major checkpoints. Firstly, at 
the G /S boundary, where cells commit to DNA synthesis, and secondly, at the GJM  
boundary where cells commit to mitotic division (20) (figure 6). Cell cycle entry is 
promoted by the actions of the Gj cyclin dependent kinases (CDKs) which associate 
with cyclins, proteins expressed at specific stages of the cell cycle. These kinases 
include Cdk4 and Cdk6 which associate with the cyclins D l, D2, D3, and also Cdk2 
which associates with cyclin E (21). The Cdk-cyclin complexes promote G 1/S phase 
progression by reversing the G, phase block enforced by the retinoblastoma protein, 
pRb^° .^ The G^  block enforced by hypophosphorylated Rb results from its ability to 
suppress the activity of the transcription factor, E2F, by sequestering this protein away 
from genes required for S-phase entry (21). However, following the phosphorylation 
of Rb by cyclin-CDK complexes, E2F is released from Rb and can interact with the 
necessary genes required for S-phase entry (20). Disruption of the Rb protein, either 
through gene mutation/deletion or hyperphosphorylation, is also present in a range of 
human cancers (22).
The ability of cyclin-CDK complexes to promote S-phase entry is tightly 
regulated within the cell by two structurally distinct families of CDK inhibitors (20). 
Firstly, the WAFl family (p21, p27 and p57) of proteins and secondly the INK4 
(inhibitor of CDK4) family (pl5, pl6, pl8 and pl9). The activity of the WAFl family 
member p27^^^ has been shown to play an important role in regulating cell growth in 
fibroblasts. In serum starved fibroblasts levels of p27^^' are high, yet decrease 
substantially upon growth-factor stimulation (21). In addition, one member of the 
INK4 family, INK4a, has been shown to have loss of function in a wide range of 
tumour types, and pathogenically, this is thought to be exceeded in frequency only by 
p53 inactivation (22). These two families act to prevent cell cycle progression in 
response to cellular stress or damage and promote growth-arrest and or apoptosis.
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Subsequently, these molecules form a link between growth promoting pathways and 
the induction of apoptosis again confirming significant cross-talk between the signalling 
pathways regulating these two opposing responses.
The ability of the p53 protein to induce arrest in cells with DNA damage, 
thus preventing the replication of faulty cells, is well documented. It is believed that 
this allows cells time to repair damaged DNA before further replication. However, 
deletion or genetic mutation to p53 plays a role in the development of most human 
cancers. When activated, p53 has been shown to increase both the expression and 
activity of p21^'"‘^  (20). In addition to inducing G, growth arrest, p53 activity is also 
known to induce apoptosis in a range of cell types including T and B lymphocytes (23). 
It has been suggested that the downstream activation of p21^^^ by p53 has a anti- 
apoptotic function because a decrease or loss of p21 gene expression induces growth 
arrest in cells that would normally undergo apoptosis (24). This suggests that p53, 
whilst directly linked to cell cycle arrest may also play additional roles in the induction 
of apoptosis.
1.5 Apoptosis - programmed cell death.
The process of programmed cell death, or apoptosis, plays an essential role in 
both developing or adult creatures. Unlike necrosis, which occurs after acute cellular 
injury and results in the cell releasing its cellular content into the surrounding area 
which may cause a damaging inflammatory response, cells initiating apoptotic 
processes die in a orderly, tidy manner, without affecting neighbouring cells. 
Morphologically, apoptotic cells can be identified due to the processes of membrane 
blebbing, cell shrinkage, chromatin condensation and DNA fragmentation (25). These 
changes are common to all apoptotic cells, independent of the trigger signal, suggesting 
that a common signalling pathway is induced leading to cell death.
The caspases, a family of evolutionary conserved cysteine proteases, have been 
shown to play crucial roles in the induction of apoptotic processes (26). Normally 
caspases exist as inactive precursors, however, upon the initiation of apoptotic signals, 
these proteases are cleaved forming active enzymes (27). Subsequently, caspase 
activation has been shown to involve the activation of a proteolytic cascade (26). 
Recently, mitochondrial function has been shown to play a key role in the induction of 
this cascade (figure 7). Induction of apoptosis has been shown to induce 
‘permeability transitions' in the mitochondrial membrane suggesting that mitochondrial 
constituents may leak into the cytoplasm during apoptosis (28). Cytochrome C release 
from the mitochondria has been shown to play crucial role in the induction of caspase 
activity (29). A number of proteins have been shown to regulate cytochrome C release 
from the mitochondria and hence regulate apoptosis. In particular, certain members of
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the Bcl-2 gene family are targeted to the mitochondria under apoptotic conditions and 
have been shown to play key roles in the release of cytochrome C. (30). In particular 
the Bid protein, a pro-apoptotic member of the Bcl-2 family, has been implicated in the 
regulation of cytochrome C release. Caspase- 8  activity has been shown to cleave Bid 
releasing a C-terminal fragment (tBED) which is targeted to the mitochondria, inducing 
cytochrome C release (30). It has been suggested that the release of cytochrome C may 
be due to the heterodimerisation of tBid with other Bcl-2 family members such as Bcl- 
Xl which may result in the inhibition of this anti-apoptotic protein (30). Other pro- 
apoptotic members of the Bcl-2 family are also believed to function by homo- or hetero­
dimerisation which is believed to neutralise anti-apoptotic members of the Bcl-2 family 
which normally act to prevent cytochrome C release from the mitochondria (31). 
However, the mechanisms underlying these processes are still unclear. One member of 
the Bcl-2 family which has attracted much attention in recent years is the pro-apoptotic 
protein, Bad. Bad has been shown to exert its apoptotic effect by forming heterodimers 
with Bcl-2 or Bcl-X^. Phosphorylation of this pro-apoptotic protein by survival signals 
has been shown to result in the block of Bad-mediated apoptosis. This has been shown 
to be due to the phosphorylation of Bad at SeF^  ^and Ser^ ^^  by the anti-apoptotic protein 
kinase, Akt (32). Serine phosphorylation is believed to promote the association of Bad 
with the phospho-serine binding protein, 14-3-3. This results in the release of Bcl-X^ 
from Bad which promotes cell survival by blocking the caspase protease cascade (33).
1.6 BCR structure.
The B cell antigen-receptor (BCR) (reviewed in (34)) is a multiprotein structure 
containing a clonatypic antigen binding component (sig) produced from the 
rearrangement of immunoglobulin heavy and light chain genes, noncovalently 
associated with disulfide linked Iga (CD79a) and Igp (CD79p) heterodimers (34) and 
plays a vital role in mediating the response of B lymphocytes to foreign antigen. There 
are five classes of immunoglobulin, IgM, IgD, IgG, IgA and IgE, and although all of 
these can be expressed as B cell antigen receptors, only IgM and IgD are expressed on 
mature naive B cells. Structurally, mig consists of homodimeric heavy chains, each 
covalently associated with a light chain, forming a symmetrical four chain structure with 
two antigen binding sites. Studies have shown mlg to consist of extracellular, 
transmembrane and cytoplasmic regions (figure 8). The precise length of the 
cytoplasmic regions have been subject to much debate with two algorithms being 
suggested. Firstly, work by Kyte and Doolittle suggested that the cytoplasmic tails of 
mIgM and mIgD immunoglobulin classes were composed of only three amino acids. 
The other immunoglobulin classes, mIgG, mlg A and mIgE were believed to consist of 
cytoplasmic tails of up to 28 amino acids (34). However, conflicting studies by Klein,
11
Kane and Delisi predicted that the cytoplasmic tails of mIgM and mIgD were much 
longer, consisting of eleven amino acids (34). However, even these longer cytoplasmic 
domains are clearly still too small to possess any intrinsic catalytic activity, suggesting 
that BCR transmembrane signalling is probably mediated by the interaction of mlg with 
accessory signal transducing molecules.
The discovery of Iga and IgP in the late 1980s provided a link between the 
BCR and the initiation of intracellular signalling mechanisms. Encoded by the mbl and 
B29 genes respectively (35), Iga (34kDa) and Igp (38kDa) exist as disulphide linked 
heterodimers with extracellular and intracellular domains (4). Like mIgM and mIgD, 
Iga and IgP do not contain any intrinsic catalytic activity. However, the presence of 
the Iga and Igp heterodimers is essential for BCR-mediated signalling events. The 
discovery of an amino acid sequence involved in signalling in T-cell and Fc receptors 
(36) termed the immunoreceptor tyrosine-based activation motif (ITAM) in the 
cytoplasmic tails of Iga and IgP provided a mechanism for the initiation of signalling 
events following BCR-ligation. Interestingly, IT AM sequences are also found in the 
accessory chains. The IT AM motif consists of two tyrosine domains separated by 13 
amino acids forming the sequence ...YXX [L/V]X^_,, YXX[L/V]... where Y is 
tyrosine, L is leucine, V is valine and X represents any amino acid. Subsequently, 
aggregation of mlg molecules due to the binding of multivalent antigens promotes the 
phosphorylation of the IT AMs (four per BCR) by Src-family protein tyrosine kinases 
(PTKs). Generally, phosphorylation of the IT AMs occurs mainly at the membrane 
proximal tyrosine residue. However, phosphorylation of both tyrosine residues creates 
a binding site for the tandem Src-homology (SH)2 domains of a related PTK, Syk (36).
In addition to Iga and Igp, other molecules have been shown to associate with 
the BCR. These include a group of ubiquitously expressed cytoplasmic proteins called 
BCR-associated proteins or BAPs (34). BAP32, 37 and 41 (numbers referring to the 
molecular weight of these proteins (kDa)) have been shown to associate with mIgM, 
whilst BAP29 and 31 appear to preferentially associate with IgD. The role of these 
proteins in BCR signalling are still poorly defined. Reports have suggested a 
transmembrane role for the BAPs in which they associate with the BCR via 
transmembrane domains (35) whilst other studies suggest these proteins are purely 
cytoplasmic and are not involved in transmembrane signalling events (34).
Additionally, kinetic experiments have shown that PTK activation following mIgD 
ligation lasts longer than that activated via mIgM, and it has been suggested that this 
may be due to the differential expression of BAP molecules with these different 
immunoglobulin isotypes (35) and the differential recruitment of scaffold proteins.
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1.7 BCR signalling.
The genes responsible for important biological responses in B lymphocytes 
such as growth and apoptosis are only now beginning to be understood. Identification 
of these genes has helped in the dissection of signalling pathways activated following 
BCR-ligation. The recruitment and activation of PTKs is the first signalling event 
mediated by BCR-ligation in both positive and negative responses (37). Presently, 
three distinct types of PTK are known to become activated following BCR engagement 
(7). These include the Src-PTKs (Lyn, Blk, and Fyn), Syk and Btk. The current 
model for induction of BCR-mediated signalling events involves the phosphorylation of 
key tyrosine residues on the IT AMs of the Iga and Igp cytoplasmic tails by Blk, Fyn 
and Lyn PTKs following BCR-ligation. The phosphorylated ITAM creates a binding 
site for Syk via its tandem, tyrosine binding, SH2 domains. Syk then becomes 
tyrosine phosphorylated and activated along with Btk (probably due to direct 
phosphorylation by the Src-PTKs) (38). This simple model, however, does not 
explain recent findings suggesting that both Lyn-/- and Syk-/- B cells can still signal 
through their BCR (17). This suggests that the BCR can activate both Lyn- and Syk- 
independent pathways. Therefore differential activation of PTKs could play key roles 
in directing BCR-mediated signalling cascades down distinct paths and ultimately, 
differential physiological outcomes.
Early studies investigating downstream signalling elements from the PTKs have 
provided evidence to suggest that the signals transduced via the BCR in both immature 
and mature B lymphocytes are very similar. Current models of B lymphocyte 
signalling suggest that the Ras-MAPKinase, PI(3)K and PLC pathways are common to 
both BCR-mediated signalling events in immature and mature B lymphocyteS(figure 
9). These signalling cascades therefore provide the core pathway for both the deletion, 
or activation of B lymphocytes. It is now clear that secondary pathways modulate these 
core signals to enhance or attenuate BCR-mediated signalling events. This can occur 
through maturation-state dependent changes in protein expression, including catalytic 
enzymes, substrates, adaptor/linker proteins or co-receptor expression. Subsequently, 
enhancement of enzyme expression would serve to amplify the signal cascade, whilst 
expression of a particular adapter/linker protein could re-direct the signalling cascade in 
a new direction.
The core signalling elements of BCR stimulation include the activation of the 
Ras-MAPKinase cascade. Activation of this pathway is believed to play important roles 
in the activation of transcriptional events (38). Activation of the Ras-MAPKinase 
pathway has been implicated in both positive and negative BCR stimulated events. 
ERK-MAPKinase has been shown to play a key role in the ability of the BCR to 
stimulate the proliferation of resting splenic B cells (39). In contrast to this, ERK-
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MAPKinase activation has been shown to correlate with BCR-induced apoptosis in the 
immature B lymphocyte cell line, WEHI-231, (40).
A wide range of adaptor or linker proteins are utilised by BCR-ligation to recmit 
specific signalling molecules in both immature and mature B lymphocytes. These 
adaptor proteins possess no intrinsic enzymatic activity, but function to direct protein- 
protein interactions between enzymatically active intermediates. Grb2, which consists 
of two SH3 and a central SH2 domain, is the prototype adaptor molecule utilised in the 
activation of Ras in many signalling cascades. In growth factor mediated responses, 
the association of Grb2 with the phosphorylated receptor via its SH2 domain and its 
binding of the guanine nucleotide exchange factor (GEE), Sos, through SH3- 
interactions, allows the Grb2-Sos complex to be located near the cell membrane and, in 
turn, near the substrate of Sos, Ras (41). However, in B lymphocyte signalling, 
another linker protein, She, which interacts with Iga and IgP IT AM motifs and IT AM- 
associated PTKs promotes the association of Shc-Grb2-Sos complexes close to the 
BCR and Ras (41). Recent data (41) also suggests, however, that BCR-induced Ras 
activation also occurs in a Shc-independent manner due to the utilisation of an additional 
adaptor/linker protein, termed B cell linker protein (BLNK). This highlights the ability 
of different adaptor molecules to modulate BCR-mediated responses.
BLNK, sometimes called SLP-65, is a 6 8 kDa protein which becomes rapidly 
tyrosine phosphorylated following BCR-ligation or treatment of B lymphocytes with 
pervanadate (36). In addition, BLNK is known to translocate to the cell membrane 
following BCR-ligation and it is known to associate with Grb2 and Sos to form a 
BLNK/Grb2/Sos complex. This complex, independent of She, brings Sos into close 
contact with Ras and represents an additional mechanism leading to the activation of the 
Ras/Raf/MAPKinase cascade in B lymphocytes.
Other adaptor/linker proteins known to regulate MAPKinase activity include the 
Crk family members which have been shown to negatively regulate Ras activation. The 
Crk family consists of three members, CrkL, Crk I and Crk II, and CrkL and Crk II 
have been shown to bind to C3G, the GEE for the Ras-related GTPase, Rapl. 
Activation of Rapl is believed to negatively regulate receptor activated responses by 
down-regulating ERK-MAPKinase activation (figure 10). Structural similarities 
between the effector binding domains of Ras and Rapl allow active Rapl to bind to 
downstream effectors of the Ras pathway such as Raf-1. This process may be 
enhanced due to the cellular localisation of these two GTPases. Whilst Ras is 
predominantly membrane bound, Rapl is located in endocytic and lysosomal vesicles, 
and this may function to enhance the ability of Rapl to sequester Ras effectors away 
from Ras itself.
However, a number of recent studies have suggested that the Crk family of 
adaptor molecules may also play key roles in the activation of a number of downstream
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effector molecules and that, in some cases, Rapl activation may actually occur in a 
Crk/C3G independent manner. Studies by York et a l, 1998 (42) have shown that 
formation of a stable complex between Rapl and B-Raf that promotes the activation of 
ERK-MAPKinase in nerve growth factor treated PCI2 cells, suggesting that Rapl 
activity can positively regulate receptor-mediated responses. To add further complexity 
to Rapl mediated activation of the MAPKinase family, studies by Blaukat et a l, 1999 
(43) have shown that the adaptor proteins pl30Cas and Crk are both required in Pyk2 
mediated activation of the INK pathway. In addition, a recent study by McLeod et a l, 
1998 (44) has provided evidence for a Crk/C3G independent activation of Rapl which 
appears to be dependent on a novel PLCy pathway.
Activation of the PI(3)K pathway by BCR ligation has been shown to be 
dependent on both PTK activation and direct binding by Ras (36). The role of PI(3)K 
in B lymphocyte signalling is still unclear. However, evidence exists for its role in both 
positive and negative BCR-mediated effects. Inhibition of PI(3)K has been shown to 
block BCR-induced growth-arrest in the human RL B cell line suggesting a negative 
role for PI(3)K in B cell proliferation (17). However, inhibition of PI(3)K in normal 
or neoplastic B lymphocytes that are in cell-cycle induces apoptosis, suggesting a 
positive role for PI(3)K in regulating B lymphocyte growth (17). PI(3)K activity 
leading to the generation of Ptdlns (3,4,5)Pg has also been shown play a role in the 
activation of other key signalling cascades activated following BCR-ligation including 
phospholipase C (PLC) activity.
PLC activation is the final element of the core signalling pathways induced by 
BCR-ligation. This was one of the first pathways shown to be activated by the BCR 
and is responsible for the hydrolysis of phosphatidylinositol 4,5-bisphosphate (Ptdlns
(4 ,5 )P2) to form diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) (38). The 
generation of these two second messengers have been shown to be important for the 
respective activation of PKC and the release of Ca^ "^  from internal stores into the 
cytoplasm (45). Activation of PLC has been shown to play positive and negative roles 
in B lymphocyte biology. Artificial elevation of intracellular Ca^  ^and PKC activation 
by calcium ionophores and phorbol esters to mimic PLC activity, has been shown to 
induce proliferation and the rescue of splenic B cells from Fas-induced apoptosis, 
whilst inducing growth-arrest/apoptosis in several B lymphoma cell lines (38).
The translocation of protein to the cell membrane is not only important in Ras 
activation, but has also been shown to be required for the activation of PLC. Previous 
studies have suggested that both Btk, via a Ptdlns (3,4,5)?^ dependent mechanism and 
Syk are required for the activation of PLC (36).
Ptdlns (3 ,4 ,5 )P3 mediated activation of PLC is believed to occur by at least two 
distinct mechanisms (7). Firstly, Ptdlns (3 ,4 ,5 )P3 by binding to the PH domain of Btk
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has been shown to mediate the activation of this protein kinase. Active Btk is then 
known to phosphorylate and activate PLC (7). Secondly, Ptdlns (3 ,4 ,5 )P3 may lead to 
the direct activation of PLC due to the binding of the PH domain of PLC to Ptdlns
(3 ,4 ,5 )P3 thereby recruiting PLC to the plasma membrane.
BCR-induced activation of Syk has long been known to play an important role 
in the activation of PLC. However, although the SH2 domain of PLC can bind to 
tyrosine-phosphorylated Syk in vitro, reconstitution of BCR signalling components 
into a non-lymphoid cell line have indicated that additional factors are required to initiate 
a BCR-mediated calcium response (41). Recent studies have shown that BCR-induced 
Syk activation leads to the phosphorylation of the linker protein, BLNK.
Subsequently, membrane recruitment and activation of PLC by BLNK has been shown 
to be the essential intermediate required for full activation of PLC (46). Indeed, studies 
using the chicken DT40 cell line have shown that disruption to the BLNK gene 
abolishes PLC phosphorylation (36).
The role of PLC activity, and hence intracellular Ca^  ^mobilisation has been 
shown to play key roles in the induction of differential signalling patterns in both 
immature and mature B lymphocytes. Studies in the early 1990s revealed that immature 
B lymphocytes mobilise intracellular Ca^"*" following BCR-ligation but fail to generate 
IP3 to the levels that are seen in mature B cell following similar stimulation (47). This 
suggests Ca^ "^  stores in immature B-cell are more sensitive to IP3 than mature B cells or 
that key signalling intermediates are missing in immature B cells.
Although intracellular Ca^  ^is known to regulate both proliferative and apoptotic 
signals, it is also known to regulate additional biological events in both immature and 
mature B lymphocytes. Studies by Benschop et. aL, 1999 (47) have provided evidence 
suggesting that BCR-mediated Ca^  ^events lead to receptor editing in immature B cells 
and upregulation of the activation markers CD8 6  (required for presenting antigen to T- 
cells), CD69 and MHC class II in mature B cells. Interestingly, this study also 
suggested that induction of receptor editing in immature B cells require much lower 
increases in intracellular Ca^  ^than the induction of activation marker expression in 
mature B cells. This therefore suggests that immature and mature B cells differentially 
activate distinct sets of genes following BCR-ligation and have different thresholds for 
the activation of these processes.
In addition to regulating Ca^  ^ flux via IP3 production, PLC activity also 
induces PKC activation due to the production of DAG. The PKC family of enzymes 
can be divided into three isotype families based on their enzymatic activities (48). The 
first of these isotype groups is the conventional, or classical, PKCs. These include 
PKCa, PKCp and PKCy and have shown to be both Ca2^ and phorbol-ester sensitive. 
The novel PKCs which include PKCe, PKCô, PKC6  and PKCrj are Ca2^-insensitive,
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but still phorbol-ester sensitive. The final PKC family are the atypical PKCs, which 
include PKCi and PKCÇ and have been shown to be both Ca2^ and phorbol-ester 
insensitive.
Important downstream targets of PKC in B lymphocytes are still being 
investigated. Recent work by King et. a l (49) has suggested a role for PKC in 
modulating B lymphocyte biological events (also reviewed in (8 )). The results from 
this study suggest that PKC-(3 is partially responsible for BCR-induced proliferative 
signals in mature B lymphocytes and that uncoupling of this PKC-pathway in immature 
B lymphocytes leads to apoptosis following BCR ligation. Interestingly, BCR-induced 
apoptosis in immature B lymphocytes was also shown to be rescued by PKC-p 
activation in this study. In addition, prolonged phorbol-ester treatment to deplete 
mature B lymphocytes of DAG-sensitive PKC isoforms has been shown to induce 
apoptosis, and not activation, following BCR-ligation of mature B cells (50). In 
addition to studying the role of PKC in both immature and mature B lymphocyte 
biology, the generation of PKC knockout mice has helped explain the role of this 
enzyme in B lymphocyte development at the molecular level. PKC-p-deficient mice 
were subsequently shown to exhibit a phenotype similar to xid mice (49), which results 
from a point mutation in the PH domain of Btk and results in a slight reduction in 
peripheral B cell numbers, with those that are present, skewed towards an immature B 
cell phenotype (7). As pro-B to pre-B transition in xid mice is normal, it is clear that 
these mice exhibit developmental defects during the antigen-dependent phases of B cell 
development. Likewise, PKCp-deficient mice also experience reduced responses to T 
cell-dependent antigens, suggesting a role for PKCp in mature B lymphocyte activation 
(49). These results also suggest that other isoforms of PKC are unable to replace 
PKCp in BCR signalling events. However, it should be noted here that whilst DAG- 
sensitive PKCs may play a role in the rescue of primary immature B lymphocyte from 
apoptosis, these signals are known to induce apoptosis in a number of cell lines such as 
DT40 and WEHI-231 cells (49).
Additional roles for PKC in modulating the biological response to BCR-ligation 
in immature and mature B lymphocytes have been reported by Carmen et. a l, 1996 
(51). These authors reported that BCR-ligation induced activation of the early G1 
kinase, cdk4 and its regulatory sub-unit cyclin D2 in both immature and mature B 
lymphocytes. However, unlike mature B lymphocytes, BCR-ligation failed to induce 
cyclin E and cdk2 expression, which is required for G /S transition, in immature B 
lymphocytes. This provides interesting data to explain the differential effects of BCR- 
ligation in immature and mature B lymphocytes. In addition, the results in this study 
reported that LPS and PMA/ionomycin, which activate Ca^ "^  sensitive PKC isoforms.
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induced cyclin E and cdk2 expression in immature B lymphocytes as well as promoting 
RNA and DNA synthesis. These results confirm a role for PKC in mediating 
proliferative signals in mature B lymphocytes and again suggest this pathway may be 
redundant in immature B lymphocytes.
In addition to the three core signalling events activated following BCR-ligation 
in B lymphocytes, the role of novel, maturation state-dependent lipid signalling 
pathways is also being investigated by a number of groups. For example studies by 
Gilbert et a l (52) presented data suggesting that the BCR on mature B lymphocytes is 
coupled to a novel, Pl-hydrolysing PLD under proliferative conditions. In contrast, the 
BCR is not coupled to PtdCho-PLD activity seen under proliferative conditions in other 
cells such as T lymphocytes. Interestingly, PtdCho-PLD was activated in mature B 
lymphocyte by ATP stimulation, which inhibits murine B lymphocyte activation 
suggesting that PtdCho-PLD is associated with anti-proliferative signals in mature B 
lymphocytes. In addition, the authors presented data suggesting that phosphatidic acid 
generated by the PI-PLD was converted to PKC-activating forms of DAG, unlike the 
phosphatidic acid generated by ATP-stimulated PtdCho-PLD. These results provide 
further evidence to suggest a role for PKC in BCR-mediated proliferative responses in 
mature B lymphocytes. The authors also addressed whether PtdCho-PLD was 
responsible for the BCR-mediated signals leading to growth-arrest/apoptosis in 
immature B lymphocytes, however PtdCho-PLD did not appear to play an early (<1 
hour) role in the induction of these negative signals.
There is evidence however, for the role of other lipid second messengers in 
transducing apoptotic or growth arrest promoting signalling pathways. The 
involvement of lipid mediators in B lymphocyte signalling is now well established. The 
involvement of cytosolic phospholipase A  ^in immature B lymphocyte responses is 
perhaps the most striking because its expression also appears to be tightly regulated at a 
developmental level. Studies (53) have shown that anti-Ig treatment of WEHI-231 cells 
leads to the activation of cPLA^ which hydrolyses phosphatidyf choline to generate lyso- 
phosphatidlycholine and arachidonic acid (AA), a known lipid second messenger with 
roles in apoptotoic cell responses. In contrast, anti-Ig treatment of mature splenic B 
lymphocytes, inducing cell activation and proliferation, did not stimulate cPLAj 
activity. Indeed, western blot analysis indicated that cPLA^ was not expressed at the 
protein level in mature splenic B lymphocytes, indicating that cPLA^ expression may 
play important roles in the mechanisms underlying B lymphocyte maturation.
Other lipid second messengers known to play a role in lymphocyte apoptosis 
include ceramide. Indeed, recent reports (54) have indicated that ceramide production 
following anti-Ig treatment correlates with the induction of apoptosis in the WEHI-231 
cell line. In addition, resistance to anti-Ig mediated apoptosis in a WEHI-231 cell 
subline appears, in-part, to be due to insufficient ceramide production (54).
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Interestingly, ceramide generation is believed, in part, to be closely regulated by AA. 
Indeed, TNFa-induced arachidonic acid release has been shown to precede activation 
of the enzyme responsible for ceramide generation, sphingomyelinase (SMase) (55), 
whilst AA has also been shown to stimulate SMase activity in a cell free system (56).
Another hypothesis that aimed to address the physiological differences between 
immature and mature B lymphocyte signalling events concerned the expression of IgD 
on the cell surface of mature, but not immature, B lymphocytes. Early suggestions put 
forward the idea that IgM was involved in negative signalling events whilst IgD was 
involved in B cell activation (57). However, recent evidence suggests that apoptosis 
can be triggered in immature/transitional B lymphocyte when either mIgM or mIgD are 
cross-linked with high avidity (58). This same study provided evidence to suggest that 
mIgD derived signals were ineffective in reversing mIgM-induced apoptosis.
However, other studies have suggested that increasing expression of mIgD does confer 
some resistance to deletion (58). Therefore the role of mIgD in the development of B 
lymphocyte remains unclear, however, it appears that intrinsic, maturation-dependent 
differences in sig-mediated signalling events play a vital role in determining the 
response to sIg ligation in immature/mature B lymphocytes.
Recent advances in the understanding of BCR mediated signalling events 
following antigen binding have suggested a role for glycosphingolipid- and cholesterol- 
rich plasma membrane microdomains, or lipid rafts, in the initiation of these events 
(59). Subsequently, it has been suggested that the BCR complex is rapidly recruited to 
these lipid rafts upon antigen binding. In addition, these rafts were shown to contain 
the Src family kinase Lyn, but not the transmembrane phosphatase, CD45R. This 
suggests that lipid rafts may function to concentrate activated BCRs and bring them into 
close contact with downstream signalling enzymes and adaptor proteins utilised by 
BCR signalling pathways.
1.8 Role of co-receptors in B lymphocyte signalling.
Previous discussions have addressed the differential biological responses 
generated by the BCR following receptor ligation in either immature or mature B 
lymphocytes. This may be due to the differential expression of signalling proteins at 
different maturational stages, or recruitment of adaptor/linker proteins, but also the 
surface expression of a number of co-receptors which have been shown to modulate, 
either positively or negatively, signals generated by the BCR. Like adaptor/linker 
proteins, these co-receptors, which include CD 19, CD22 and FcyRIIB function by 
recruiting signalling enzymes which modulate BCR signalling events.
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1.8.1 CD19
CD 19, a B lymphocyte restricted glycoprotein, is expressed throughout B cell 
development until plasma cell differentiation ( 1 0 , 60) and forms part of a complex also 
containing CD21 and CD81. Co-ligation of CD 19 with the BCR is known to reduce 
the threshold for B cell activation and CD 19-/- mice have been shown to be hypo- 
responsive to BCR stimulation (41). Although CD 19 is expressed throughout the B 
cell lineage, deletion of CD 19 appears to have little effect on B cell development until 
the mature B cell stage of development. Studies have shown that lack of, or 
overexpression of CD 19 leads to decreases in the number of conventional B 
lymphocytes in the periphery (17, 61). In the latter case, the reduction in peripheral B 
lymphocytes can presumably be explained by the hyperresponsiveness of immature B 
lymphocytes to antigen receptor ligation and hence enhanced negative selection in the 
bone marrow. However, in normal physiological situations, co-ligation of CD 19 with 
the BCR substantially increases mature B cell activation leading to increased release of 
intracellular calcium, increased DNA synthesis, increased ERK-MAPKinase activation 
and antibody production (62). Additional evidence for CD19-mediated regulation of the 
threshold for BCR signalling comes from studies using double HEL-transgenic mice. 
These mice express a BCR specific for HEL (anti-HEL) and also soluble HEL (sHEL). 
Mature B lymphocytes from these mice are anergic in nature and do not produce auto 
(anti-HEL) antibodies. However, overexpression of CD 19 in these mice has been 
shown to induce autoantibody production which is believed to be due to CD19- 
mediated lowering of the threshold for BCR-mediated signalling (17).
CD 19- and CD21-deficient mature B cells have also been reported to have 
lowered responses to T-cell dependent antigens and subsequent lack of germinal centre 
formation and decreased affinity maturation of serum antibodies (60) suggesting that 
CD19-CD21 signalling is important for T dependent B cell responses. This is because 
CD19-CD21 signalling not only lowers the threshold for BCR-mediated B lymphocyte 
activation, but also signalling via CD21 has been shown to be co-stimulatory for anti- 
CD40 stimulated splenic B cell growth and these two signals result in enhanced B 
lymphocyte differentiation (60). In addition, studies have also shown that CD40 
ligation also results in tyrosine phosphorylation of CD 19 and activation of PI(3)K (63) 
suggesting that CD40 may also regulate CD 19 signalling and hence alter the threshold 
for activation by the BCR.
How co-ligation of CD 19 with the BCR augments B cell activation remains 
unclear, however, new insights into CD 19 signalling mechanisms have helped unravel 
this process. Upon BCR-ligation, CD 19 becomes tyrosine-phosphorylated which 
provides binding sites for PI(3)K, the GEE Vav, She and the Src-family PTKs. The 
phosphorylation of the cytoplasmic tail of CD 19 is believed, in part, to be due to the
2 0
actions of Lyn, which is activated following BCR ligation and subsequently 
phosphorylates and binds to CD 19. Studies using CD 19-deficient mice have shown 
that lack of CD 19 leads to a reduction in the tyrosine phosphoiylation of multiple 
effector molecules downstream of the BCR following BCR-ligation (61). In addition, 
in vitro kinase assays have shown that the kinase activity of purified Lyn was 
significantly increased when co-incubated with purified CD 19. These results suggest 
that CD 19 functions to amplify PTK activity downstream of BCR-ligation and that loss 
of this PTK-amplification may account for the hyporesponsiveness of BCRs in CD 19 
deficient mice.
The signalling mechanisms behind the ability of CD 19 to augment BCR- 
mediated intracellular calcium and ERK-MAPKinase signals are also becoming clear. 
As previously mentioned, BCR-mediated phosphorylation of CD 19 enhances Vav 
binding, which, coupled to its co-localisation with BCR-activated PTKs, leads to its 
enhanced tyrosine phosphorylation and hence activation. Vav acts as a GEF for the 
Rho-GTPases which in turn can activate PI(5)K which has been shown to result in 
PLC activation, IP3 generation and hence calcium mobilisation (36, 60). Additional 
studies have accounted for the ability of CD 19 to augment BCR-mediated ERK- 
MAPKinase activation (62). This study provided data to suggest that co-ligation of 
CD 19 and BCR lead to the synergistic enhancement of MEKl activity. Interestingly, 
these studies also presented data suggesting that BCR-mediated ERK-MAPKinase 
activation was both Ras- and PKC-dependent. However, CD 19 mediated enhancement 
of MEKl activity was shown to be independent of both Ras and PKC suggesting a 
novel route of MEKl activation.
1.8.2 CD22
Another co-receptor restricted to the B cell lineage which has been shown to 
modulate BCR-mediated signalling events is CD22. The surface expression of CD22 
has been shown to remain low during early stages of B lymphocyte development, but 
increases as B lymphocytes mature in the periphery (17). Like CD 19, CD22 rapidly 
associates with the BCR and becomes tyrosine phosphorylated by Lyn after BCR- 
ligation. This creates phosphotyrosine motifs that recmit multiple SH2 domain 
containing effector molecules. However, unlike CD 19, CD22 has been shown to be a 
negative regulator of BCR signalling events, increasing the threshold for BCR 
activation. This occurs under physiological conditions where the BCR and CD22 
molecules are in close association with each other. Other studies have shown that 
CD22, when ligated separately from the BCR, actually acts to promote BCR-mediated 
responses. This has been proposed to be due to the ability of CD22 to sequester 
inhibitory signalling elements such as the tyrosine phosphatase, SHP-1, away from the
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BCR (64). However, the physiological relevance of these studies are unclear. 
Therefore, it is the negative, and more physiological role of CD22 in B cell signalling 
that has attracted much of the attention over the last few years.
BCR-mediated phosphorylation on immunoreceptor tyrosine-based inhibitory 
motifs (ITIMs) of CD2 2  recruits intracellular signalling molecules including SHP-1, 
Lyn, PI(3)K and PLCy 1(60). It is the active recruitment of the protein tyrosine 
phosphatase SHP-1 to the BCR-CD22 complex that permits BCR-mediated signalling 
events to become suppressed. Studies using CD22-/- mice have shown CD22-/- B celL 
exhibit increased calcium responses following BCR-ligation compared to wild-type B 
cells confirming that CD22 acts to suppress BCR-mediated signalling events (41). 
Phenotypically, CD22-/- mice exhibit normal early B cell development and normal 
numbers of B cells in the spleen (60). However, peripheral B cells were shown to 
express decreased levels of mIgM and increased levels of MHC class II, similar to pre­
activated B cells (17). These results, and observations suggesting that SHP-1 deficient 
mice deliver similar phenotypic abnormalities, confirm a negative role for CD22 
(increasing BCR threshold for activation), mediated by SHP-1, in modulating BCR- 
mediated signalling events.
What signalling mechanisms are negatively regulated by CD22 when complexed 
with the BCR are still unclear. Studies by Tooze et.al, 1997 (65) provided good 
evidence to suggest that CD22 was an important regulator of BCR-mediated 
MAPKinase activation in mature splenic B lymphocytes. Interestingly, cross-linking of 
CD22 with the BCR appeared to selectively suppress BCR-mediated ERK-MAPKinase 
and to a lesser extent INK activity, whilst p38-MAPKinase activity was unchanged. 
This suggests that CD22/SHP-1 are capable of selectively inhibiting some pathways, 
but not others, and this could re-direct the balance of BCR-mediated signalling events.
Although CD22 appears to be able to modulate BCR-mediated responses, it is 
itself under intense regulation. A recent study by Greer et. a l, 1999 (6 6 ) provided 
evidence to suggest that the transmembrane protein tyrosine phosphatase, CD45, played 
an important role in regulating CD22 phosphorylation. Indeed, CD45-deficient B cells 
were shown to have increased tyrosine phosphorylation of CD22, but also increased 
levels of SHP-1 associated with CD22 after BCR-ligation. Therefore, CD45 appears to 
play a role in regulating the level of CD22 phosphorylation following BCR-ligation.
1.8.3 FcyR IIB
B lymphocytes can receive signals that can modify the activation signals 
delivered through the BCR. These include the CD22 molecule described above, but 
also the Fc receptor, FcyRIIB, which contains immunoreceptor tyrosine-based
2 2
inhibitory motifs (ITIMs) in its cytoplasmic tail. It widely reported that the activation of 
naive mature B lymphocytes can be inhibited by co-ligation of the BCR with the Fc 
receptor.
FcyRIIB mediated inhibition of BCR-mediated signalling events, like CD22, 
involves the recruitment of phosphatases. FcyRIIB recruits SHP-1 and SHP-2, 
however, unlike CD22, FcyRIIB also recruits the lipid phosphatase SHIP. SHIP 
catalyses the hydrolysis of Ptdlns (3,4,5)Pg to Ptdlns (3,4)P^. FcyRIIB mediated 
recruitment of SHIP therefore attenuates BCR-mediated activation of both Btk and Akt 
as both of these enzymes require Ptdlns (3,4,5)Pg levels (41, 67). In addition, recent 
studies have suggested that SHIP plays a negative role in BCR-mediated signalling by 
acting as an adaptor molecule (6 8 ). This report suggests that FcyRIIB mediates the 
inhibition of ERK-MAPKinase by the recruitment of SHIP which in turn acts as a 
binding site for p62dok and RasGAP. The linker protein She is also believed to play 
key roles in FcyRIIB mediated suppression of ERK-MAPKinase (17, 69). Thus, it is 
thought that increases in the association between SHIP and She following BCR and 
FcR cross-linking reduce Shc/Grb2 interactions and hence Ras activation.
1.8.4. CD40
CD40, and its ligand CD40L (CD 154) are known to play crucial roles in the 
regulation of the humoral immune response including cell activation, proliferation, 
immunoglobulin isotype switching and germinal centre B cell formation (70).
In addition to having roles in mediating B lymphocyte biology during normal 
development, recent studies have also suggested an important role for CD40 in 
antitumour strategies against B lymphocyte malignancies (reviewed in (71)), These 
studies have indicated that CD40 stimulation leads to the up-regulation of 
adhesion/costimulatory molecules on the cell surface of tumour cells which aids the 
immune recognition of these malignant cells. In addition, CD40 stimulation of tumour 
cells has also been shown to induce the release of anti-tumour cytokines by the tumour 
itself. However, limitations to the effectiveness of CD40 as a viable therapy against 
some B lymphocyte malignancies have been discovered due to the anti- 
apoptotic/proliferative signals delivered by CD40-ligation in some low-grade B 
lymphocyte malignancies. Therefore current reseai'ch into CD40-mediated tumour 
therapy is focused on avoiding pro-tumourigenic effects of CD40 stimulation whilst 
understanding the role of CD40 in tumour recognition and the stimulation of the 
immune system.
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1.8.4.1 CD40 structure and expression.
Since the identification of CD40 almost 15 years ago and the discovery that it 
plays crucial roles in T cell-mediated B cell activation, much has been learnt about the 
signalling pathways activated by the receptor following ligation with CD40L or soluble 
CD40 antibodies (anti-CD40). The CD40 receptor is a 48-k.Da. transmembrane 
glycoprotein and is a member of the TNF receptor (TNFR) superfamily (72) (figure 
11). Structurally, human CD40 consists of a 193 amino-acid extracellular domain, a 
22 amino-acid transmembrane domain and a 62 amino-acid cytoplasmic domain. The 
extracellular domain consists of four homologous, repeating, cysteine-rich extracellular 
domains characteristic of TNFR family motifs (73). It has been shown that murine 
CD40 shares approximately 60% homology to human CD40, with the greatest 
homology (78%) to the human form in the cytoplasmic domain (74). This cytoplasmic 
domain contains no sequence of known protein tyrosine kinase activity. Indeed, the 
cytoplasmic tail of human CD40 contains no tyrosine residues, whilst only one exists in 
the murine form. Nevertheless, the cytoplasmic domain of CD40 is constitutively 
phosphorylated which is believed to be due to serine and threonine residues, in which 
Thr-234 has been shown to be crucial for signal transduction (74).
Although CD40 expression was originally thought to be a B lymphocyte specific 
receptor it is now known to be widely expressed on human and mouse dendritic cells, 
monocytes, macrophages, mouse fibroblasts and human smooth muscle cells (7 5 ). 
Although CD40 has been reported to be expressed on virtually all B lymphocytes, the 
level of CD40 expression varies depending on the maturational stage of the cell.
Studies by Hasbold et a l (76) provided data indicating that murine CD40 is expressed 
at low levels on 30-40% of pre-B cells, at intermediate levels on 80% of immature B 
cells and on essentially all mature B cells, suggesting that CD40 expression may be 
more important in later stages of B lymphocyte maturation.
1.8.4.2 CD40 signal transduction.
Like both the p55 and p70 isoforms of the TNF receptor, CD40 has no 
intracellular kinase domain and no consensus sequence for binding kinases (72). 
However CD40 ligation is known to rapidly activate the protein tyrosine kinases Lyn 
and Syk (77) whilst also inducing the tyrosine phosphorylation of phosphcttidylinositol 
3-kinase (PI3-K), phospholipase C-y2 (72) and also activating serine/threonine kinases 
(70). However, like all signalling mechanisms, it is important to be careful when 
comparing data from different cell types. Consequently, studies highlight quite distinct 
differences in proximal CD40 signalling events in B lymphocytes depending on
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whether the cells used were resting, activated or EBV-transformed (74, 77). In 
addition, some studies suggest that instead of phosphorylating and activating a number 
of protein tyrosine kinases, CD40 engagement de-phosphorylates the Src family PTKs 
or syk (17).
As well as regulating protein tyrosine kinase activity, CD40 is known to 
associate with intracellular proteins termed TNF receptor-associated proteins (TRAFs). 
TRAF2, TRAF3 and TRAF 5 are known to associate with a specific region in the 
cytoplasmic domain of CD40 (73) (figure 11). TRAF3 or CD40 receptor-associated 
factor (CRAFl) is specific to CD40 signal transduction and does not bind to other 
membrane proteins such as p70 TNFRII (74), One fascinating feature of the TRAFs is 
their ability to bind both membrane elements (such as CD40) and also DNA. This latter 
function is due to the five zinc ring finger motifs encoded in the N-terminal domain of 
TRAF 2 and 3. In addition, TRAF proteins share homology in a C-terminal TRAF 
binding domain. This allows the various TRAFs to form homo- or heterodimers 
following CD40 ligation (73). These complexes (much like the ST AT family of 
proteins) may then translocate to the nucleus to function as transcriptional activators. 
Indeed, TRAF2 is predicated to play a crucial role in CD40-mediated activation of the 
transcription factor NF-kB.
Whilst we understand the importance of CD40 signalling in B lymphocytes we 
are still a long way from understanding the precise signalling mechanisms utilised by 
this receptor. What is clear however, is that CD40 signalling in B lymphocytes 
involves both nuclear and cytoplasmic elements, with additional differential roles 
determined by a cells activation or developmental state. In addition the role of CD40- 
induced signalling pathways in the regulation of apoptosis is currently attracting much 
attention. A recent review by Craxton et. a l (17) highlights the role of CD40 in both 
the induction or prevention of apoptosis in B lymphocytes which appears to be closely 
regulated by the developmental stage of the cell.
1.9 Aims and objectives.
The aims and objectives of this investigation were to:
I. determine the signalling mechanisms involved in the deletion of immature B 
lymphocytes following BCR-ligation.
II. investigate the signalling mechanisms involved in the rescue of immature B 
lymphocyte from deletion by co-stimulation with anti-CD40.
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Figure 1. Stages of B lymphocyte Maturation. B lymphocyte maturation 
starts in the bone marrow with the commitment of haematopoietic stem cells to the B 
lymphocyte lineage. These cells develop in an antigen-independent manner. Pro-B 
cells express a functionally rearranged immunoglobulin heavy chain in addition to the 
surrogate light chains and which are important for allelic exclusion. Cells then 
enter the pre-B cells stage and express cytoplasmic \i chains. Light chain 
rearrangement occurs, leading to the expression of mIgM on the cells surface. The B 
cell now enters the antigen-dependent stage of B lymphocyte development as an 
immature B cell where the B lymphocyte repertoire is determined by the selection of B 
lymphocyte expressing non-self antigen receptors. Those cells which pass this section 
process will respond to subsequent antigen exposure (specific to their BCR) by 
differentiating into either a plasma cell or memory cell depending on the nature of T cell 
help.
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Figure 2. B lymphocyte development is associated vyith differential
expression of a number of cell surface markers. During development 
numerous markers are expressed on the cell surface which can be used to determine the 
developmental stage of the B lymphocyte.
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Figure 3. B lymphocytes react differently to self-antigen and express 
BCRs of different maturity depending on their developmental stage.
Immature B cells are the first cells of the B lymphocyte lineage to express fully 
functional BCRs. Self-antigen block the developmental progression of immature B 
cells and initiates receptor editing. Transitional B cells response to self-antigen 
exposure by the rapid induction of apoptotic machinery. Mature B cells that have 
successfully traversed the selection process respond to antigen exposure by initiating 
activation programmes.
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Figure 4. B lymphocyte development is accompanied by the ordered 
expression of different “surrogate” and then finally, a fully mature 
BCR. The various stages of B lymphocyte development can be defined by the 
rearrangement of the immunoglobulin heavy and light chain genes. Genetic mutations 
to specific genes have been used to generate knockouts which result in the 
developmental arrest of B lymphocyte maturation. Those commonly used are shown.
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Figure 5. Germinal centre formation. During Independent activation resting 
naive B cells ( 1 ) migrate from the follicular mantle into B cell follicles. Here they 
differentiate into proliferating centroblast (2) where they form the germinal centre dark 
zone. This is the region where somatic mutation in the variable region of the 
immunoglobulin gene occurs. These centoblasts then differentiate into centrocytes (3) 
and undergo positive selection, depending on the affinity of their mutated antigen 
receptors, in the light zone of the germinal centre. Those cells with low affinity and 
autoreactive antigen receptors undergo spontaneous apoptosis. Positively selected 
centrocytes may undergo CD40-mediated isotype switching, become protected from 
Fas-induced apoptosis. and differentiate into either plasma cells (4) or memory B cells 
(5).
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Figure 6. The cell-cycle of a cell proceeds in a logical number of 
stages. Replication of DNA occurs in the S (synthesis) phase of the cell cycle The 
interval before this is called the G, phase, and the phase between the end of DNA 
synthesis and mitosis (M) is called the G  ^phase. These two G (or gap) phases allow 
the cell to deteimine if they are the right size to commence DNA replication and also 
determine whether DNA replication has occurred without any errors.
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Figure 7. Role of the mitochondria in the initiation of apoptosis. Death 
signals can be transmitted to the nucleus through pro-apoptotic members of the Bcl-2 
family, including Bid, Bax and Bad. This results in cytochrome c release, and apaf-1- 
caspase 9 activation. In addition, cytochrome c release can be induced by caspase-8 
activity, mediated by death signals such as those generated through the tumour- 
necrosis-factor (TNF) receptor. Activation of death signals through the TNFR can also 
bypass the mitochondrial step and directly activate caspase-3. Anti-apoptotic members 
of the Bcl-2 family, such as Bcl-x^ can prevent apoptosis by preventing the release of 
cytochrome C from the mitochondria.
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Figure 8. Structure of the mature BCR. Diagram shows the association of mig 
with disulfide linked heterodimers Iga and Igp. The Iga and Ig|3 heterodimers contain 
ITAM motifs which act as the signalling elements of the mature BCR.
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Figure 9. Signalling pathways activated upon BCR-iigation in immature 
B lymphocytes. Three classical signalling pathways are activated upon BCR-ligation 
in immature B lymphocytes. These include the Ras/Raf/MAPKinase leading to the 
activation of ERK-MAPKinase. Activation of the PI(3)K pathway leading to the 
generation of Ptdlns(3,4,5)Pg and activation of the PLC pathways leading to DAG and 
IP3 generation. These pathways are also known to be activated by receptor-ligation in 
mature B lymphocytes.
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Figure 10. Activation of Rapl by BCR-ligation, BCR-ligation induces the 
tyrosine phosphoiylation of the membrane associated docking proteins p i30*^ “" and 
pl20^^ Crk proteins can then bind to these tyrosine phosphorylated proteins via their 
SH2 (tyrosine-binding) domains. This subsequently recruits the guanine nucleotide 
exchange factor, C3G, to the cell membrane where it associates with and activates 
Rapl.
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Figure 11. Schematic representation of the structure of the CD40 
receptor. Figure shows the binding of TRAF2, TRAF3 and TRAF5 to C-terminal 
TRAF binding domains on the intracellular tail of CD40. Arrows represent signal 
transduction pathways leading to the activation of NFidB and regulation of protein 
tyrosine kinases.
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CHAPTER 2 - Materials and Methods. 
2.1 Cells, reagents and antibodies.
The murine B cell lymphoma, W EHI231 was cultured in RPMI-1640 medium 
containing 5 % foetal calf serum, L-glutamine (2 mM), penicillin (100 U/ml) and
streptomycin (100 pg/ml) (RPMI complete) at 37®C in 5 % CO^. RPMI complete media
for WEHI-231 B cells was additionally supplemented with 2-mercaptoethanol (50 pM). 
All cell culture reagents were obtained from GIBCO (Paisley, Scotland).
PD98059, H-89 (dihydrochloride), Ly 294002, L-a-Phosphatidylinositol- 
3,4,5-trisphosphate (Dialmitoyl-Heptaammonium Salt (PtdIns(3,4,5)P))), rolipram and 
propidium iodide were obtained from CALBIOCHEM (Cambridge, MA, USA).
U0126 was obtained from PROMEGA (UK). SB230580 and N,N-Dimethyl-D“ 
erythro-sphingosine (DMS) were obtained from ALEXIS BIOCHEMICALS. 
Cilostamide was obtained from ICN BIOCHEMICALS (Aurora, Ohio). Wortmannin 
and IBMX were obtained from SIGMA CHEMICAL COMPANY (Poole, Dorset,
UK). [6 -^H]thymidine (5 Ci/mmol) and L-[3 -% serine (33.0 Ci/mmol) were obtained 
from AMERSHAM INTERNATIONAL (Buckinghamshire, UK). Carboxy- 
fluorescein diacetate succinimidyl ester (CFSE) was obtained from Molecular Probes 
(Leiden, Netherlands).
All other reagents were obtained from Sigma Chemical Company (Poole,
Dorset, UK).
Phospho-specific p44/p42 MAPKinase (ERK-MAPKinase/pERK), p44/42 
MAPKinase (wERK), phospho-specific SAPK/JNK (pJNK), SAPK/JNK (wJNK), 
phospho-specific p38 MAPKinase (pp38), p38 MAPKinase (wp38) and anti-rabbit 
immunoglobulin-horseradish peroxidase antibodies were obtained from NEW 
ENGLAND BIOLABS (Hitchin, HERTS. UK). Anti-p85a (PI(3)K) and anti-PAC-1 
were obtained from SANTA CRUZ BIOTECHNOLOGY (Santa Cruz, CA, USA).
2.2 Purification of anti-CD40 antibody
Equal volumes of saturated ammonium sulphate solution and tissue culture 
supernatant (FGK 45) were mixed and the immunoglobulin fraction allowed to 
precipitate overnight at 4°C. The precipitated immunoglobulin was harvested by 
centrifugation at 1 0 , 0 0 0  rpm and then dialysed exhaustively in malonate buffer (per 
litre; malonic acid sodium salt (6.5g), malonic acid (1.2g), betaine (Ig). A column 
consisting of a glass wool-stoppered 20ml syringe was then filled with 5ml S sepharose 
fast-flow. The antibody solution was loaded onto the column which was then washed
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with malonate buffer until the eluant A^ gq reached a steady state (consistently about
0.05). The antibody was then eluted using the malonate buffer containing 0.5M NaCl 
in 1ml fractions, the profile of the elution was followed and the amount of protein 
estimated by measuring A^q (an OD of 1.4 being approximately equivalent to 1 mg/ml 
of protein) .being followed using A^ gq. The antibody solution was then extensively 
dialysed against PBS, filter sterilised and stored at -20°C.
2.3 Purification of anti-lg (anti-mouse fx-chain) antibody
Equal volumes of saturated ammonium sulphate solution and tissue culture 
supernatant (B.7.6) were mixed and the immunoglobulin fraction allowed to precipitate 
overnight at 4°C. The precipitated immunoglobulin was harvested by centrifugation at 
10,000 rpm and then dialysed exhaustively in PBS. A column, consisting of a glass 
wool-stoppered Pasteur pipette containing 1 ml of or Protein G-sepharose (capacity: 35 
mg/ml)) was prepared, and this was connected to a reservoir made from a 50 ml 
syringe. PBS (20 ml) was then run through the column to wash away the ethanol from 
the protein-G storage buffer. Tissue culture supernatant was then run through the 
column, and the flow-through retained. The column was washed with PBS until the 
level of eluted protein (as measured at A^ gq) had reached a steady state. The bound 
antibody was eluted using 1 ml aliquots of 0.2M acetic acid which were collected in 
vials containing an equal volume (100 |il) of IM Tris buffer (pH 8 .8 ). The elution was 
followed and the amount of protein estimated by measuring A^ gq (an OD of 1.4 being 
approximately equivalent to 1 mg/ml of protein). The appropriate fractions were then 
pooled and dialysed in PBS overnight, filtered sterilised and stored in 1 ml aliquots at 
4"C or -20°C .
2.4 Measurement of DNA synthesis.
For measurement of DNA synthesis, WEHI 231 cells (10^ cells/ well) were 
cultured in triplicate in round bottom microtitre plates in RPMI-1640 medium 
supplemented with glutamine (2 mM), sodium pymvate (1 mM), 1% non-essential 
amino acids, 2-mercaptoethanol (50 pM), penicillin (100 U/ml), streptomycin (100 
mg/ml) and 5% FÇS, in the presence of the appropriate agonist in a total volume of 
200pl. Cells were cultured at 37“C in a 5% (v/v) CO^ atmosphere at 95% humidity for 
48. [^Hjthymidine (0.5 pCi/ well) was added 4 hours prior to harvesting of the cells 
with an automated cell harvester (Skatron). Incorporated label was estimated by liquid 
scintillation counting and is represented as DPM ± SEM.
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2.5 Cell Stimulation and Lysate Preparation
WEHI 231 cells (10 cells) were stimulated as required in RPMI-1640 medium 
supplemented with glutamine (2 mM), sodium pyruvate (1 mM), 1% non-essential 
amino acids, 2-mercaptoethanol (50 pM), penicillin (100 U/ml), streptomycin (100 
mg/ml) and 5% PCS. Reactions were terminated by the addition of 2 x ice-cold 
modified RIPA lysis buffer (50 mM Tris (pH 7.4), 150 mM sodium chloride, 2% (v/v) 
NP 40, 0.25% (w/v) sodium deoxycholate, 1 mM EGTA) plus 10 mM sodium 
orthovanadate, 0.5 mM phenylmethylsulfonylfluoride, chymostatin (10 p.g/ml), 
leupeptin (10 p.g/ml), antipain (10 p-g/ml), and pepstatin A (10 p,g/ml)) and lysates 
solubilised for 30 minutes on ice before centrifugation at 12, 000 rpm for 15 minutes. 
The resulting supernatants (whole cell lysate) were stored at -20”C before being used 
for immunoprécipitation or western blot analysis.
2.6 Immunoprécipitation
Whole cell lysates (100-300 p.g total protein) were normalised to 1 p,g/p,l in RIPA 
buffer. Lysates were then precleared with 10 p.1 protein-G-sepharose (50% slurry) for 
30 minutes at 4'^ C with constant rotation. Lysates were then centrifuged at 13,500 rpm 
for 5 minutes at 4°C and the supernatant transferred to fresh tubes. Proteins to be 
analysed were immunoprecipitated from precleared lysate by the addition of the 
appropriate antibody (1-2 pg). Samples were incubated overnight at 4°C with constant 
rotation. The immunocomplex was captured with 10 pi protein-G-sepharose (50% 
slurry) for 2  hours at 4°C with constant rotation. Lysates were then centrifuged at 
13,500 rpm for 5 minutes at 4°C and the immunocomplex washed twice in ice-cold 
modified RIPA buffer. The beads were then resuspended in 30 pi 2 x loading buffer 
(100 mM Tris (pH 6 .8 ), 4% (v/v) bromophenol blue, 0.2% SDS and 20% (v/v) 
glycerol) + 5% 2-Mercaptoethanol (2-Me), boiled for 5 minutes at 100°C and stored at - 
20°C or pulse centrifuged at 10,000 rpm and subjected to SDS-PAGE electrophoresis 
as described below.
2.7 SDS-Polyacrylamide Gel Electrophoresis and Western Blotting.
2.7.1 SDS-Polyacrylamide Gel Electrophoresis.
Gel apparatus and glass plates were cleaned with 70% ethanol and assembled 
according to manufacturers instructions.
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Polyacrylamide gels were prepared as follows (enough for two gels):
10% Polyacrylamide running gel - 5.9 ml dH^O, 5.0 ml 30% acrylamide mix (BIO­
RAD), 3.8 ml 1.5 M Tris (pH 8 .8 ), 150 pi 10% SDS, 150 pi 10% ammonium 
persulphate and 6  pi TEMED.
5% Polyacrylamide stacking gel - 5.0 ml dH^O, 0.83 ml 30% acrylamide mix (BIO­
RAD), 0.63 ml 1.0 M Tris (pH 6 .8 ), 50 pi 10% SDS, 50 pi 10% ammonium 
persulphate and 5 pi TEMED.
The running gel was then poured into the gel apparatus, overlaid with 70% 
ethanol and allowed to set for approximately 30 minutes. The layer of ethanol was 
removed and the gel border washed with dHjO. The stacking gel was then poured, a 
well comb was inserted and the gel allowed to set for approximately 30 minutes. The 
comb was removed and the wells washed with dH^O. The gel apparatus was then 
placed in an electrophoresis tank which was filled with electrophoresis buffer (25 mM 
Tris, 250 mM glycine and 0.1% SDS (w/v)).
Whole cell lysates (of known protein concentration) were denatured in the 
appropriate volume of 2x sample buffer + 5% 2-Me by heating for 5 min at 100°C. 
Samples were loaded into individual wells with molecular weight rainbow markers (10 
pi) also loaded into one or two wells. The samples were electrophoresed into the 
stacking gel at 150V and then resolved in the separating gel at 200V in ice-cooled 
PAGE apparatus.
2.7.2 Transfer of resolved proteins to PVDF millipore membrane.
SDS-PAGE-resolved proteins were transferred to PVDF membrane using a 
Bio-Rad Transfer equipment. The gel was placed onto two sheets of transfer-buffer 
soaked filter paper within a transfer cassette and any air bubbles were removed with a 
buffer-wetted gloved finger. PVDF membrane (pre-activated in methanol for 30 
seconds and then washed in transfer buffer for 5 minutes) was placed on the gel, and 
any air bubbles were removed. Two sheets of buffer-soaked filter paper were placed on 
top of the gel/ filter sandwich. The transfer cassette(s) was then placed in the transfer 
tank and subjected to 200 mA (constant current) for 3 hours or 50 mA (constant 
current) overnight.
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2.7.3 Western Blot analysis of protein expression.
Following transfer, PVDF membranes were washed once in PBS/Tween-20 
(0.1%) and blocked with PBS/Tween-20 (0.1%)/10% non-fat milk for 2 hours. 
Membranes were then incubated with the appropriate primary antibody overnight (4°C) 
or 2  hour at room temperature. All antibody solutions were diluted in PBS/Tween-20 
(0.1%)/10% non-fat milk. Following primary antibody incubation, PVDF membranes 
were washed ( 3x15 minutes) with PBS/Tween-20 (0.1%). PVDF membranes were 
then incubated with the appropriate secondary antibody for 1 hour at room-temperature. 
PVDF membranes were then washed (5 x 10 minutes) with PBS/Tween-20 (0.1%) and 
protein bands visualised using the ECL system (Amersham International pic) on Kodak 
X-ray film (Kodak, UK).
2.8 Flow cytometry analysis of DNA content and cell cycle analysis.
WEHI-231 cells (approximately 5 xlO^) were harvested and washed once in 
PBS/2mM EDTA. Cells were resuspended in 200 jxl ice-cold hypotonic buffer (0.1% 
(w/v) sodium(tri) citrate, 0.1% Triton X-100 (v/v) and 50 (ig/ml propidium iodide (PI)) 
and incubated at 4°C for 10 minutes, and then at room temperature for 35 minutes.
Cells were analysed for PI fluorescence at an excitation wavelength of 488nm on a
BECTON DICKINSON FACSCallbar™ using Cell Quest for analysis.
Cell cycle analysis was used to determine the % of cells which were either 
apoptotic, in arrest, in S phase or in G^/M of the cell cycle (figure 12). Briefly, 
FL-2 voltage settings were altered until the large G, peak (representing 2N DNA levels) 
sat between 100-200. A marker (40 units wide) was set 20 units either side of the 
peak. The 2N DNA peak was doubled (representing 4N DNA) and markers set 30 
units either side of this number. Markers were also set below the 2N peak 
(representing sub-diploid DNA or apoptotic cells) and also between the 2N and 4N 
peaks, representing cells in the S phase (those with DNA levels between 2N and 4N).
In addition to PI staining, merocyanine 540 dye was also used as a indication of 
apoptosis. Briefly, 5x10^ cells were stimulated as required. Cells were harvested and 
resuspended in 200 j L i l  PBS + 40 pg/ml merocyanine 540. Cells were incubated in the 
dark for 30 minutes at room temperature and then analysed by for merocyanine 
fluorescence (FL-1) on a BECTON DICKINSON FACSCalibar™ using Cell Quest for 
analysis. Apoptotic cells were taken to be represented by the merocyanine high 
population which represent cells with increased membrane potential and permeability.
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2.9 Cell proliferation by CFSE dye analysis.
WEHI-231 cells were washed in sterile PBS (approximately 1.25 x lOVml). Cells 
were then incubated in 2.5 mM CFSE (diluted in PBS) at approximately 3.5 x 10^  
cells/ml for 10 minutes at 37°C in the dark. Cells were then washed twice in RPMI- 
1640 + 5% FCS. Cells were then stimulated as required (cell sample of approximately 
1 0 '^  cells was taken to determine the intensity of dye loaded into cells at time zero).
After cell stimulation, cells were washed twice in FACS buffer (PBS/2% FCS),
resuspended in FACS FLOW (approximately 3.5 x 107 cells/ml). At least lO"^  stained
cells were analysed (FL-1) using a BECTON DICKINSON FACScan™ using Lysis II 
software for analysis. Data files were converted on CELL QUEST software and the 
number of cell divisions per stimulation determined as follows. Briefly, cells analysed 
at time zero were measured for dye intensity on a histogram which gave a reading of 
total dye uptake. Markers were set so that each marker range equalled half of the 
previous setting (eg. 8000, 4000, 2000, 1000 etc.) as each cell division results in 
daughter cells with half the dye intensity. The percentage of cells within each marker 
range for a particular stimulation was then determined.
2.10 PI(3)K assay.
WEHI-231 cells were washed in phosphate free RPMI-1640 and then 
resuspended ( 2  x lOVml) in phosphate free RPMI-1640 containing 5% dialysed 
(against phosphate free RPMI-1640) FCS in the presence of 0.5mCi/ml [^^P]PO  ^(HCl 
free) for 90 minutes at 37“C. Following labelling, cells were washed in phosphate free 
RPMI-1640 and then stimulated in RPMI-1640 supplemented with glutamine (2 mM), 
2-mercaptoethanol (50 pM), penicillin (100 U/ml), streptomycin (100 mg/ml) and 5% 
FCS. Cell Emulation over a 0-60 minute time course was initiated by the addition of 50 
pi of stimulus (x 2 concentration) to glass vials containing cells (50 pl/5 x 10^  total 
cells) and vials were incubated in at 37“C for the appropriate time. Cells stimulated 
over a longer time course were incubated at 5 xlOVml (5x10^ total) with the 
appropriate stimuli. Reactions were terminated by the addition of 500 p,l ice cold 
methanol, followed by 350 p.1 PBS and 500 pi chloroform (final ratio of 0.9:1:1 
(water:methanol:chloroform)). In the case of longer time courses, cells were harvested 
and resuspended in 100 pi RPMI-1640 supplemented with glutamine (2 mM), 2- 
mercaptoethanol (50 pM), penicillin (100 U/ml), streptomycin (100 mg/ml) and 5%
FCS prior to reaction termination as described above. After the termination of the 
reaction and lipid extraction, cell samples were vortexed and centrifuged at 1 0 0 0  rpm 
for 5 minutes at 4°C to achieve phase separation.
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Whatman silca gel (A-150) TLC plates were impregnated with potassium 
oxalate by developing in a TLC tank overnight with a solvent system containing 1.2% 
potassium oxalate in methanol/water (2:3 v/v). Plates were then air dried and activated 
by heating at 100”C for 15 min and allowed to cool on the bench. An aliquot (450 pi) of 
the lower chloroform phase was removed from each sample to a clean glass vial, spiked 
with unlabelled PtdIns(3,4,5)Pg (2 pg) and dried by vacuum centrifugation. Each dried 
sample was redissolved in chloroform (30 pi) and applied to a pre-absorbent strip of the 
TLC plate along with a further wash of the vial. The plate was then developed in a 
paper-lined tank pre-equilibrated with the solvent chloroform : acetone : methanol : acetic 
acid:water (80:30:26:24:14 v/v/v/v/v) for approximately 15 hours. PtdIns(3 ,4 ,5 )P3 was 
located by exposure of the plate to iodine vapour and the radioactivity associated with 
each sample was then determined by Phospholmager analysis (STORM) or scraping 
and liquid scintillation counting.
Although both analysis methods were shown to produce similar trends between 
replicates, Phosphor-Imager analysis, measured by band volume, was open to possible 
errors due to uneven back-ground levels between plates. Therefore, liquid scintillation 
spectrometry was used as a more accurate measure to quantify PtdIns(3,4,5)Pg 
generation. Figure 13 shows the Phosphor-Image of a TLC plate and in particular the 
separation of different lipid species following TLC including PtdIns(3 ,4 ,5 )P3.
2.11 Sphingosine-l-phosphate assay.
WEHI-231 cells were washed in phosphate free RPMI-1640 and then resuspended (2 x 
lOVml) in phosphate free RPMI-1640 containing 5% dialysed (against Earles salts)
FCS in the presence of 20pCi/ml [^HJserine overnight (approximately 15 hours) at 
37°C. Following labelling, cells were washed in ice-cold RPMI-1640, lOmM HEPES, 
5% FCS and then stimulated in RPMI-1640 supplemented with glutamine (2 mM), 2- 
mercaptoethanol (50 pM), penicillin (100 U/ml), streptomycin (100 mg/ml) and 5% 
FCS plus 0.1 mM L-canaline and the pyridoxal phosphate analogue 4-deoxypyridoxine 
(0.5 mM) to inhibit the pyridoxine-dependent sphingosine-1 -phosphate lyase. Cell 
simulation over a 0-60 minute time course was initiated by the addition of 50 pi of 
stimulus (x 2 concentration) to glass vials containing cells (50 pl/5 x 10^  total cells or 1 
X 10^  total primary B lymphocytes) and vials were incubated in at 37°C for the 
appropriate time. Cells stimulated over a longer time course were incubated at 5 
xlOVml (5 X 1 0  ^total) with the appropriate stimuli.
Reactions were terminated by the addition of 350 pi ice-cold HCl (O.IM), 
followed by 350 p,l ice-cold methanol and 500 pi chloroform (final ratio of 0.9:1:1 
(aqueous : methanol :chloroform)). In the case of longer time courses, cells were
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harvested and resuspended in 100 [i\ RPMI-1640 supplemented with glutamine (2 
mM), 2-mercaptoethanol (50 pM), penicillin (100 U/ml), streptomycin (100 mg/ml) 
and 5% FCS prior to termination of the reaction as described above. After the 
termination of the reaction and lipid extraction, cell samples were vortexed and 
centrifuged at 1000 rpm for 5 minutes at 4®C to achieve phase separation.
Whatman silca gel (G-60) TLC plates were pre-mn in solvent 
(chloroform:methanol:acetic acid:water (90:90:15:6 v/v/v/v)) in a TLC tank for 
approximately 2 hours and plates were then air dried. An aliquot (450 pi) of the lower 
chloroform phase was removed from each sample to a clean glass vial, spiked with 
unlabelled SPP (1 pi of 10 mM stock) and dried by vacuum centrifugation. Each dried 
sample was redissolved in chloroform (30 pi) and applied to a pre-absorbent strip of the 
TLC plate along with a further wash of the vial. The plate was then developed in a 
paper-lined tank pre-equilibrated with the solvent mix: chloroform:methanol:acetic 
acid: water (90:90:15:6 v/v/v/v)) until the solvent front reached the top of the plate. SPP 
was located by exposure of the plate to iodine vapour and the radioactivity associated 
with each sample was then determined by scraping and liquid scintillation counting.
In order to examine the separation of lipid species under these conditions, a 
untreated cell sample was analysed by TLC under the above conditions along with lanes 
loaded with SPP standard. Lipids were visualised using iodine vapour which showed a 
band corresponding to the Rf value of SPP standards present in the cell sample. The 
whole lane was then scraped, in 0.5cm segments, to determine both the number and 
separation of lipid species (figure 14). These results indicated that SPP ran with an 
approximate Rf value of 0.7 with clear separation from other contaminating lipids so 
that SPP bands could be excised accurately and analysed.
2.12 Cytosolic Phosphoiipase assays
Cytosolic phosphoiipase A  ^(cPLA^) activity in whole cell lysates or 
mitochondrial fractions was determined using a commercial cPLA^ assay KTT 
(CAYMAN CHEMICAL COMPANY, Ann Arbor, MI) based on spectrophotometric 
detection (A^,J of free thiol by Ellman’s reagent (5,5’-dithiobis(2-nitrobenzoic acid); 
DTNB) following hydrolysis of the arachidonyl thioester bond at the sn-2 position of 
the cPLAj substrate, arachidonyl thio-phosphatidylcholine. A role for iPLA^ activity 
was excluded by the use of the selective inhibitor bromoenol lactone and the 
requirement for calcium for PLAj activity.
In addition, in some experiments CPLA2 activity was assessed by measurement
of [^HJarachidonic acid release as described previously [Gilbert, 1996 #2818]. This 
activity was blocked by the inhibitor arachidonyl trifluoromethyl ketone (selective for
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iPLA^ and cPLA^) excluding a role for sPLA^. Briefly, prior to each experiment, cells 
were washed, resuspended in fresh isotope-free medium and cultured for a further hour
at 37®C. The cells were then washed three times in Hanks buffered saline, pH 7.4, 
containing 2% (w/v) bovine serum albumin and 10 mM glucose (HBG), resuspended
in this buffer at 10  ^cells/ml and equilibrated for 30 minutes at 37^C. Cells (lO^/assay)
were then stimulated with the appropriate agent for the indicated time at 37°C.
Reactions were terminated by the addition of 1 ml ice-cold methanol/15 pi glacial acetic 
acid followed by a further 0.5 ml methanol and 0.75 ml chloroform and the cells 
extracted for 30 minutes on ice. Phases were split by the addition of chloroform and 
water and the chloroform phase was then dried under vacuum. For measurement of
[^H]arachidonate levels, 30 pi samples (prepared in ehloroform;methanol (2:1)) were 
spotted onto Silica Gel 60 thin layer plates and developed in hexane: diethylether : 
formic acid (80: 2 0 : 2 , by volume). After exposure to iodine vapour, arachidonate was 
identified by comparison with standards, the plate was sprayed lightly with water, and 
the corresponding silica gel scraped from the plate and assayed for radioactivity.
2.13 Measurement of intracellular PGE^.
Prostaglandin (PGEj) activity in whole cell lysates or cell supernatant was 
determined using a PGE^ competitive binding immunoassay assay KIT (R & D 
SYSTEMS EUROPE, Abingdon, UK) based on spectrophotometric detection (A^ ^^ ) as 
described in kit protocol. Briefly, 50 pi whole cells lysate (protein levels standardised 
to 1 pg/pl) or 1 0 0  pi cell supernatant was added to 1 0 0  pi assay buffer, followed by 
50 pi PGE2 conjugate (conjugated to alkaline phosphatase) and 50 pi PGE2 antibody 
solution. Samples and appropriate controls were incubated at room temperature for two 
hours. 200 pi pNPP substrate was added to all wells and samples incubated for one 
hour at room temperature. The optical density of each well was then determined using a 
microplate reader set to 405 nm with wavelength correction set at 570 and 590 nm.
2.14 Measurement of Ras activity.
Ras activity of cell samples was determined using a Ras Activation Assay Kit 
(UPSTATE BIOTECHNOLOGY, Lake Placid, NY) according to manufacturers 
protocol. Briefly, cells were stimulated as required (1 x lOVsample), harvested and 
lysed in 200 pi 5x Mg^  ^lysis buffer. Cell lysates were diluted to approximately 1 
pg/pl with 5x Mg^  ^lysis buffer and preeleared with 10 pi glutathione agarose for 30 
minutes at 4°C with constant rotation. Samples were then centrifuged at 13,500rpm for
45
Rc=>
CM
O
Or--
2NDNA  
(40 units) ^
Subdiploid DNAI
1 0 ' 10
s  phase
FL2-H
4N DNA 
(60 units)
■rniT T i
io '
Figure 12
Figure 13. Lipid separation of PtdIns(3,4,5)P3 by thin-layer 
chromatography (TLC). Lipids were extracted from WEHI-231 cells as described 
in materials and methods. Organic phase was dried under vacuum-centrifugation.
Lipids were resuspended in ChC^ and applied to G40 Silica TLC plates. Samples were 
run as described in Materials and Methods and analysed on a Storm Phosphor-Imager 
(Molecular Dynamics) following a 4 hour exposure.
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Figure 14. Separation by TLC of lipid fractions from pHJserine 
labelled cells clearly separates SPP from other lipid species. W EHI-231 
cells (IxlOVml) were lysed and lipids extracted from the sample as described in 
materials and methods. Lipid samples were dried under vacuum-centrifugation and 
subject to TLC analysis. One complete lane was scraped in 0.5cm segments and 
[%]serine levels quantified by liquid scintillation counting. SPP standards were also 
mn on adjacent lanes and location of SPP, visualised by iodine staining, is marked.
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CHAPTER 3 - Characterisation of a model system of immature B 
lymphocyte apoptosis and repertoire selection.
3.1 Apoptosis of Immature B lymphocytes.
During the generation of a functional B lymphocyte repertoire it is necessary to 
regulate the maturation of immature B cells to prevent the emergence of cells that bind 
self-antigen and which are therefore potentially auto-reactive. This major check-point in 
B lymphocyte development occurs not only in the bone marrow, but also in the 
periphery in cells termed as ‘transitional immature B lymphocytes’ (8). These 
transitional B lymphocytes remain sensitive to deletion upon leaving the bone marrow 
as some self-antigens are only encountered when these cells exit the bone marrow into 
the periphery. Thus, in contrast to mature B lymphocytes which generally undergo a 
process of activation following antigen encounter, immature/transitional B lymphocytes 
undergo a process of negative selection which may involve deletion, anergy or 
replacement of the self-reactive receptor with a non-self reactive BCR. Additional 
factors such as the cells microenvironment or co-stimulation by IL-4 or CD40 are also 
believed to play important roles in determining cell fate, the latter suggesting that these 
cells are responsive to some form of T cell help (50). The ability of T cell-derived 
signals to rescue B lymphocytes from apoptosis is well documented. For example, 
many reports have described the role of anti-CD40 antibodies in the rescue of self­
reactive immature B lymphocytes from deletion, mimicking the ability of T cell help to 
bypass tolerance induction in immature B lymphocytes (78). This rescue provides a 
mechanism for these cells to undergo further rounds of immunoglobulin gene 
rearrangement in the hope of generating a non-self BCR. In addition, a combination of 
signals delivered by BCR-ligation and CD40, presumably from CD40L expressed on 
T-cells, is also known to override apoptotic signals delivered by the BCR and maintain 
germinal centre B cell survival. The rescue from apoptosis by CD40 in germinal 
centres has been shown to be an essential process in the development of high affinity 
antibody producing memory B cells (73).
Antigen-induced apoptosis in both immature thymocytes and mature T 
lymphocytes is thought to involve Fas:FasL interactions (79) with TCR ligation 
inducing the upregulation of Fas and FasL surface expression and cell death being 
initiated with FasL interacting with Fas in an autocrine manner. However, Fas-FasL 
induced cell death appears to be more important at the mature T cells stage as mutations 
to Fas lead to the uncontrolled proliferation of mature T cells but does not affect early T 
cell development (80). In addition, mature B lymphocytes are also susceptible to Fas- 
mediated apoptosis, which is believed to be mediated by FasL-expressing T -cells. The 
apoptotic process activated in immature B lymphocytes following BCR ligation has
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been suggested to be Fas-independent. Evidence for this (80) comes from studies 
showing FasL is expressed at low levels on the WEHI-231 cell line, which is widely 
used in the study of negative selection of B lymphocytes, and that these cells do not 
appear to upregulate FasL mRNA when activated via their BCR.
Over the years much progress has been made in determining the mechanisms of 
BCR-induced cell death in immature B lymphocytes. However, early studies using 
primaiy cell-cultures proved difficult to work with. This was because murine primary 
immature B cells are relatively difficult to purify in large numbers because of low yields 
per animal, but also because these cells are largely resistant to long-term culture in vitro 
(81). The introduction of immortalised cell-lines has helped resolve this problem. In 
particular, the study of BCR-induced cell death in immature primary B lymphocytes has 
been helped to a large extent by the murine B lymphoma cell line, WEHI-231 which has 
proved a popular model for the study of the biochemical and molecular mechanisms 
underlying immature B lymphocyte cell death.
3.2 The WEHI-231 B cell lymphoma: a cell line model for immature B 
cell selection.
The murine B cell lymphoma cell line WEHI-231 is used as a model for 
immature B lymphocyte clonal deletion because it has a cell surface phenotype of an 
immature B lymphocyte (mlgM^, mIgD FcR’°'^ , Fas’°'^  and MHC class 11’°'^ ) and 
undergoes growth arrest and apoptosis following BCR ligation (54, 82, 83). In 
addition, co-ligation of CD40 can rescue these cells from apoptosis, although the 
biochemical and molecular mechanisms responsible for this are still unclear.
BCR-induced apoptosis in the WEHI-231 cell line has been shown to include 
the regulation of the c-myc oncogene, in addition to p53 and its transcriptional target 
gene a cyclin-dependent kinase (CDK) inhibitor. Overexpression of c-
myc is known to induce apoptosis in certain cell types. However, studies have shown 
that BCR-mediated apoptosis in WEHI-231 cells correlates with a decrease in c-myc 
mRNA and protein expression (84). This decline has been shown to result from 
decreases in the binding of NF-icB/rel to DNA, activity vital for maintaining c-myc 
levels and the prevention of cell death (23). Indeed, the transcription factor NF-kB has 
been shown to be important for B lymphocyte activation and development, and 
inhibition of NF-KB activity with protease inhibitors, which prevents receptor mediated 
breakdown of IkB, has been shown to induce apoptosis in a number of B lymphocyte 
cell lines (85). Other studies have shown that anti-CD40 stimulation is able to rescue 
WEHI-231 cells from apoptosis by inducing NF-kB activity, thereby maintaining c-
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myc RNA levels. This provides further evidence for the role of this transcription factor 
in regulating the fate of immature B lymphocytes (84).
Studies from the same group have also highlighted a role for the tumour- 
suppressor gene p53 in WEHI-231 cell death. p53 protein is known to play important 
roles in Gj to S-phase cell-cycle progression. Wu et. al. showed that anti-Ig treatment 
of WEHI-231 cells increased protein expression of both p53 and p21^^^’^ '^*’^  (23). 
Interestingly, is known to be a downstream transcriptional target for p53
and anti-Ig mediated increases in protein levels were delayed relative to
p53 increases. As p21 protein is known to convert active cyclin-dependent kinases into 
their inactive forms, increases in p21 protein levels following anti-Ig treatment may play 
an important role in the induction of growth-arrest in WEHI-231 cells.
Other effectors implicated in BCR mediated apoptosis in WEHI-231 cells 
include the caspases. Although the role of caspases in the negative selection of 
immature B lymphocytes has not been widely studied, a recent report indicates the role 
of caspase-7, but not caspase 2 or 3, in the induction of apoptosis in WEHI-231 cells 
following BCR-ligation (86). Interestingly, this report also suggested that BCR- 
mediated growth arrest was caspase-7 independent, which indicated that BCR-mediated 
growth arrest and apoptosis may be regulated by different biochemical pathways.
3.3 CD40.
Following antigen encounter, not all immature B lymphocytes undergo 
apoptosis. Consequently, some cells undergo receptor editing whilst some enter an 
anergic state. This may reflect the influence of additional, external, signals. One such 
signal that has been shown to play an important role in immature B lymphocyte 
signalling is that via CD40, which has been implicated in the rescue of these cells from 
apoptosis in the periphery due to T-cell dependent interactions. Therefore, the ability of 
immature B cells to respond to T-cell derived signals may induce the recruitment of 
antigen-reactive immature B cells into an ongoing immune response where T-cell help is 
already triggered. Thus, if only antigen triggered T cells are recruited into this scenario, 
and the interaction between immature B cell and T cell are antigen dependent, then 
autoimmune reactions should not develop. This risk is further reduced because T cell 
selection is much more vigorously regulated in T cells than in B cells. Therefore the 
chance of a self-reactive T cell recruiting and driving the proliferation of immature B 
cells is very slim.
Although the ability of CD40 to rescue both immature B lymphocytes from 
BCR-mediated apoptosis (8, 83, 87) and prevent the spontaneous death of germinal- 
centre cells is well documented the signalling pathways employed by CD40 ligation in 
these situations are not.
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One group of molecules that has attracted attention in this field is the Bel family 
of proteins. In particular, studies have highlighted the role of the anti-apoptotic protein 
Bcl-x^. Studies by Choi et. a l (83) showed the ability of CD40 ligation to up-regulate 
the expression of Bcl-x^ protein in the WEHI-231 cell line within just 6 hours (also 
reviewed by Craxton et. a l (17)). In addition to new protein production (Bcl-xJ, anti- 
CD40 mediated rescue from BCR-induced growth-arrest/apoptosis has been shown to 
overcome other BCR-induced signalling events. For example, anti-CD40 treatment 
prevents BCR-mediated increases in the cyclin-dependent kinase inhibitor 
(Craxton et. a/. (17)) and subsequent decrease in Cdk2 activity which is required for cell 
cycle progression in the late Gj phase.
3.4 Aims of project.
The aims of this research project are to further elucidate the signalling pathways 
activated in immature B lymphocyte apoptosis. In addition, further studies aim to 
identify proximal signalling pathways activated by CD40 ligation and how these prevent 
BCR-mediated apoptosis.
This chapter aims to characterise the biology of BCR-induced growth-arrest and 
apoptosis in the WEHI-231 cell line model. In particular, it aims to address:
1. the kinetics of BCR-mediated signalling events and the ability of co­
treatment with anti-CD40 to overcome these inhibitory signals.
2. the morphological events associated with the induction of growth-
arrest/apoptosis including cell size and granularity and how co-stimulation 
with anti-CD40 can modulate these events.
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3.5 Results.
3.5.1 Ligation of the BCR on WEHI-231 cells induces growth-arrest.
Treatment of WEHI-231 immature B lymphocytes with Fab^’ fragments of 
anti-Ig antibodies (anti-Ig) is known to inhibit DNA synthesis and induce apoptosis 
(88). As shown in figure 15A, treatment of WEHI-231 cells with anti-Ig causes a 
dose-dependent increase in growth arrest, with a 50% decrease in DNA synthesis 
occurring at a concentration between 0.01 and 0.1 pg/ml. In addition, co-stimulation 
of WEHI-231 cells with anti-CD40 is known to reverse anti-Ig mediated growth arrest 
(83). Therefore, figure 15A also shows that co-stimulation with anti-CD40 restores 
DNA synthesis levels, measured by thymidine uptake, back to basal levels. Figure 
15B shows that anti-CD40 co-stimulation rescues WEHI-231 cells from anti-Ig 
mediated growth arrest in a dose-dependent manner, with maximal effects observed at a 
concentration of 10 pg/ml.
3.5.2 Fas-mediated growth-arrest and apoptosis.
In addition to examining the effect of BCR ligation on DNA synthesis, the susceptibility 
of WEHI-231 cells to other agents was also examined. Both TNF-a and Fas are 
known to induce growth-arrest and apoptosis in a wide range of cells types including 
human cancer cell lines (HeLa) or T lymphocytes (Jurkat). Previous studies have 
shown splenic B lymphocytes and immature B lymphoma cells lines to be resistant to 
anti-Fas induced apoptosis (80), yet the former is sensitive to T-cell mediated FasL- 
induced death. In addition, recent reports (89) have suggested that transitional B 
lymphocytes may be susceptible to Fas-mediated cell death subsequent to signalling via 
the BCR. We therefore investigated the effect of anti-Fas stimulation, or TNF-a 
treatment, to examine whether WEHI-231 cells may actually represent a late-immature 
or transitional B lymphocyte phenotype. The results obtained (figure 16A) confirm 
that the growth-arrest inducing pathway activated by FasiFasL interactions in many T 
lymphocytes is not functional in WEHI-231 cells. Indeed, treatment of WEHI-231 
cells with anti-Fas antibodies appeared to induce a slight proliferative response relative 
to control cells. Treatment with recombinant TNF-a caused no change in DNA 
synthesis levels relative to control cells indicating that TNF-a plays no role in WEHI- 
23 1 growth-arrest mechanisms, results consistent with data from Scott et. al. (80). 
However, anti-Fas treatment does induce an apoptotic response in WEHI-231 cells 
(figure 16B) suggesting that WEHI-231 express the necessary machinery required for 
Fas-mediated cell death. Although the ability of Fas to induce apoptosis, but not
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growth arrest would appear contradictory, these results may reflect that anti-Fas 
stimulation only results in the death of a particular population of WEHI-231 cells. This 
may mimic the ability of Fas to only induce apoptosis in cells that have been “primed” 
for Fas-mediated cell death. Indeed, Fas stimulation of “un-primed” may be 
proliferative in nature. Therefore the slight increase in proliferation of anti-Fas treated 
cells, compared to control cells, may result from the balance between apoptosis and the 
induction of proliferative signals.
3.5.3 Kinetics of anti-lg-mediated growth arrest and CD40-mediated 
rescue.
As previous studies (8) have suggested that the negative signals generated 
following BCR-ligation in immature B lymphocytes progress in an ordered kinetic 
manner, we decided to examine the kinetics of both growth-arrest induction and rescue 
from this by co-stimulation with anti-CD40. Whilst cells stimulated with anti-Ig for the 
whole 48 hours showed, as expected, almost complete growth arrest, those stimulated 
for only the last 24 hours also showed high (approximately 70%) levels of growth 
arrest (figure 17A). Interestingly, stimulation of cells with anti-Ig for the last 1- 6 
hours of culture was sufficient to cause some 30% reduction in DNA synthesis. These 
results indicate that early BCR-mediated signals are sufficient to induce a substantial 
commitment to growth arrest which are confirmed/enhanced by one or more additional 
late (6-24 hours) signals mediated by BCR ligation.
Interestingly, the kinetic pattern of these results correlate with recent findings 
within our group (Katz et al. Journal of Immunology - in press). These studies show 
that BCR-ligation of WEHI-231 cells promotes the induction of an early (within 5 
hours), but substantial, decrease in mitochondrial transmembrane potential, 
followed by a profound dissipation of A\|/^ which was maximal by 20-24 hours. In 
contrast, mature splenic B cells, which proliferate rather than undergo apoptosis 
following BCR-ligation, did not exhibit this decrease in A\|/m within 5 or 24 hours. In 
addition, BCR-ligation was also shown to induce a decrease in cellular ATP which 
occurred after the onset of mitochondrial membrane disruption suggesting that ATP 
depletion resulting from mitochondrial disruption may play a role in BCR-mediated 
growth arrest/apoptosis in WEHI-231 cells.
In addition, and consistent with other findings (87) we found that anti-CD40 
could mediate strong rescue signals even when added up to 8 hours post anti-Ig 
ligation, suggesting that CD40-ligation can effectively rescue cells that have already 
initiated growth-arrest promoting signals (figure 17B) Interestingly, further findings 
within our group (Katz et. al. Journal of Immunology - in press) have shown that
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costimulation with anti-CD40 acts to stabilise (albeit at an intermediate A\|/^ ) and 
prevent the profound dissipation of A\|/^ observed in anti-Ig-treated cells over a 24 hour 
period. These results suggest that BCR-mediated decreases in mitochondrial 
transmembrane potential may be reversible and can be stabilised by costimulation with 
anti-CD40.
3.5.4 Ligation of the BCR in WEHI-231 cells induces apoptosis.
The above experiments (figures 15A and 17A) confirmed that BCR-ligation 
induced growth-arrest in WEHI-231 cells, a process that could be reversed by co­
stimulation with anti-CD40. However, these studies give no indication as to the levels 
of apoptosis induced by these agents. We therefore measured apoptosis by determining 
the number of cells within a certain population that expressed sub-diploid DNA 
measured by FACS analysis using the DNA-binding dye propidium iodide (PI).
Figure 18 shows the effect of BCR-ligation and also co-stimulation with anti-CD40 
on WEHI-231 cells. The results confirm the ability of WEHI-231 cells to readily 
undergo apoptosis following BCR-ligation. This phenomenon was also shown to be 
dose-dependent with 10 |Lig/ml anti-Ig inducing maximal apoptosis. In addition, they 
also confirm the ability of co-treatment with anti-CD40 antibodies to reverse anti-Ig 
mediated apoptosis (figure 18). Cells were also treated with a combination of anti-Ig 
plus the glucocorticoid, dexamethasone (figure 18), which is known to induce a 
strong apoptotic response as a positive control for the assay.
The kinetics of induction of apoptosis in WEHI-231 cells following BCR- 
ligation has been shown in a number of reports. Studies by Bras et. al. (86) have 
shown that 24 hours post anti-Ig treatment WEHI-231 cells enter a state of growth 
arrest with increased numbers of cells in G/G^. However, by 48 hours, a large 
proportion (approximately 30%) of the cells are apoptotic. These results are similar to 
findings in our own group (Caroline Lord; unpublished observations) and indicate that 
the induction of apoptosis in WEHI-231 may require prior G^  arrest.
3.5.5 Cell Division Analysis of WEHI-231 cells.
To investigate whether co-stimulation of anti-Ig treated cells with anti-CD40 
treatment of WEHI-231 cells restores basal proliferation or promotes increased cell 
proliferation of a subset of WEHI-231 cells, we quantified the number of cell divisions 
under-taken by cells following stimulation by use of the cell-permeable dye CFSE. 
Initial observations indicated that cell cycle progression, measured by the number of 
total cell divisions relative to untreated/basal (control) cells, varied according to cell
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treatment (figure 19). Compared to control cells, anti-Ig stimulation was shown to 
increase the number of cells entering four or five rounds of cell division whilst blocking 
those entering a sixth. In comparison, and in agreement with previous data (figure 
ISA), cell division analysis indicated that anti-CD40 co-stimulation could release anti- 
Ig treated cells from growth arrest restoring levels of cell division to that of untreated 
(basal) cells.
3.5.6 Rescue from BCR-induced apoptosis in WEHI-231 cells by anti- 
CD40 co-stimulation is accompanied by morphological changes in the 
cell population.
Morphological changes associated with the induction of DNA synthesis and 
apoptosis were also examined. Untreated (control) WEHI-231 cells grow, in culture, 
in close proximity to each other, forming either a loose monolayer on the flask/plate 
floor (figure 20A) or as large clumps of cells in suspension in the media. However, 
ligation of the BCR, causes clear morphological changes in the cell population with 
some cells forming small, distinct clumps whilst others clearly undergo apoptosis and 
its associated morphological events such as membrane blebbing. In stark contrast, co­
treatment of anti-Ig treated cells with anti-CD40 causes substantial morphological 
changes in the cell population. Associated with both the rescue from growth-arrest 
(figure 15A) and apoptosis (figure 18) is a large increase in cell-cell contact, with 
the formation of large near spherical clumps of cells.
In addition to gross morphological changes to the whole cell population, BCR- 
ligation and/or co-stimulation resulted in changes in cell size at the single cell level. The 
induction of apoptosis by BCR-ligation was shown to correlate with a reduction in cell 
size. Figure 20B shows the effect of BCR-ligation on cell size (PCS) and granularity 
(SSC) measured by FACs analysis. Untreated cells can be divided into two 
populations, a substantial population of large, relatively non-granular cells and a lesser 
population of smaller, yet equally granular cells. However, upon BCR-ligation, the 
balance of these populations shifts towards the smaller sized cells, whilst anti-CD40 co­
stimulation restores the balance back to the population of cells that are large in size.
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3.6 Discussion.
The results obtained in this chapter not only confirm the WEHI-231 cell line to 
be a viable model for the study of both BCR-mediated growth-arrest and apoptosis but 
also as a model for the examination of CD40-mediated rescue from growth-arrest and 
apoptosis. How CD40 functions in vivo in the protection of immature B lymphocytes 
remains unclear. CD40 has similarly been shown to play an important role in the 
prevention of spontaneous apoptosis of isolated germinal centre B cells (78), which 
may play important roles in the development of high-affinity antibody generating 
memory B cells. The role of CD40 in re-directing immature B cell fate, like that of GC 
B cells, is likely to occur in the periphery and not the bone marrow. Indeed, it has been 
suggested that CD40 expressed on activated T cells rescues the deletion of antigen- 
reactive cells re-programming them towards a proliferative response. This would have 
the effect of recmiting antigen-specific immature B cells into a immune response where 
T cell help already exists (8).
In addition to reversing anti-Ig mediated death signals, the results in this section 
suggest that anti-CD40 stimulation promotes cell-cell contact resulting in cell clumping. 
These observations are similar to another study in which anti-CD40 treatment resulted 
in cellular clumping in addition to rescue from apoptosis. Results from Sumimoto et. 
al. (90) using the human B lymphoma cell line, DND-39, described an associated 
increase in cell aggregation during rescue from BCR-mediated apoptosis by anti-CD40 
antibody co-stimulation. These increases in cell aggregation were thought to be due to 
the ability of anti-CD40 antibodies to activate the adhesive functions of LFA-l/ICAM-1 
and disruption of cell adhesion by co-treatment with anti-LFA-1 and anti-ICAM-1 
antibodies prevented the rescue of cells from apoptosis. Whether CD40-induced 
increases in cell-cell contact are responsible for mediating some of anti-CD40’s anti- 
apoptotic properties in WEHI-231 cells is still unclear.
We have also shown that the kinetic length of antigen exposure can determine 
the level of commitment into growth arrest. Consequently, we have also shown that 
where we appear to get a final commitment of cells into growth arrest, then this appears 
to be the final time point where these cells can be effectively rescued by anti-CD40 
treatment (figures 17A and 17B). The progression of anti-Ig stimulated immature B 
lymphocytes through a series of “temporal windows” resulting, finally, in the induction 
of apoptosis has also been described in other reports (8). This orderly progression 
through initiation of an apoptotic programme, followed by a delay in which the fate of 
the cell can be re-directed is believed to allow external signals such as those delivered 
through CD40 to redirect the fate of the cell. Additionally, this “temporal window” is 
believed to allow self-reactive immature B lymphocytes time to initiate receptor editing
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in order for them to alter their receptor specificity and re-enter the B lymphocyte pool 
before further maturation. However, failure to successfully rearrange their BCR, or 
receive external help, will ultimately result in deletion of these cells from the B 
lymphocyte pool. The ability of WEHI-231 cells to develop through similar “temporal 
windows” in which short term BCR-ligation initiates a negative signal, which, if no 
additional signal is forth-coming (anti-CD40), ultimately leads to cell death confirm that 
this cell line represents a good model for the study of immature B lymphocyte deletion 
or activation. Dissection of the biochemical and molecular events at these stages would 
allow for a greater understanding of immature B cells biology and the development of 
immunocompetent mature B lymphocytes in the periphery.
As previous results have suggested, the kinetics of commitment to growth-arrest 
correlate with decreases in the mitochondrial membrane potential observed in WEHI- 
231 cells following BCR-ligation. Previous studies (53) have suggested a role for 
cytosolic PLAj in the induction of apoptosis in WEHI-231 cells. Interestingly, recent 
work in our group (Katz et. al. Journal of Immunology - in press) has shown the 
collapse of A\\f^ can be mimicked by addition of exogenous arachidonic acid (AA), the 
product of cytosolic PLA^ activity. These results suggest that BCR-mediated induction 
of cytosolic PLA2 activity and generation of arachidonic acid may play a key role in the 
collapse of A\|/^ and commitment to apoptosis in WEHI-231 immature B cells. Indeed, 
these studies also indicated that BCR-ligation induced the translocation of cytosolic 
PLA2 to the mitochondria which was reversed with co-stimulation with anti-CD40.
Therefore, the observation that even short exposures to anti-Ig are capable of 
inducing moderate levels of growth-arrest (figure 17A) may reflect the ability of 
BCR-ligation to induce a rapid (1-5 hours) decrease in A\j/  ^via cytosolic PLA^ 
activation. Furthermore, longer incubations (8-24 hour) incubations with anti-Ig 
(figure 17A), which commit the majority of cells to growth-arrest, were seen to 
correlate with a later, more pronounced decrease in A\|/^ (Katz et. al. Journal of 
Immunology - in press) and leakage of ATP suggesting that the greater the decrease in 
A\|/ ,^ the greater the level of commitment to growth-arrest/apoptosis. The ability of 
anti-CD40 co-stimulation to rescue WEHI-231 cells from BCR-induced growth-arrest 
up to approximately 8 hours post anti-Ig treatment (figure 17B) suggests that the 
early decrease in A\\f^ mediated by BCR-ligation is reversible and is stabilised by anti- 
CD40 co-stimulation. However, if the A\j/  ^is allowed to drop below a critical 
threshold before CD40 co-stimulation is received, then the ability to stabilise A\|/^ and 
restore depleted ATP levels may be lost, and hence account for the inability of late (>8 
hour) anti-CD40 additions to rescue anti-Ig treated cells from growth arrest. The 
signalling pathways utilised by CD40 under these conditions are not known and 
warrant further investigation.
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As described above, studies within our group have suggested a key role for 
cytosolic PLA2 in mediating BCR-induced death signals in WEHI-231 cells. However, 
the signalling cascades utilised by the BCR in the induction of cytosolic PLA2 activity 
and hence cell death are still unknown. Activation of cytosolic PLAg is known to 
require upstream input from calcium and also MAPkinase activity. Therefore, we have 
investigated the ability of BCR-ligation to modulate MAPkinase activity in order to 
determine if MAPkinase signalling in immature B lymphocyte plays a role in the 
induction of death signals.
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Figure 15. Anti-Ig treatment causes growth arrest in WEHI-231 cells.
A. WEHI-231 cells (lOVwell) were cultured in the presence of various concentrations 
of anti-Ig, or, for the combination of both anti-Ig and anti-CD40 (both at 10 jULg/ml). 
Proliferation was assessed by measuring pHJthymidine uptake at 48 hours. Values are 
the means ± SD of quadruplicate wells. B. WEHI-231 cells (lOVwell) were cultured 
in the presence of anti-Ig (10 |ig/ml) with or without increasing doses of anti-CD40 
(0.1-10 |ig/ml). Proliferation was assessed by measuring pH]thymidine uptake at 48 
hours. Values are the means ± SD of quadruplicate wells.
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Figure 16. Neither Fas or TNF-a induce growth arrest in WEHI-231 
ce lls .
A. WEHI-231 cells (lOVwell) were cultured in the presence or absence of anti-Ig (10 
pg/ml), anti-CD40 (10 |ig/ml), anti-Fas (1 | L i g / m l )  or TNF-a (1 ng/ml). Proliferation 
was assessed by measuring [^HJthymidine uptake at 48 hours. Values are the means ± 
SD of quadruplicate wells. B. WEHI-231 (5xlOVml) were cultured in the presence or 
absence of anti-Ig (1 fig/ml) or anti-Fas (1 p.g/ml). Levels of apoptosis were 
determined by merocyanine binding and FACS analysis after 48 hours as described in 
Materials and Methods.
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Figure 17. Kinetics of anti-Ig mediated growth arrest and CD40- 
mediated rescue. A, WEHI-231 cells (lOVwell) were cultured for the indicated time 
periods in the presence of 10 p.g/ml anti-Ig. Proliferation was assessed by measuring 
[■^H]thymidine uptake at 48 hours. Values shown are means ± SD of quadruplicate 
wells. B, WEHI-231 cells (lOVwell) were incubated with anti-Ig (10|Xg/ml). anti- 
CD40 (lOjig/ml) was added at the indicated time periods post anti-Ig treatment. 
Proliferation was assessed by measuring [^H]thymidine uptake at 48 hours. Values 
shown are means ± SD of quadruplicate wells.
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Figure 18. Anti-Ig treatment causes apoptosis in WEHI-231 cells which 
is reversed by co-treatment with anti-CD40 antibodies.
WEHI-231 (SxlOVml) were cultured in the presence or absence of anti-Ig at 10 |ig/ml, 
anti-CD40 at 10 jLig/ml or dexamethasone at 1 |LiM. Levels of apoptosis were 
determined by PI staining and FACS analysis after 48 hours as described in Materials 
and Methods.
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Figure 19. BCR ligation suppresses cell division in WEHI-231 cells.
WEHI-231 cells were loaded with the cell permeable dye CFSE (2.5 |iM). Cells were 
then left untreated, or stimulated with combinations of anti-Ig and anti-CD40 (both 10 
jig/ml) for 48 hours. Cells were then harvested, washed and analysed by FACS for the 
fluorescence intensity of CFSE, which gives an indication of the number cell divisions 
per population for each stimulation.
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Figure 20. Morphological changes in WEHI-231 cells undergoing 
apoptosis or rescue from apoptosis via anti-CD40 co-treatment.
A. WEHI-231 cells (SxlOVml) were treated for 48 hours with medium only (control) 
(A), lOjag/ml anti-Ig (B), 10|ig/ml anti-Ig and 1{XM dexamethasone (C), or lOjig/ml of 
both anti-Ig and anti-CD40 . Magnification x200. B. WEHI-231 cells (SxlOVml) 
were treated for 48 hours with medium only (control), lOjXg/ml anti-Ig or 10|Lig/ml of 
both anti-Ig and anti-CD40. Cells were then examined by FACS analysis for size 
(ESC) plotted against granularity (SSC).
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CHAPTER 4 - Differential Role for MAPKinases in WEHI-231 cell 
apoptosis/survival. 
4.1 Overview of protein kinases.
Signal transduction cascades play important roles in the physiology of a wide 
range of cell types ranging from muscle cells to the cells of the immune system and can 
mediate signals leading to proliferation, differentiation or apoptosis. These signalling 
cascades are activated by the binding of a wide range of stimuli, including growth 
factors, hormones and cytokines to specific cell surface receptors. Upon surface 
receptor ligation, the signal is amplified by the utilisation of specific signalling 
cascades. These cascade mechanisms recruit a wide range of intracellular enzymes, 
each of which fulfil a specific role in the amplification of a particular physiological 
signal. Some of these enzymes are responsible for a wide range of post-translational 
modifications made to proteins which function to further amplify the signalling cascade.
Protein phosphorylation is perhaps the most well studied of the post- 
translational modifications made to proteins in signalling. The addition of a phosphate 
group to a specific amino acid is carried out by a family of enzymes called protein 
kinases. The alcoholic groups of serine and threonine as well as the phenolic group of 
tyrosine provide the major phosphorylation-sites for many of these kinases (91). 
Although many families of protein kinases have been discovered, protein kinases can be 
assigned to one of three groups, depending on the specificity of their amino acid 
substrates. Consequently, protein kinases can either be classified as serine/threonine 
(Ser/Thr) kinases, tyrosine (Tyr) kinases, or perhaps the most interesting, dual 
specificity kinases. Dual specificity kinases can phosphoiylate both Ser/Thr as well as 
Tyr residues and are known to play central roles in the regulation of cell fate.
Following the activation of a signalling cascade by cell surface receptor ligation, these 
three families of protein kinases are known to act in signalling modules to both 
communicate and amplify these signals.
4.2 MAPKinase family.
The MAPKinase family of protein kinases are activated under a wide range of 
physiological stimuli and have central roles in a wide range of cellular responses 
including proliferation and cell death. One fascinating aspect of MAPKinase signalling 
is the ability of these protein kinases to regulate different biological mechanisms within 
the same cell. Perhaps the clearest example of this phenomenon occurs in the PC 12 
neuronal cell line. These cells have been shown to differentiate into neurons or undergo 
proliferation depending on whether the ERK-MAPKinase family is activated by nerve
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growth factor (NGF) or epidermal growth factor (EGF) respectively (92). The 
regulation of these differential responses has been suggested to be due to the activation 
of distinct sets of transcription factors. However, recent studies have also suggested 
the manner of MAPKinase activation in PCI2 cells to have profound effects on the 
overall biological outcome of cell stimulation (42) in that transient Ras-dependent 
MAPKinase activation results in proliferation, whilst sustained Rap 1-dependent 
MAPKinase activation induces differentiation.
Presently, there are three known MAPKinase families. These include the 
classical ERK-MAPKinase family (extracellular signal-regulated kinases), the c-Jun N- 
terminal kinases (JNK), also known as the stress-activated protein kinases (SAPKs) 
and finally, the p38 MAPKinases (93). The regulation and activation of these different 
MAPKinase families is due to distinct upstream MAPKinase kinases (MEKs), which 
lead to dual phosphorylation on both a tyrosine and threonine residue in a threonine-X- 
tyrosine activation motif. Each family of the MAPKinase group is activated by specific 
MEKs allowing independent activation and regulation following cell stimulation. ERK- 
MAPKinase, JNK and p38 MAPKinases are known to phosphorylate different sets of 
transcription factors (figure 21). These include the transcription factors Elk-1 and c- 
Myc activated by ERK-MAPKinase MAPKinase, c-Jun and ATF-2 by JNK, and ATF- 
2 and MAX by p38 MAPKinase (93). Previous work on U937 human monoblastic 
leukaemia cells (94) has suggested that the balance between the ERK-MAPKinase and 
the stress-activated protein kinases (SAPKs) was an important factor in determining cell 
fate suggesting that the pattern of transcription factor activation and hence new mRNA 
and protein production may play key roles in determining cell fate.
In a typical MAPKinase signalling module, the kinase-core consists of a 
minimum of three kinases (91) (95), an upstream Ser/Thr kinase, a middle dual 
specificity kinase and a downstream Ser/Thr kinase. Perhaps the most well known, 
and documented mammalian example of this consists of the Raf-MAPKinase cascade. 
This signalling cascade is common to many cell types and is activated by many cell 
surface receptors including the EGFR (figure 22). In order to initiate the signalling 
cascade, the effector molecule. She, is recruited to the cytoplasmic tail of the receptor 
molecule. The molecule She is then phosphorylated which allows it to interact with the 
adaptor molecule, Grb2, through its SH2 (tyrosine-binding) domains. This allows 
Grb2 to recruit the Ras guanine nucleotide exchange factor SOS (SH3 domain 
interaction) to the complex which coverts Ras from its GDP-bound inactive form, into 
its active GTP-bound form (96). Ras is then converted into its active, GTP-bound, 
state and facilitates the translocation of the Ser/Thr kinase Raf-1 to the plasma 
membrane, where it associates with and is activated by Ras. Active Raf-1, 
subsequently, activates the dual-specificity kinase MEKl (MAPKinase-kinase 1) and 
MEK2 (MAPkinase-kinase 2) through the phosphorylation of Ser^ '^ ^^ ^^  and Ser^ '^
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residues. MEKl and MEK2 then proceed to activate ERKl (p44) and ERK2 (p42) 
MAPK, respectively, on specific Thr^ ®^  and Tyr °^  ^residues within a characteristic TP Y 
motif. Activated ERK-MAPKinase has been shown to act on a wide range of 
downstream molecules, including cytoplasmic molecules such as cPLA^ (53) and 
nuclear factors such as Elk-1 and c-Myc (97).
In addition to regulatory control by specific upstream MEKs, the MAPKinase 
family of enzymes are also under the control of a wide range of other signalling 
intermediates. This is particularly true for the ERK-MAPKinase family. Over the past 
5-10 years a wealth of literature has arisen highlighting the importance of molecules 
such as PKC, PI(3)K, GTPase-activating proteins, adaptor proteins and phosphatases 
in the regulation of ERK-MAPKinase activation or inactivation.
4.3 Role of MAPKinases in lymphocyte signalling.
BCR-mediated activation of ERK-MAPKinase is well documented (93, 97, 98). 
These studies also show that the BCR is coupled to ERK-MAPKinase activation at 
different developmental stages of B lymphocyte development. Together, these studies 
suggest that ERK-MAPKinase may be involved in different cellular responses at 
distinct stages of B lymphocyte development such as cell proliferation or death. Studies 
using the chicken DT40 B cell line (reviewed in (36)) have also shown that BCR- 
mediated ERK-MAPKinase activation is under the control of a number of signalling 
pathways including those regulated by PKC or She. Figure 23 (adapted from (36)) 
shows current models leading to ERK-MAPKinase activation following BCR-ligation.
In addition to ERK-MAPKinase, the role of the other members of the 
MAPKinase family following BCR-ligation have also been closely studied. Indeed, 
studies by Graves et. al. (99) have indicated that JNK and p38 MAPKinases, but not 
ERK-MAPKinase, are downstream targets in BCR-mediated cell death in the human 
B 102 immature B cell line. Other groups have also shown the activation of both JNK 
and p38 MAPKinase in both mature splenic B lymphocytes and also in the immature 
WEHI-231 B cell line following BCR crosslinking. However, because BCR-ligation 
in these cell types brings about different cellular responses, proliferation and cell death 
respectively, it is difficult to draw conclusions concerning their precise roles in BCR 
signalling.
In addition to BCR ligation, the MAPKinase families have also been shown to 
be activated in B lymphocytes following CD40 ligation (93, 97, 100). Since it is well 
known that CD40 ligation can rescue immature B lymphocytes from BCR-mediated cell 
death, the MAPKinase family may play a key role in this phenomenon. In addition, 
papers by Berberich et. al. and Sutherland et. al. (93, 100) have suggested that BCR
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and CD40 ligation lead to different patterns of MAPKinase family activation suggesting 
that the overall balance of MAPKinase activation could determine B lymphocyte fate.
Moreover, although it has been shown that both BCR and CD40 ligation both 
lead to ERK-MAPKinase activation, it has been suggested that these receptors utilise 
different up-stream signalling pathways in this process. Purkerson et. al. (97) showed 
that, both BCR- and CD40- resulted in MEK activation in splenic B lymphocytes. Pre­
treatment of these cells with cholera toxin, an agent known to cause an increase in 
intracellular cAMP, was shown to abolish BCR-mediated ERK-MAPKinase activation, 
however, the same treatment had no effect on ERK activation following CD40 ligation. 
In addition, BCR-ligation, but not CD40-ligation, was shown to induce She 
phosphorylation and induce Raf-1 phosphorylation. This suggests that CD40-mediated 
activation of ERK-MAPKinase is PK-A insensitive and utilises a unidentified MEKK, 
rather than Raf-1, to regulate ERK-MAPKinase activity (figure 24). This study 
highlights the ability of different receptors to couple to MAPKinase pathways by the 
utilisation of distinct signalling pathways.
4.4 Aims of chapter.
This chapter aims to dissect the roles of the MAPKinases in the fate of WEHI- 
23 1 cells. In particular, it shall focus on:
1. the pattern of MAPKinase activation during BCR-induced growth arrest and 
apoptosis.
2. the signalling pathways involved in the coupling of the BCR to these MAPKinase 
pathways.
3. the role of the MAPKinases in CD40-mediated rescue in the WEHI-231 cell line and 
their kinetics of activation.
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4.5 Results.
4.5.1 BCR-ligation of WEHI-231 cells induces ERK-MAPKinase 
activation.
Treatment of WEHI-231 immature B lymphocytes with anti-Ig has previously 
been shown to inhibit DNA synthesis and induce apoptosis (figures 15A and 18).
In addition, previous work in our group has shown this may be due to the activation of 
an early cPLA^ pathway leading to AA generation (53). Interestingly, activation of this 
negative cPLA^ signal is known to require both calcium and MAPK activation. We 
therefore investigated whether BCR-ligation induced the activation of ERK-MAPKinase 
and whether this coupled the BCR to a PLA^-dependent apoptotic pathway. In order to 
determine if the ERK family of MAPKs was activated under these conditions, western 
blot analysis of activated ERK-MAPKinase was carried out on whole cell lysates from 
cells treated with anti-Ig at a concentration of 10 |Lig/ml as this concentration was 
previously shown to induce maximum growth-arrest in WEHI-231 cells. We chose to 
utilise one of the commercially available antibodies specific to the dually- 
phosphorylated form (active form) of p44 and p42 ERK-MAPKinase as an indication 
of ERK-MAPKinase activation. Anti-Ig (10 pg/ml) treatment resulted in the activation 
of ERK as early as 1 minute, with maximal ERK activity after 30 minutes (figure 
25A).
4.5.2 BCR ligation induces ERK-MAPKinase activation in a Ras- 
dependent manner only under conditions favourable to apoptosis.
Previous experiments (figure 15A) have shown that anti-Ig treatment induces 
growth-arrest in a dose-dependent manner in WEHI-231 cells. In addition, the 
experiment described above suggests that BCR-ligation induces the activation of an 
early ERK-MAPKinase signal. In order to confirm that ERK-MAPKinase activation 
was central to the induction of apoptosis, WEHI-231 cells were treated with increasing 
amounts of anti-Ig to examine under what conditions ERK-MAPKinase was activated 
(figure 25B).
In addition, studies were carried out to examine the induction of apoptosis in 
WEHI-231 cells treated with increasing concentrations of anti-Ig. Figure 26 shows 
that anti-Ig concentrations of 10 |Xg/ml are required to induce apoptosis in WEHI-231 
cells. These results indicate that ERK-MAPKinase activation correlates with the 
induction of apoptosis in WEHI-231 cells. Interestingly, these results also show that 
anti-Ig concentrations that induce growth-arrest need not necessarily lead to the
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activation of ERK-MAPKinase. These results suggest that the induction of growth 
arrest and apoptosis by BCR-ligation may be regulated by two distinct mechanisms.
Further studies were carried out to characterise the mechanisms of ERK- 
MAPKinase activation under these conditions. In order to determine if the BCR- 
mediated activation of ERK-MAPKinase was Ras-dependent, studies were carried out 
to examine the pattern of Ras activation under similar experimental conditions. These 
studies utilised the availability of glutathione-coupled Ras-RBD substrates, which bind 
selectively to active-GTP-bound Ras and not inactive-GDP-bound Ras. Therefore, the 
levels of activated Ras after cell stimulation can be assayed by the selective pull-down 
of active-Ras from whole-cell lysates as indicated by figure 25C. Ras activation was 
shown to precede the kinetics of anti-Ig mediated ERK-MAPKinase activation, 
indicating that the BCR utilises a Ras-dependent mode of ERK-MAPKinase activation. 
These results suggest that a Ras/ERK-MAPKinase may be coupled to the BCR under 
conditions that lead to the induction of apoptosis.
4.5.3 Inhibition of BCR-mediated ERK-MAPKinase activation reduces 
BCR-mediated apoptosis.
In order to address whether ERK-MAPKinase activated by the BCR was 
coupled to apoptotic pathways, we utilised the ERK-MAPKinase inhibitor U0126 to 
examine whether inhibition of ERK-MAPKinase activity could abolish BCR-induced 
apoptosis. This inhibitor blocks ERK-MAPKinase activation by preventing the 
catalytic activity of its upstream MAPKinase-kinase (MEK). Initial experiments 
confirmed the ability of U0126, and another ERK-MAPKinase inhibitor, PD98059, to 
inhibit the activity of ERK-MAPKinase in WEHI-231 cells stimulated with anti-Ig (10 
pg/ml) for 30 minutes (previously shown to strongly activate ERK-MAPKinase, 
figure 25A). As shown in figure 27A and 27B, PD98059 and U0126 were 
effective in the inhibiting ERK phosphorylation in both a time (pre-treatment prior to 
BCR ligation) and dose-dependent manner. Identical studies using the p38 MAPKinase 
inhibitor, SB203580, indicated that inhibition of p38 MAPKinase had no affect on the 
activation of early ERK-MAPKinase signals induced following BCR-ligation (figure 
31C). This was used as a specificity control for the inhibition of ERK-MAPKinase by 
PD98059 and U0126, but also indicates that p38 MAPKinase plays no role in the 
upstream regulation of ERK-MAPKinase activation in WEHI-231 cells.
We were therefore interested to examine whether inhibition of this early ERK- 
MAPKinase signal would prevent BCR-mediated apoptosis in WEHI-231 cells. 
WEHI-231 cells were pre-treated with different concentrations of U0126 for 1 or 2 
hours prior to cell stimulation. Cells were then left unstimulated, or stimulated with 
anti-Ig or a combination of anti-Ig and anti-CD40. Cell-cycle analysis experiments
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using propidium iodide incorporation was used as a measure of sub-diploid, or 
apoptotic cells. Unstimulated cells (figure 28A) were shown to have low levels of 
apoptotic cells which increased upon anti-Ig treatment (figure 28B) from 14.8% to 
28.9%. Co-treatment of anti-Ig treated cells with anti-CD40 substantially reduced 
BCR-induced apoptosis (figure 28C) whilst also reducing cells in Gj arrest and 
therefore driving cells into cell-cycle. Pre-treatment of WEHI-231 cells with different 
concentrations of U0126 caused no increases in either basal apoptosis or basal G1 
arrest compared to untreated (control) cells (figures 28 D-E). However, pre­
incubation with U0126 were shown to reduce anti-Ig mediated apoptosis (figures 28 
F-G). Similar results were obtained with both 1 and 2 hour pre-incubations, therefore 
only the results for the 2 hour pre-incubations are shown. In addition, another MEK 
inhibitor, PD98059 was also shown to reproducibly block BCR-induced apoptosis, but 
not as effectively as U0126.
Interestingly, these results also show that anti-Ig induced growth-arrest at the 
G,-phase of the cell-cycle appeared to be unaffected by pre-treatment of cells with either 
PD98059 or U0126 suggesting that BCR-ligation may induce the initiation of two quite 
distinct mechanisms, one apoptotic and one promoting growth-arrest whilst also 
suggesting that ERK-MAPKinase is necessary for cell growth.
These results confirm a negative regulatory role for ERK-MAPKinase following 
BCR ligation in WEHI-231 cells which may be linked to the induction of cPLA^ activity 
and AA generation as previously described (53).
4.5.4 Anti-CD40 stimulation does not induce ERK-MAPKinase 
activation, but does alter BCR-mediated ERK-MAPKinase activity.
Previous experiments have shown the ability of anti-CD40 stimulation to 
prevent BCR-mediated apoptosis in WEHI-231 cells. We therefore examined not only 
whether anti-CD40 stimulation induced ERK-MAPKinase activation, but also if it 
modulated BCR-mediated ERK-MAPKinase activation. In contrast to anti-Ig 
stimulation, anti-CD40 (10 pg/ml), which does not induce growth arrest or apoptosis, 
was shown to be ineffective in inducing ERK-MAPKinase activation (figure 29A). 
This is in contrast to another study (101) who reported early ERK activation following 
anti-CD40 stimulation in the same cell line. However, in our study we used antibodies 
to detect dually-phosphorylated ERK, which is known to be required for full activation 
of this enzyme. The study by Kashiwada et a l (101) detected increases in tyrosine 
phosphorylation only, and therefore may not reflect true activation of this enzyme.
However, anti-CD40 co-stimulation was shown to alter the kinetics of ERK- 
MAPKinase activation in anti-Ig treated WEHI-231 cells. Figure 29B shows that co­
treatment with CD40, known to prevent BCR-induced growth-aiTest and apoptosis,
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altered the kinetics of anti-Ig mediated ERK activation leading to an early peak at 5 
minutes, but strongly down-regulated ERK MAPKinase activation after this time 
period. Interestingly, Ras activity was also altered with anti-CD40 co-treatment 
(figure 29C) with similar kinetics to the activation of ERK-MAPKinase. This 
suggests that co-treatment with CD40 may rescue WEHI-231 cells from apoptosis by 
uncoupling the BCR from an early Ras/ERK-MAPKinase/cPLA^ pathway. Indeed, 
recent data from our lab has shown that CD40 co-stimulation can reduce BCR-mediated 
generation of A A in a dose-dependent manner (figure 30).
4.5.5 BCR ligation does not activate JNK or p38 MAPKinase in WEHI- 
231 cells.
In addition to examining the role of ERK-MAPKinase in BCR -mediated 
apoptosis, both JNK and p38 MAPKinases were also examined. Previous studies (93, 
102) have shown only weak activation of either p38 and JNK following BCR ligation. 
Both studies, however, examined enzyme activation with stimulation times lasting 10- 
15 minutes. We therefore decided to utilise phospho-specific antibodies to both p38 
MAPKinase and also the p46- and p54-isoforms of JNK, but examine their activity 
following BCR-ligation over a 60 minute period.
In contrast to the above studies by Salmon et. a l and Sutherland et. al no 
activation of either p38 or JNK MAPKinase could be detected (figures 31A and 
31B) following BCR-ligation. Therefore, because we were unable to detect p38 
MAPKinase activation, we wanted to verify that p38 MAPKinase was not involved in 
BCR-induced apoptosis. Subsequently, WEHI-231 cells were pre-incubated with the 
p38 MAPKinase inhibitor SB203580 90 minutes prior to anti-Ig stimulation. No 
significant decrease in either BCR-induced apoptosis or growth-arrest was noted 
(figures 32 G-I), data consistent with other studies (102) indicating that p38 
MAPKinase does not appear to play a role in BCR-mediated apoptosis of WEHI-231 
cells. Pre-incubation with SB203580 was also shown to be ineffective in reversing 
anti-CD40-mediated rescue from BCR-induced growth arrest and apoptosis (figures 
32 J-L). Cells only treated with 5 |xM SB203580 did show increases in apoptotoic 
cell numbers (42.0%) relative to untreated cells (27.3%) (figure 32F). Vehicle studies 
for this concentration (data not shown) produced similar levels of apoptosis to that 
found in untreated cells (30.8% as opposed to 27.3%) suggesting that p38 MAPKinase 
activity may play a role in the basal proliferation and survival of WEHI-231 cells. 
Parallel studies performed in macrophages confirmed that SB203580 was active as 
these results showed that pre-incubation with SB203580 blocked LPS-stimulated p38 
MAPKinase activation and production of IL-12 and NO (results not shown).
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No specific inhibitors for the JNK (S APK) MAPKinases are, at present, 
commercially available and therefore similar studies examining the role of JNK 
MAPKinase in BCR mediated apoptosis were not possible.
4.5.6 Anti-Ig treatment of WEHI-231 cells causes the long-term down- 
regulation of ERK-MAPKinase activity.
Apoptosis of WEHI-231 B cells resulting from ligation of the BCR cannot be 
detected until 24-48 hours post-treatment. In addition, results from figure 17A 
suggest that WEHI-231 cells require anti-Ig stimulation for periods greater than 8 hours 
to fully commit to growth-arrest. Thus, we decided to investigate the pattern of 
MAPKinase activation over a 48 hour time period. Interestingly, in untreated WEHI- 
231 cells, basal ERK-MAPKinase activity was observed, which appeared to follow a 
cyclic pattern over a 48 hour period (figure 33A). This may be linked to the 
suggested role of ERK MAPKinase in Gj cell-cycle progression (21). In contrast to 
this, BCR-ligation was shown to initiate an early transient activation of ERK 
MAPKinase, but abolished ERK-MAPKinase activation after this time point (figure 
33B).
Taken together, these results suggest that there may be a potential requirement 
for ERK-MAPKinase activity in the basal proliferation of WEHI-231 cells and that the 
removal of this signal, due to BCR-ligation, may be sufficient to induce growth arrest 
and/or apoptosis. In addition previous studies have also shown that BCR ligation 
initiates the activation of an early, ERK-MAPKinase dependent, apoptotic pathway 
(figures 25A and 28). These results suggest differential roles for ERK-MAPKinase 
in WEHI-231 signalling, with both proliferative and apoptotic properties.
4.5.7 Anti-CD40-induced rescue from growth arrest involves the re­
establishment of ERK-MAPKinase activity.
CD40 has previously been reported to be a very weak activator of ERK- 
MAPKinase in WEHI-231 cells and a potent activator of ERK-MAPKinase in mature B 
lymphocytes (93, 101). Our initial results would agree with previous reports in WEHI- 
231 cells. However, these studies have only analysed ERK-MAPKinase activation 
within 1 hr of anti-CD40 stimulation. Due to the proliferative nature of anti-CD40 
treatment in WEHI-231 cells we analysed ERK-MAPKinase activation in cells treated 
with anti-CD40 over the 48 hour time period required for rescue from anti-Ig induced 
apoptosis. As shown in figure 33D, anti-CD40 treatment appears to induce a late, yet 
sustained, cyclic activation of ERK-MAPKinase. Although the pattern of ERK- 
MAPKinase activity is similar to that of untreated proliferating cells, densitometric
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analysis indicates that anti-CD40 stimulation enhances ERK-MAPKinase activation 
relative to untreated cells.
Although the ability of CD40 to rescue WEHI-231 cells from anti-Ig-mediated 
growth arrest is well known, the precise signalling pathways involved are not. 
Previously (figure 33B) we showed that anti-Ig treatment caused the long-term 
downregulation of ERK-MAPKinase activation. Interestingly, treatment of cells with 
anti-Ig in combination with anti-CD40 treatment did not show any down-regulation of 
ERK-MAPKinase activation (figure 33C). Indeed, it appears that anti-CD40 
treatment can both re-establish and strengthen ERK-MAPKinase activation in WEHI- 
23 1 cells under conditions in which CD40 rescues mig-mediated growth arrest and 
apoptosis. This finding highlights a potential mechanism by which CD40 mediates it 
rescue signal.
4.5.8 Activation of p38 and JNK MAPKinases in long-term WEHI-231- 
231 stimulations.
In addition to examining MAPKinase activation under growth-arrest/apoptotic 
conditions as well as during CD40-mediated rescue, the activation kinetics of both p38 
MAPK and JNK MAPK were also examined. Interestingly, p38 MAPK was weakly 
activated (24-48 hours) during basal proliferation of WEHI-231 cells, but anti-Ig 
treatment did not appear to activate p38 MAPK over the whole time course (figures 
34A and 34B). Indeed, anti-Ig appeared to downregulate basal p38 MAPKinase 
activation. p38 MAPKinase was however, activated in a bi-phasic manner following 
co-treatment with anti-CD40 (figure 34C). This suggests a possible role for p38 
MAPK in the rescue of WEHI-231 cells from growth-arrest/apoptosis by CD40 
ligation, and interestingly, its kinetics of activation preceded that of ERK-MAPKinase 
in similarly stimulated samples. However, results obtained in figure 32 suggested 
that p38 MAPKinase does not play an essential role in CD40-mediated rescue. 
Therefore further studies have to done to address this issue. In contrast to p38 
MAPKinase JNK appeared to be weakly activated by anti-Ig treatment (figure 34D ). 
In contrast, no JNK activity could be detected in basal or anti-CD40 (either alone or in 
combination with anti-Ig)-treated cells suggesting, but as yet unconfirmed, that it may 
play a role in the induction of negative signalling pathways.
Additional studies were carried out to examine the activation of Rac and Cdc42, 
known upstream activators of JNK. These results indicated that neither of these 
molecules were activated in either basal; anti-Ig treated or anti-Ig and anti-CD40 treated 
cells sWoWi^*
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4.5.9 ERK activity contributes to the basal proliferation of WEHI-231 
cells, but does not appear to be involved in CD40-mediated rescue.
Due to the prolonged, but cyclic, activation of ERK-MAPKinase in untreated 
cells and the ability of CD40 stimulation to restore ERK-MAPKinase activity in BCR 
stimulated WEHI-231 cells, additional studies were carried out using the MEK 
inhibitors PD98059 and U0126 to confirm a role of ERK-MAPKinase in proliferative 
WEHI-231 cell responses. Initial studies suggested that ERK inhibition (PD98059) 
could weakly block basal proliferation of WEHI-231 cells (approximately 30% 
reduction in thymidine incorporation at 5 (XM, figure 35A). Vehicle studies 
confirmed this was not due to toxic effects of the PD98059 vehicle medium, suggesting 
a role for ERK-MAPKinase in the basal proliferation of WEHI-231 cells. However, 
pre-incubation with PD98059 was ineffective in reversing BCR-mediated growth-arrest 
(figure 35A). Interestingly, earlier studies (figure 28) confirmed that pre-incubation 
of anti-Ig treated cells with U0126, whilst effective in reversing BCR-mediated 
apoptosis, did not reverse BCR-mediated growth arrest, data consistent with the above 
results (figure 35A). This data is also consistent with other findings (figure 33B) 
which suggested that BCR-ligation down-regulated ERK-MAPKinase activity in 
WEHI-231 cells, confirming a positive role for ERK-MAPKinase in WEHI-231 cell 
proliferation.
To provide further evidence for a role of ERK-MAPKinase in WEHI-231 cell 
proliferation but not BCR-mediated growth arrest, a dose-response study was carried 
out comparing varying the concentrations of both anti-Ig and PD98059. Figure 35B 
shows that costimulation of non-growth arrest promoting concentrations of anti-Ig with 
PD98059 results in the induction of growth arrest in a dose-dependent manner. 
Interestingly, at higher anti-Ig concentrations, which themselves induce growth-arrest, 
the affect of co-stimulation with PD98059 was reduced. This suggests the ability of 
BCR-ligation to suppress ERK-MAPKinase activity has reached saturation at these 
higher anti-Ig concentrations. Further studies using U0126 suggested that this inhibitor 
could actually enhance anti-Ig mediated growth arrest (figure 36B). However, this is 
probably due a reduction in the levels of growth-arrest normally expected at higher (1- 
10 jxg/ml) anti-Ig concentrations in this particular experiment. This suggests that BCR- 
mediated suppression of basal ERK-MAPKinase activity may also be reduced, allowing 
U0126 to enhance growth-arrest even at anti-Ig concentrations where growth-arrest is 
normally at saturated levels.
The role of ERK-MAPKinase in CD40-mediated rescue of WEHI-231 cells was 
also examined. Pre-incubation of cells with increasing doses of PD98059 were only 
marginally effective in blocking rescue from growth-arrest following co-treatment with
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anti-CD40 (figure 35A). In addition to PD98059, the MEK inhibitor U0126 was 
applied in similar experiments. Like PD98059, U0126 was effective in inducing 
growth arrest in otherwise untreated cells (figure 36A). In addition, co-stimulation of 
anti-Ig and anti-CD40 treated cells with U0126 was capable of reversing CD40- 
mediated rescue from growth-arrest. Additional studies have shown that this reduction 
in DNA synthesis is not due to the inhibitor vehicle (results not shown) suggesting that 
ERK-MAPKinase inhibition is sufficient to block CD40-mediated rescue.
However, these results do confirm that ERK-MAPKinase plays an important 
role in WEHI-231 cell proliferation and, coupled to previous findings (figure 33C), 
suggests that CD40 stimulation plays an important role in restoring vital ERK- 
MAPKinase-dependent proliferative signals in WEHI-231 cells.
4.5.10 Prolonged ERK-MAPKinase inhibition can block basal 
proliferation and CD40-mediated rescue.
Previous results which utilised the MEK inhibitors, PD98059 and U0126, 
suggested that U0126 was more efficient in its ability to promote growth arrest in 
WEHI-231 cells. Therefore, we wanted to examine the efficacy of both MEK 
inhibitors in blocking ERK-MAPKinase activation especially over a 48 hour time 
period. Unstimulated WEHI-231 cells, which express a level of basal ERK- 
MAPKinase activity, were pre-incubated with either PD98059 (1 |xM) or UO126 (1 
|iM) and cultured for an additional 1, 6 or 24 hours before they were harvested and 
lysed. Our results indicated that whilst U0126 was effective in blocking early, basal, 
ERK-MAPKinase signals, both inhibitors were ineffective in blocking basal ERK- 
MAPKinase activity in long-term cultures (>12 hours) (results not shown).
In order to re-evaluate the role of ERK-MAPKinase in basal proliferation and 
CD40-mediated rescue from growth arrest cells were treated with PD98059 (1 jxM) and 
U0126 (1 |xM) or a combination of both. However, in order to overcome the instability 
of these two inhibitors, further doses were given every four hours of the stimulation, 
up to a total of 32 hours. Following a stimulation time of 48 hours both inhibitors were 
effective in inducing growth arrest of basal (untreated) cells as well as enhancing 
growth arrest from cell treated with anti-Ig alone. Both inhibitors were, in addition, 
effective in preventing CD40-mediated rescue from growth arrest (figure 37A). 
Interestingly, a combination of the two inhibitors, compared to each individually, 
appeared to enhance growth arrest under all stimulation conditions (figure 37B), 
although this probably reflects the different mechanisms used by these two inhibitors to 
suppress ERK-MAPKinase activity. PD98059 inhibits ERK-MAPKinase activation by 
binding to MEK and preventing its phosphorylation by Raf, conversely, U0126 blocks
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ERK-MAPKinase activation by directly inhibiting the catalytic activity of MEK. Our 
results are also similar to other studies which have shown that PD98059 was ineffective 
in the complete inhibition of ERK-MAPKinase, and the authors suggested this may be 
due to incomplete inhibition of MEK2, which possesses an ICgg 10-fold higher than 
MEKl for PD98059 (103). Moreover, lAoaU is equally effective on both MEKl and 
MEK 2. In addition, vehicle studies indicate that, at the concentrations of inhibitors 
used, no adverse effect on basal cells was apparent. These results suggest a role for 
ERK in both the basal proliferation of WEHI-231 cells and in the rescue of WEHI-231 
cells from anti-Ig mediated growth arrest by CD40, confirming earlier observations.
4.5.11 CD40-mediated activation of ERK protects WEHI-231 cells from  
anti-Ig induced growth arrest.
In order to determine if the results indicated in growth arrest studies (figure 
37B) were a consequence of apoptosis, DNA content levels were determined by FACS 
analysis utilising cell-cycle analysis by propidium iodide incorporation (table 1). 
Unstimulated cells showed cell-cycle profiles consistent with this cell type. However, 
prolonged ERK-MAPKinase inhibitor treatment (PD98059 and U0126 at IpM every 4 
hours) appeared to drive these cells into apoptosis to levels similar to anti-Ig treatment 
suggesting that deprivation of cycling ERK-MAPKinase activity results in cell death. 
Interestingly, whilst cells treated with a combination of both PD98059 and U0126 and 
anti-Ig, appeared to be rescued from apoptosis, they were driven strongly into growth 
arrest at G/G, again confirming that inhibition of an early ERK-MAPKinase signal can 
prevent BCR-mediated apoptosis.
Previous studies (figure 33D) have shown that anti-CD40 treatment of WEHI- 
231 cells can enhance ERK-MAPKinase activation in these cells. In addition anti-CD40 
treatment leads to [^H]thymidine incorporation to levels comparable with unstimulated 
basal cells (figures 37A and 37B). Analysis of the DNA content suggests that 
CD40 treatment may in some way alter the kinetics of cell-cycle progression, with more 
cells appearing in Gj/M phase as compared to unstimulated cells (table 1). CD40 
stimulation of WEHI-231 cells may therefore promote cell-cycle progression in WEHI- 
231 cells. These results suggest a potential role of ERK-MAPKinase in driving B 
lymphocyte proliferation following CD40 treatment. Indeed, prolonged ERK- 
MAPKinase inhibition of CD40-stimulated cells reduced the numbers of cells found in 
S and G^/M phases of the cell cycle whilst increasing percentages found in Gj. 
Interestingly, CD40 co-stimulation was shown to rescue cells from apoptosis induced 
by the inhibition of ERK-MAPKinase. These cells were however driven into Gj arrest 
(table 1) suggesting that CD40 stimulation generates ERK-MAPKinase independent 
rescue signals. Moreover, prolonged ERK-MAPKinase inhibition did not reverse
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CD40-mediated rescue from BCR-induced apoptosis, although these cells were still 
shown to be in Gj arrest (table 1). These results again suggest that CD40 delivers 
ERK-MAPKinase independent signals in the rescue of WEHI-231 cells from apoptosis, 
whilst ERK-MAPKinase is important for the proliferation of these cells.
We also examined the ability of prolonged ERK-MAPKinase inhibition to block 
cell division measured by CFSE labelling (figure 38). Our results indicated that 
prolonged ERK-MAPKinase inhibition resulted in a reduction in the number of 
unstimulated cells entering a sixth round of cell division, with increased cells 
undergoing four or five rounds of cell division before undergoing growth arrest. 
Interestingly, prolonged ERK-MAPKinase inhibition appeared to enhance BCR- 
induced growth arrest, with increasing numbers of cells undergoing only three or four 
rounds of cell division. Prolonged ERK-MAPKinase inhibition also reduced in the 
number of cell divisions in cells co-stimulated with anti-Ig and anti-CD40. These 
results confirm earlier observations that ERK-MAPKinase is important for the basal 
proliferation of WEHI-231 cells and represents a target of CD40 signalling in the rescue 
of WEHI-231 cells from BCR-induced growth arrest.
In summary, these results suggest that CD40 rescues cells from BCR-mediated 
growth-arrest by re-establishing an essential, ERK-MAPKinase-dependent, 
proliferative signal suppressed following BCR ligation, but also initiates an anti- 
apoptotic signalling cascade. In addition, these results suggest that whilst ERK- 
MAPKinase is essential for the proliferation and survival of basal cells, they are not 
essential for cell survival in the presence of rescue signals provided by CD40.
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4.6 Discussion.
It is well documented that BCR-ligation on WEHI-231 cells is a potent activator 
of ERK-MAPKinase (93). Whilst this may be true in the short term (0-60 minutes), 
which our data confirms, we have also shown that long-term BCR-ligation, under 
conditions which induce growth-arrest also results in the down-regulation of basal 
ERK-MAPKinase activity important for cell proliferation.
Studies in this chapter suggest that activation of an early (0-30 minute) ERK- 
MAPKinase signal correlates with the induction of apoptosis in WEHI-231 cells. 
Previous studies within our group have shown that BCR ligation of WEHI-231 cells 
also leads to the activation of cPLAj, which is MAPKinase dependent. Our results 
suggest that BCR -mediated ERK-MAPKinase activation, which appears to be Ras- 
dependent, may play a role in the induction of apoptosis in WEHI-231 cells by the 
activation of an apoptotic cPLA^ pathway. Indeed, studies have shown that inhibition 
of BCR-mediated ERK-MAPKinase activation, which prevents apoptosis, by using the 
ERK-MAPKinase inhibitors PD98059 or U0126 also reduces BCR-mediated activation 
of cPLAg activity (figure 39).
A role for ERK-MAPKinase in the induction of apoptotic mechanisms has also 
been reported in T-lymphocytes. However, in contrast to our studies where ERK- 
MAPKinase appears to link the BCR to the generation of apoptotic second messengers, 
ERK-MAPKinase activity in T lymphocytes has been reported to induce the expression 
of FasL (103, 104), allowing these cells to then undergo Fas-mediated cells death.
Although our results showed that BCR-mediated apoptosis of WEHI-231 cells 
can be reversed with co-stimulation with ERK-MAPKinase inhibitors, BCR-mediated 
growth-arrest remained intact. In addition, our studies indicate that ERK-MAPKinase 
follows a cyclic pattern of activation (presumably in response to serum- or autocrine 
factors) which may correlate with the reported ability of ERK-MAPKinase to drive cells 
through G, to the S phase of the cell cycle (21). We have also shown that inhibition of 
ERK-MAPKinase activity leads to growth-arrest in WEHI-231 cells confirming a role 
for ERK-MAPKinase in the basal proliferation of this cell line. Interestingly, BCR- 
ligation was shown to abolish ERK-MAPKinase activation in WEHI-231 cells after 
approximately 2-4 hours. This suggests a possible mechanism for the induction of 
BCR-mediated growth arrest in WEHI-231 cells. The ability of anti-CD40 co­
stimulation to rescue WEHI-231 cells from BCR-mediated growth arrest was also 
shown to mirror the re-establishment of basal ERK-MAPKinase activity suggesting that 
CD40 co-stimulation reverses the signal delivered by BCR-ligation switching off this 
proliferative signal.
Our studies therefore indicate that ERK-MAPKinase may induce differential 
physiological responses in WEHI-231 cells which is dependent on its time and possibly
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mode of activation. It appears that early ERK-MAPKinase signals (0-60 minutes) may 
induce, or precede, a “death signal” whilst late ERK-MAPKinase activation by CD40 
stimulation may be protective and either activate survival signals or down-regulate 
“death signals”.
In an attempt to dissect the role of differential, early and late, ERK-MAPKinase 
activities further studies were carried out to block the induction of these signals. 
Prolonged ERK-MAPKinase inhibition was shown to:
1. block basal proliferation and induce apoptosis in these cells.
2. block BCR-mediated apoptosis but not relieve growth arrest and finally,
3. block CD40-mediated rescue of BCR-induced growth arrest but not reverse 
CD40-mediated rescue from BCR-apoptosis (suggesting CD40-mediated 
rescue from apoptosis is partially ERK-MAPKinase independent).
These results confirm a role for ERK-MAPKinase as an essential proliferative 
signal in WEHI-231 cells and removal of this signal induces growth arrest and 
apoptosis. This is similar to the responses of PC 12 neuronal cells in which withdrawal 
of nerve-growth-factor (NGF) leads a reduction of ERK-MAPKinase activity and the 
induction of apoptosis (105). Additionally, inhibition of the early, BCR-stimulated 
ERK-MAPKinase signal has been shown to block apoptosis, yet these cells still remain 
at Gj arrest. This is presumably due to the inhibition of long-term, proliferative ERK- 
MAPKinase activity in WEHI-231 cells which we have also shown to be 
downregulated by BCR-ligation.
CD40 stimulation of WEHI-231 cells has been shown to upregulate the anti- 
apoptotic protein Bcl-x^ at both transcriptional and translational levels (17) and this has 
shown to play a key role in the rescue of WEHI-231 cells from BCR-mediated 
apoptosis (83). Although the signalling mechanisms required for the increase in Bcl-x^ 
expression following BCR-ligation are not known it, would be interesting to address 
whether they are ERK-MAPKinase independent or dependent. Additionally, Bcl-x^ has 
also been shown to inhibit the activation of cPLA^ in breast carcinoma cells (106). As 
cPLA^ has previously been implicated in BCR-mediated apoptosis in WEHI-231 cells it 
would be of interest to examine whether CD40-mediated increases in Bcl-x^ expression 
resulted in changes in cPLA^ activity. In addition to Bcl-x^, other molecules have been 
implicated in CD40 mediated rescue from BCR-induced apoptosis. In particular, a 
recent study has highlighted the role of another member of the Bcl-2 family, the anti- 
apoptotic protein A1 (107). Overexpression of this protein was shown to render 
WEHI-231 cells resistant to BCR-mediated apoptosis and CD40 stimulation was also 
shown to increase A1 RNA expression. However, the role of A1 in non-transfected
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WEHI-231 cells remains to be explored, and the molecular mechanisms leading to its 
expression and activation elucidated.
The results in this chapter describe a differential role for ERK-MAPKinase in 
mediating both apoptotic and proliferative responses in WEHI-231 cells. How these 
differential ERK signals regulate two distinct biological responses is still unclear, but 
may in some way be related to the ability of ERK to act in both cytosolic and nuclear 
compartments as suggested by other studies (101). Indeed we have preliminary results 
to suggest that CD40 stimulation enhances nuclear ERK-MAPKinase activity, whilst 
BCR-stimulation results in largely cytoplasmic ERK-MAPKinase activity, but also 
some nuclear ERK-MAPKinase activity. These results are similar to recent findings by 
Shirakata e t a l (108). Whether the enhanced nuclear activity of ERK-MAPKinase 
results from the translocation of activated, cytosolic ERK-MAPKinase to the nucleus 
remains to be determined. However, the role of nuclear ERK-MAPKinase activity 
induced by CD40-stimulation fits current models relating to increased transcription 
factor activation (for example NF-kB) and new protein synthesis.
In addition to ERK-MAPKinase our results suggest that JNK and p38 
MAPKinase may play roles in BCR-mediated apoptosis and CD40-mediated rescue 
respectively. However, both these signals appear to be very weak, and subsequently 
are difficult to examine by the use of inhibitors. Examination of these enzymes by in 
vitro kinase assay should help these sensitivity problems and help determine the pattern 
of activation of these enzymes under proliferative or apoptotic responses.
Currently however, our data suggests that p38 MAPKinase appears to be 
activated by CD40 with kinetics preceding that of ERK-MAPKinase. Utilisation of the 
p38 MAPKinase inhibitor, SB230580 however, suggests that p38 MAPKinase plays 
no apparent role in CD40-mediated rescue from growth-arrest and apoptosis, but does 
suggest that it may play a role in the basal proliferation of WEHI-231 cells. 
Interestingly, western blot analysis also detected low levels of p38 MAPKinase activity 
in untreated (basal) WEHI-231 cells (figure 34A).
In summary, the results obtained in this chapter indicate that ERK-MAPKinase 
can play differential roles in the biology of WEHI-231 immature B lymphocytes. Our 
results indicate that BCR-ligation leads to the activation of an ERK-MAPKinase- 
dependent apoptotic signal which is induced within 30 minutes of BCR-ligation. 
However, our results also indicate that ERK-MAPKinase plays an essential role in the 
proliferation of WEHI-231 cells. Interestingly, BCR-ligation appears to suppress this 
prolonged ERK-MAPKinase signal during the induction of growth-arrest, whilst 
CD40, which restores BCR-mediated growth arrest also re-establishes this ERK- 
MAPKinase signal. In addition we have also shown that CD40 stimulation appears to 
rescue WEHI-231 cells from BCR-mediated apoptosis by uncoupling ERK-
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MAPKinase from a cPLA^ dependent apoptotic signal, however, the role for an ERK- 
MAPKinase independent anti-apoptotic signal cannot be ruled out. Therefore we can 
begin to generate a model for the regulation of ERK-MAPKinase and the induction of 
apoptosis, growth-arrest and proliferation of WEHI-231 cells (figure 40).
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Figure 21. MAPKinase signalling cassettes utilise different upstream  
elements for their activation. Activation of the MAPKinase family of protein 
kinases results from the initiation of a signalling cascade. Each member of the 
MAPKinase family is activated by an upstream MEK (MAPK 2), which was itself 
activated by a MEKK (MAPK 3). These MEKKs and MEKs are specific for each 
family member of the MAPKinase family. However, extensive cross-talk mechanisms 
exist in MAPKinase mediated activation of transcription factors.
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Figure 22. EGFR-mediated activation of the Ras/Raf/MAPKinase 
signalling cascade. EGFR-ligation induces the rapid tyrosine phosphorylation of 
both She and BLNK/SLP-65 and an increase in the association of these molecules with 
the adaptor molecule Grb2 and Sos. Now Sos is recruited to the cell membrane, it 
directly activates Ras, which in-tum recruits and activates Raf-1 at the cell membrane. 
Raf-1 is then free to phosphorylate downstream MEKs which in turn phosphorylate 
their downstream substrates, the ERK-MAPKinases. Activated ERK-MAPKinase has 
both cytoplasmic and nuclear targets and its activity is tightly regulated post-activation 
by molecules such as phosphatases.
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Figure 23. Summary diagram showing mechanisms leading to ERK- 
MAPKinase activation following BCR-ligation. BCR-ligation leads to the 
activation of ERK-MAPKinase by the activation of multiple signalling pathways.
These include the classical Ras/Raf/MEK pathway regulated by the adaptor proteins She 
or BLNK, but also activation via DAG-sensitive PKC isoforms.
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Figure 24. Recent studies have shown that the BCR and CD40 utilise 
different pathways to activate ERK-MAPKinase which overlap at MEKl.
Diagram adapted from Purkerson et. a l, (97),
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Figure 25. BCR-ligation activates an early but transient, Ras- 
dependent, ERK-MAPKinase signal. A. WEHI-231 cells (IxlOVml) were
stimulated as follows; lane 1, cells left untieated for 0 minutes, lane 2, cells treated 
with anti-Ig (10 pg/ml) for 1 minute, lane 3, cells treated with anti-Ig (10 pg/ml) for 5 
minutes, lane 4, cells treated with anti-Ig (10 pg/ml) for 10 minutes, lane 5, cells 
treated with anti-Ig (10 fig/ml) for 30 minutes, lane 6, cells treated with anti-Ig (10 
pg/ml) for 60 minutes, lane 7, cells left untreated for 60 minutes. Levels of 
pERK/wERK expression were determined by Western blotting (15pg/lane). 
Densitometry shows relative band density of p42 ERK-MAPKinase measured on Gel- 
Pro Analysis software. B. WEHI-231 cells (IxlOVml) were stimulated as follows: 
lane 1, cells left untreated for 30 minutes, lane 2, cells treated with anti-Ig (0.1 
pg/ml) for 30 minutes, lane 3, cells treated with anti-Ig (1 pg/ml) for 30 minutes, 
lane 4, cells treated with anti-Ig (5 pg/ml) for 30 minutes, lane 5, cells treated with 
anti-Ig (10 pg/ml) for 30 minutes, lane 6, cells treated with anti-Ig (25 fxg/ml) for 30 
minutes. Levels of pERK/wERK expression were determined by Western blotting 
(15pg/lane). Ç. WEHI-231 cells (IxlOVml) were stimulated as follows: lane 1, cells 
left untreated for 0 minutes, lane 2, cells treated with anti-Ig (10 jxg/ml) for 1 minute, 
lane 3, cells treated with anti-Ig (10 pg/ml) for 5 minutes, lane 4, cells treated with 
anti-Ig (10 pg/ml) for 10 minutes, lane 5, cells treated with anti-Ig (10 pg/ml) for 30 
minutes, lane 6, cells treated with anti-Ig (10 pg/ml) for 60 minutes, lane 7, cells left
untreated for 60 minutes. GTP-bound Ras was then immunoprecipitated using Raf-1- 
RBD as bait. Ras activation was then determined by Western blotting using a anti-Ras 
antibody to equal levels of cell sample. Densitometry shows relative band density of 
Ras measured on Gel-Pro Analysis software.
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Figure 26. Anti-Ig treatment induces a dose-dependent increase in 
WEHI-231 cell apoptosis.
WEHI-231 (5xlOVml) were cultured with increasing concentrations of anti-Ig (0, 0.1, 
1, 10 and 50 |Xg/ml). Levels of apoptosis were determined by PI staining and FACS 
analysis after 48 hours as described in Materials and Methods.
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Figure 27. PD98059 and U0126 both inhibit anti-Ig induced ERK- 
MAPKinase activation in a time and dose-dependent manner A.WEHI-
231 cells (5 X lOVml) were stimulated as follows: lane 1, cells left untreated for 0 
minutes, lane 2, cells left untreated for 210 minutes, lane 3, cells treated with anti-Ig 
(10 |ig/ml) for 30 minutes, lane 4, cells treated simultaneously with 0.1 jiM PD98059 
and anti-Ig (10 gg/ml) for 30 minutes, lane 5, cells treated simultaneously with 1 jiM 
PD98059 and anti-Ig (10 |ig/ml) for 30 minutes, lane 6, cells treated simultaneously 
with 5 |iM PD98059 and anti-lg (10 |ig/ml) for 30 minutes , lane 7, cells were pre­
incubated with PD98059 (0.1 |iM) for 60 minutes and then stimulated with anti-Ig (10 
|Lig/ml) for 30 minutes, lane 8, cells were pre-incubated with PD98059 (1 pM) for 60 
minutes and then stimulated with anti-Ig (10 pg/ml) for 30 minutes, lane 9, cells were 
pre-incubated with PD98059 (5 pM) for 60 minutes and then stimulated with anti-lg 
(10 pg/ml) for 30 minutes, lane 10, cells were pre-incubated with PD98059 (0.1 pM) 
for 3 hours and then stimulated with anti-lg (10 pg/ml) for 30 minutes, lane 11, cells 
were pre-incubated with PD98059 (1 pM) for 3 hours and then stimulated with anti-lg 
(10 pg/ml) for 30 minutes, lane 12, cells were pre-incubated with PD98059 (5 pM) 
for 3 hours and then stimulated with anti-Ig (10 pg/ml) for 30 minutes. Levels of 
pERK/wERK expression were determined by Western blotting (15 pg/lane). B.* 
WEHI-231 cells (5 x lOVml) were stimulated as follows: lane 1, cells left untreated for 
3 hours, lane 2, cells treated with anti-Ig (10 pg/ml) for 30 minutes, lane 3, cells pre- 
incubated with U0126 (0.1 pM) for 3 hours and then stimulated with anti-lg (10 pg/ml) 
for 30 minutes, lane 4, cells pre-incubated with U0126 (5 pM) for 3 hours and then 
stimulated with anti-lg (10 pg/ml) for 30 minutes, lane 5, cells pre-incubated with 
U0126 (20 pM) for 3 hours and then stimulated with anti-Ig (10 pg/ml) for 30 minutes, 
lane 6, cells pre-incubated with U0126 (50 pM) for 3 hours and then stimulated with 
anti-lg (10 pg/ml) for 30 minutes. Levels of pERK/wERK expression were determined 
by Western blotting (20 pg/lane).
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Figure 28. Inhibition of an early BCR-induced ERK-MAPKinase signal 
reduces apoptosis in WEHI-231 cells. WEHI-231 cells (5 x lOVml) were pre- 
incubated with U0126 for two hours. Cells were then treated with the indicated stimuli 
(anti-Ig and anti-CD40 both at 10 pg/ml) for 48 hours. Levels of apoptosis were 
determined by PI staining and FACS analysis after 48 hours as described in Materials 
and Methods.
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Figure 29. CD40 ligation does not activate ERK-MAPKinase in WEHI- 
231 cells. A. WEHI-231 cells (IxlOVml) were stimulated as follows: lane 1, cells 
left untreated for 0 minutes, lane 2, cells treated with anti-CD40 (10 |U.g/ml) for 1 
minute, lane 3, cells treated with anti-CD40 (10 fig/ml) for 5 minutes, lane 4, cells 
treated with anti-CD40 (10 |ig/ml) for 10 minutes, lane 5, cells treated with anti- 
CD40 (10 fig/ml) for 30 minutes, lane 6, cells treated with anti-CD40 (10 jlg/ml) for 
60 minutes, lane 7, cells left untreated for 60 minutes. Levels of pERK/wERK 
expression were determined by Western blotting (15|Xg/lane). B. WEHI-231 cells 
(IxiOVml) were stimulated as follows: lane 1, cells left untreated for 0 minutes, lane 
2, cells treated with anti-Ig plus anti-CD40 (both 10 p-g/ml) for 1 minute, lane 3, cells 
treated with anti-Ig plus anti-CD40 (both 10 |ig/ml) for 5 minutes, lane 4, cells 
treated with anti-Ig plus anti-CD40 (both 10 |ig/ml) for 10 minutes, lane 5, cells 
treated with anti-Ig plus anti-CD40 (both 10 jxg/ml) for 30 minutes, lane 6, cells 
treated with anti-Ig plus anti-CD40 (10 pg/ml) for 60 minutes, lane 7, cells left 
untieated for 60 minutes. Levels of pERK/wERK expression were determined by 
Western blotting (15pg/lane). Densitometry shows p42 ERK-MAPKinase band 
density measured on Gel-Pro Analysis software. Ç. WEHI-231 cells (IxlOVml) 
WEHI-231 cells (IxlOVml) were stimulated as follows: lane 1, cells left untreated for 
0 minutes, lane 2, cells treated with anti-Ig plus anti-CD40 (both 10 pg/ml) for 1 
minute, lane 3, cells treated with anti-Ig plus anti-CD40 (both 10 pg/ml) for 5 
minutes, lane 4, cells treated with anti-Ig plus anti-CD40 (both 10 pg/ml) for 10 
minutes, lane 5, cells treated with anti-Ig plus anti-CD40 (both 10 pg/ml) for 30 
minutes, lane 6, cells treated with anti-Ig plus anti-CD40 (10 pg/ml) for 60 minutes,
lane 7, cells left untreated for 60 minutes. GTP-bound Ras was then 
immunoprecipitated using Raf-1-RED as bait. Ras activation was then determined by 
Western blotting using a anti-Ras antibody to equal levels of cell sample. Densitometry 
shows band density of Ras measured on Gel-Pro Analysis software.
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Figure 30. CD40 co-stimulation reduces BCR-mediated A A generation.
Increasing concentrations (0.1-10 pg/ml as indicated) of anti-CD40 inhibit anti-Ig (1 
pg/ml) stimulated PLA^ activation as determined by the decreased generation of anti-Ig- 
stimulated [^H]arachidonic acid production observed in WEHI-231 cells (30 minute 
stimulation).
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Figure 31. BCR-ligation does not activate either p38-MAPKinase or 
JNK. A. WEHI-231 cells (IxlOVml) were stimulated as follows; lane 1, cells left 
untreated for 0 minutes, lane 2, cells treated with anti-lg (10 pg/ml) for 1 minute, 
lane 3, cells treated with anti-Ig (10 pg/ml) for 5 minutes, lane 4, cells treated with 
anti-Ig (10 pg/ml) for 10 minutes, lane 5, cells treated with anti-Ig (10 pg/ml) for 30 
minutes, lane 6, cells treated with anti-lg (10 pg/ml) for 60 minutes, lane 7, cells left 
untreated for 60 minutes. Levels of pp38/wp38 expression were determined by 
Western blotting (15pg/lane). B. WEHI-231 cells (IxlOVml) were stimulated as 
follows: lane 1, cells left untreated for 0 minutes, lane 2, cells treated with anti-lg (10 
pg/ml) for 1 minute, lane 3, cells treated with anti-lg (10 pg/ml) for 5 minutes, lane 
4, cells treated with anti-lg (10 pg/ml) for 10 minutes, lane 5, cells treated with anti- 
lg (10 pg/ml) for 30 minutes, lane 6, cells treated with anti-lg (10 pg/ml) for 60 
minutes, lane 7, cells left untreated for 60 minutes. Levels of pp38/wp38 expression 
were detennined by Western blotting (15pg/lane). Ç. WEHI-231 cells (5 x lOVml) 
were stimulated as follows, lane 1, cells left untreated for 30 minutes, lane 2, cells 
left untreated for 60 minutes and then stimulated with anti-Ig (10 pg/ml) for 30 
minutes, lane 3, cells were pre-incubated with SB230580 (1 pM) for 60 minutes and 
then stimulated with anti-Ig (10 pg/ml ) for 30 minutes, lane 4, cells were pre- 
incubated with SB230580 (5 pM) for 60 minutes and then stimulated with anti-Ig (10 
pg/ml ) for 30 minutes pre-incubated with or without SB230580 (1 and 5pM) for 1 
hour. Levels of pERK/wERK expression were determined by Western blotting (15 
pg/lane).
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Figure 32. p38-MAPKinase is not essential for BCR-induced apoptosis.
WEHI-231 cells (5 x lOVml) were stimulated as indicated (anti-Ig and anti-CD40 both 
at lOpg/ml). Cells treated with SB203580 were pre-incubated in the presence of the 
indicated concentration of SB203580 for 90 minutes prior to further cell stimulation (if 
indicated). Levels of apoptosis were detennined by PI staining and FACS analysis after 
48 hours as described in Materials and Methods.
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Figure 33. Anti-Ig treatment causes the long-term down-regulation of 
pERK expression which can be re-established by co-stimulation with 
anti-CD40. A, WEHI-231 cells (5 x lOVml) were stimulated as follows: lane 1, 
cells left untreated for 0 hours, lane 2, cells left untreated for 1 hour, lane 3, cells left 
untreated for 2 hours, lane 4, cells left untreated for 4 hours, lane 5, cells left 
untreated for 8 hours, lane 6, cells left untreated for 24 hours, lane 7, cells left 
untreated for 48 hours. Levels of pERK/wERK expression were determined by 
Western blotting (30 pg/lane). Densitometric analysis shows fold increase of p42 
ERK-MAPKinase relative to lane 1. B, WEHI-231 cells (5 x lOVml) were stimulated 
as follows, lane 1, cells left untreated for 0 hours, lane 2, cells treated with anti-Ig (1 
pg/ml) for 1 hour, lane 3, cells treated with anti-Ig ( 1 pg/ml) for 2 hours, lane 4, cells 
treated with anti-Ig ( 1 pg/ml) for 4 hours, lane 5, cells treated with anti-Ig ( 1 pg/ml) 
for 8 hours, lane 6, cells treated with anti-Ig (1 pg/ml) for 24 hours, lane 7, cells 
treated with anti-Ig ( 1 pg/ml) for 48 hours. Levels of pERK/wERK expression were 
determined by Western blotting (30 pg/lane). Densitometric analysis shows fold 
increase of p42 ERK-MAPKinase relative to lane 1. Ç, WEHI-231 cells (5 x lOVml) 
were stimulated as follows, lane 1, cells left untreated for 0 hours, lane 2, cells 
treated with anti-Ig (1 pg/ml) and anti-CD40 (10 pg/ml) for 1 hour, lane 3, cells 
treated with anti-Ig (1 pg/ml) and anti-CD40 (10 pg/ml) for 2 hours, lane 4, cells 
treated with anti-Ig (1 pg/ml) and anti-CD40 (10 pg/ml) for 4 hours, lane 5, cells 
treated with anti-Ig (1 pg/ml) and anti-CD40 (10 pg/ml) for 8 hours, lane 6, cells 
treated with anti-Ig (1 pg/ml) and anti-CD40 (10 pg/ml) for 24 hours, lane 7, cells 
treated with anti-Ig (1 pg/ml) and anti-CD40 (10 pg/ml) for 48 hours. Levels of 
pERK/wERK expression were determined by Western blotting (30 pg/lane). D, 
WEHI-231 cells (5 x lOVml) were stimulated as follows, lane 1, cells left untreated 
for 0 hours, lane 2, cells treated with anti-CD40 (10 pg/ml) for 1 hour, lane 3, cells 
treated with anti-CD40 (10 pg/ml) for 2 hours, lane 4, cells treated with anti-CD40 
(10 pg/ml) for 4 hours, lane 5, cells treated with anti-CD40 (10 pg/ml) for 8 hours, 
lane 6, cells treated with anti-CD40 (10 pg/ml) for 24 hours, lane 7, cells treated 
with anti-CD40 (10 pg/ml) for 48 hours. Levels of pERK/wERK expression were 
determined by Western blotting (30 pg/lane). Densitometric analysis shows fold 
increase of p42 ERK-MAPKinase relative to lane 1.
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Figure 34. Activation of p38-MAPKinase or JNK in WEHI-231 cells.
A, WEHI-231 cells (5 x lOVml) were stimulated as follows: lane 1, cells left 
untreated for 0 hours, lane 2, cells left untreated for 1 hour, lane 3, cells left 
untreated for 2 hours, lane 4, cells left untreated for 4 hours, lane 5, cells left 
untreated for 8 hours, lane 6, cells left untreated for 24 hours, lane 7, cells left 
untreated for 48 hours, lane 8, hypoxic rat fibroblast positive control. Levels of 
pp38/wp38-MAPKinase expression were determined by Western blotting (30 jig/lane).
B, WEHI-231 cells (5 x lOVml) were stimulated as follows, lane 1, cells left 
unti-eated for 0 hours, lane 2, cells treated with anti-Ig (1 jxg/ml) for 1 hour, lane 3, 
cells treated with anti-Ig (1 jiig/ml) for 2 hours, lane 4, cells treated with anti-Ig (1 
pg/ml) for 4 hours, lane 5, cells treated ’with anti-Ig (1 Jig/ml) for 8 hours, lane 6, 
cells treated with anti-Ig (1 pg/ml) for 24 hours, lane 7, cells treated with anti-Ig (1 
pg/ml) for 48 hours. Levels of p-p38/w-p38-MAPKinase expression were determined 
by Western blotting (30 jig/lane). Ç, WEHI-231 cells (5 x lOVml) were stimulated as 
follows, lane 1, cells left untreated for 0 hours, lane 2, cells treated with anti-Ig (1 
pg/ml) and anti-CD40 (10 pg/ml) for 1 hour, lane 3, cells treated with anti-Ig ( 1 
p,g/ml) and anti-CD40 (10 jig/ml) for 2 hours, lane 4, cells treated with anti-Ig (1 
pg/ml) and anti-CD40 (10 pg/ml) for 4 hours, lane 5, cells treated with anti-Ig (1 
pg/ml) and anti-CD40 (10 pg/ml) for 8 hours, lane 6, cells treated with anti-Ig (1 
pg/ml) and anti-CD40 (10 pg/ml) for 24 hours, lane 7, cells treated with anti-Ig (1 
pg/ml) and anti-CD40 (10 pg/ml) for 48 hours. Levels of pp38/w38 MAPKinase 
expression were determined by Western blotting (30 jig/lane). D, WEHI-231 cells (5 
X lOVml) were stimulated as follows, lane 1, cells left untreated for 0 hours, lane 2, 
cells treated with anti-Ig (1 pg/ml) for 1 hour, lane 3, cells treated with anti-Ig (1 
fxg/ml) for 2 hours, lane 4, cells treated with anti-Ig (1 fig/ml) for 4 hours, lane 5, 
cells treated with anti-Ig (1 pg/ml) for 8 hours, lane 6, cells treated with anti-Ig (1 
p.g/inl) for 24 hours, lane 7, cells treated with anti-Ig (1 pg/ml) for 48 hours. Levels 
of pJNK/wJNK expression were determined by Western blotting (30 pg/lane).
98
(A) 1
untreated
5 6 7 8
pp38
wp38
(B)
anti-Ig 
(1 pg/ml)
5 6 7 8
pp38
wp38
(C)
anti-Ig (1 pg/ml) + 
anti-CD40 (10 |Lig/ml)
3 8
pp38
wp38
(D)
anti-Ig 
(1 pg/ml)
7 8
pJNK
wJNK
Figure 34
Figure 35. ËRK activity is not involved in CD40-mediated rescue from 
growth arrest. A. WEHI-231 cells (lO'^  cells/well) were pre-incubated for 3 hours 
in PD98059 (0.1-5 pM) prior to stimulation with anti-Ig (10 pg/ml); anti-CD40 (10 
pg/ml) or a combination of both. Proliferation was assessed by measuring 
[^HJthymidine uptake at 48 hours. Values shown are the means ± SD of quadruplicate 
wells. B. WEHI-231 cells (lO'* cells/well) were pre-incubated for 3 hours in PD98059 
(0.1-5 pM) prior to stimulation with anti-Ig (0.001-10 pg/ml) or otherwise left 
untreated. Proliferation was assessed by measuring [^H]thymidine uptake at 48 hours. 
Values shown are the means ± SD of quadruplicate wells.
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Figure 36. U0126 enhances basal and anti-Ig-mediated growth-arrest.
A. WEHI-231 cells (lO'^  cells/well) were left untreated or treated with 10(ig/ml anti-Ig 
or 10)J,g/ml anti-Ig and antl-CD40. Were indicated, cells were pre-incubated for 3 
hours in UO126 (1, 5, or 20pM) prior to stimulation with anti-Ig (10 pg/ml) and anti- 
CD40 (10 pg/ml) or left otherwise untreated. Proliferation was assessed by measuring 
thymidine uptake at 48 hours. Values shown are the means ± SD of quadruplicate 
wells. B. WEHI-231 cells (10"^  cells/well) were pre-incubated for 3 hours in 
UO 126(0.05-10 pM) prior to stimulation with anti-Ig (0.001-10 pg/ml) or otherwise 
left untreated. Proliferation was assessed by measuring pH]thymidine uptake at 48 
hours. Values shown are the means ± SD of quadruplicate wells.
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Figure 37. Sustained ERK inhibition prevents normal cell proliferation 
BUT also inhibits CD40-mediated rescue from anti-Ig induced growth 
arrest. A. WEHI-231 cells (lO'^  cells/well) were pre-incubated for 3 hours with 
PD98059 or U0126 (both IjiM). Cells were then treated as indicated with lOjig/ml 
anti-Ig or lOjag/ml anti-CD40 or a combination of both. Cells treated with PD98059 
and U0124 were treated with an additional dose (1 jLiM) every 4 hours for a total of 28 
hours post-pre-incubation. Proliferation was assessed by measuring [^HJthymidine 
uptake at 48 hours. Values shown are the means ± SD of quadruplicate wells. B. 
WEHI-231 cells (lO'* cells/well) were pre-incubated for 3 hours with PD98059 and 
U0126 (both 1 |L i M ) .  Cells were then treated as indicated with 10|i,g/ml anti-Ig or 
lOjig/ml anti-CD40 or a combination of both. Cells treated with PD98059 and U0124 
were treated with an additional dose (1 jxM) every 4 hours for a total of 28 hours post- 
pre-incubation. Proliferation was assessed by measuring [^H]thymidine uptake at 48 
hours. Values shown are the means ± SD of quadruplicate wells.
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TABLE 1 ERK inhibition drives cells into apoptosis which is reversed 
by anti-CD40 treatment. WEHI-231 cells (5 x lOVml) were pre-incubated with 
PD98059 (1 jiM) and U0126 (1 |iiM) or a combination of the two for 3 hours. Cells 
were then stimulated as indicated with 10 jag/ml anti-Ig or 10 )ig/ml anti-CD40 or a 
combination of both. Cells originally treated with PD98059 or U0126 (or both) were 
treated with additional doses (1 p.M) every 4 hours for a total of 28 hours post-pre­
incubation. Cells were then harvested after a total of 48 hours and DNA content 
analysed by PI staining and FACS analysis as described in Materials and Methods.
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Figure 38. Inhibition of ERK-MAPKinase suppresses cell division in 
WEHI-231 cells. WEHI-231 cells were loaded with the cell permeable dye CFSE 
(2.5 p,M). Cells were then left untreated, or stimulated with combinations of anti-Ig 
and anti-CD40 (both 10 p-g/ml) for 48 hours, both in the presence and absence of 
PD98059 and U0126 (1 |xM) which were added every 4 hours over a 32 hour time 
period. Cells were then harvested, washed and analysed by FACS for the fluorescence 
intensity of CFSE, which gives an indication of the number cell divisions per 
population for each stimulation.
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Figure 39. PD98059 and U0126 reduce BCR-mediated cPLAj activity in 
WEHI-231 cells. WEHI-231 cells (5 x 10^  total) were left untreated or pre- 
incubated with either PD98059 (10 jiM) or U0126 (10 jiM) or a combination of both 
for 60 minutes. Cells were then stimulated with anti-Ig (10 jig/ml) for 30 minutes 
before being analysed for cPLA^ activity by colourimetric analysis as described in 
Materials and Methods.
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Figure 40. Model for the role of ERK-MAPKinase in WEHI-231 
apoptosis, growth-arrest and proliferation. BCR ligation initiates the 
activation of an early, transient ERK-MAPKinase signal positively coupled to apoptotic 
signals including cPLA^ activity. BCR ligation also suppresses basal ERK- 
MAPKinase activity which is required for WEHI-231 cell proliferation. CD40 co­
stimulation rescues WEHI-231 cells from BCR-induced apoptosis and growth arrest by 
uncoupling the BCR from activation of the early, apoptotic ERK-MAPKinase signal, 
and re-establishes the long-term basal ERK-MAPKinase activity. CD40 co-stimulation 
also initiates the activation of other anti-apoptotic signals including those mediated by 
BcI-Xl-
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CHAPTER 5 - Downstream mediators of BCR and CD40 signalling. 
5.0 Introduction.
The studies outlined in the previous chapter have described differential 
biological roles for ERK-MAPKinase in WEHI-231 cells. We have shown that BCR- 
ligation not only leads to the activation of an early, transient, apoptotic signal, but also 
suppresses basal ERK-MAPKinase signals required for WEHI-231 cell proliferation. 
Moreover, CD40 treatment rescues these cells from growth-arrest and apoptosis by re­
establishing basal ERK-MAPKinase activity and downregulating early BCR-coupled 
ERK-MAPKinase signals respectively. Both routes of ERK-MAPKinase activation 
appear to be Ras-dependent. Thus, how do signals transduced through ERK- 
MAPKinase lead to such different physiological responses. One possibility may be due 
to the differential activation of downstream intermediates following BCR or CD40 
ligation. Previous studies within our lab have proposed a role for cytosolic PLA^ as a 
key mediator of the apoptotic responses in WEHI-231 B cells (53).
5.1 PLA2 family enzymes.
Membrane phospholipids provide an important source of lipid second 
messengers following receptor aggregation and activation. A family of phospholipases 
hydrolyse membrane phospholipids in a specific manner to yield a wide range of lipid 
products responsible for different physiological responses. The phospholipase A  ^
(PLAj) family of enzymes hydrolyse fatty acid from the sn-2 position of phospholipids 
generating a range of free fatty acids including arachidonic acid ( AA) and 
lysophospholipids. In recent years, modern molecular biology cloning techniques has 
allowed this enzyme family to be characterised into distinct sub-sets according to 
different structural and functional properties. These include the secretory PLA^
(sPLAj), Ca^^-independent PLA^ (iPLA^) and cytosolic PLA^ (cPLAj) families of PLAj 
enzymes.
sPLAjS are low molecular weight (~14-kDa) enzymes that require millimolar 
concentrations of Ca^  ^to exert their full enzymatic activity (109) and are abundantly 
expressed in the mammalian pancreas where they function as digestive enzymes for 
dietary phospholipids.
On the other hand, iPLA^ has been shown to be Ca^^-independent and exists in 
both 26-kDa lysosomal and a 86-kDa cytosolic forms and evidence exists for their role 
in phospholipid remodelling of the cell plasma membrane (109).
cPLAj is a 85-kDa protein, which shares no homology with other PLA^s and 
preferentially hydrolyses sn-2 arachidonic acid from membrane phospholipids (110).
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However, both sPLA2 and iPLA^, which are non-specific for fatty acid species at the 
sn-2 position of phospholipid substrates, are also known to promote A A generation. 
Nevertheless it is cPLAj that plays the major role in the generation of AA from 
membrane phospholipids and is tightly regulated by post-receptor signalling events and 
its activity has been implicated in a range of biological responses, including 
inflammation (111).
5.2 Regulation of cPLA^ activity.
5.2.1 Regulation of cPLAj activity by calcium.
Unlike sPLA^ which requires millimolar levels of Ca^  ^for enzymatic activity, 
cPLAj only requires submicromolar concentrations of Ca^  ^(109). Ca^ "^  has been 
shown to be essential for the translocation and binding of cPLA^ to the lipid membrane 
bringing the enzyme into close proximity with its chosen substrate. This is due to a N- 
terminal calcium-dependent phospholipid binding domain that has been shown to share 
close homology to the C2 domains of the conventional (Ca^  ^dependent) isoforms of 
PKC (110). In vitro experiments using phospholipid vesicles as substrate have shown 
that Ca^  ^concentrations required to promote cPLA^ catalytic activity also correlate with 
Ca^  ^concentrations required for membrane binding of cPLAj (110). These reports are 
consistent with the hypothesis that cPLAj is held in a cytoplasmic state at low Ca^  ^
concentrations and that receptor mediated calcium influxes promote its translocation to 
the lipid membrane. Additional studies by Hirabayashi et. al., 1999 (112), have since 
addressed how these Ca^  ^signals regulate Ca^  ^translocation. They reported that 
selective inhibition of platelet-activating factor receptor mediated Ca^  ^influxes using the 
Ca^ "^  chelator EOT A were effective in preventing AA release (and therefore cPLA^ 
activity) after critical time periods. This suggests that the duration of [Ca^ j^j elevation 
plays a key role in cPLA^ translocation and subsequent activation.
5.2.2 Regulation of cPLAj activity by protein kinases.
In addition to a N-terminal calcium-dependent phospholipid binding domain, 
cPLAj contains a MAPKinase-phosphorylation site at Ser^ ®^  (113). Phosphorylation of 
CPLA2 at this site by ERK-MAPKinase induces a gel shift of cPLA^ as seen by SDS- 
PAGE and this has been used as a indicator of cPLA^ activation. Phosphorylation of 
Ser^ °^  is also essential for the in vivo activation of cPLAj as overexpression of mutant 
CPLA2 (S505A) in Chinese hamster ovary cells failed to generate A A release seen in 
wild-type cells under similar conditions (110). Other protein kinases have been
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implicated in regulating cPLA^ activity. PKC, presumably via PKC-mediated activation 
of MAPKinase, and PKA, have both been shown to phosphorylate cPLA^ in vitro.
No evidence exists for PKC mediated phosphorylation of cPLA^ in vivo however.
One additional study also suggests that sPLA^ may play an important role in cPLA^ 
activation by directly activating ERK-MAPKinase (113).
The phosphorylation and activation of CPLA2 is therefore both calcium- and 
MAPKinase-dependent. However, a number of studies have suggested that the order 
in which these activation signals are delivered is vital for proper enzymatic activation of 
CPLA2. Subsequently, it has been proposed that phosphorylation of cPLAj by 
MAPKinases must precede the influx of calcium, which is required for the translocation 
of this enzyme from the cytoplasm to the cell membrane (110, 114). This data suggests 
that CPLA2 cannot be phosphorylated after it has translocated to the cell membrane.
5.3 Downstream Effectors of cPLAj Signalling.
AA is a well known lipid second messenger, but also plays a vital role as the 
major substrate for a number of lipid pathways including the lipoxygenase and cyclo- 
oxygenase enzyme systems. AA has also been shown to regulate a wide range of 
intracellular signalling molecules including PLCy, p2P‘^ GAP and certain PKC 
isoforms. In addition, TNFot mediated AA generation has also known to be a co­
mitogen in the Swiss 3T3 cell line (115). However, it is its role as a mediator of 
TNFa-mediated cell death that has received much of the effort of investigators 
examining A A in signalling mechanisms. TNF signalling has been shown to activate a 
neutral SMase which in turn hydrolyses membrane sphingomyelin to ceramide. 
Ceramide has been shown to activate a 97-kDa kinase termed ceramide-activated protein 
kinase (CAPK). This kinase is capable of phosphorylating and activating Raf-1 on 
ThF^ ,^ thus linking ceramide to the activation of ERK-MAPKinase (116, 117). This 
has been shown to result in CPLA2 activation and AA generation (111). However, it 
has also been reported that AA can induce the activation of SMase with resultant 
generation of ceramide. This suggests that ceramide production can also lie 
downstream of cPLA2 activity.
In addition to TNFa signalling, AA is also known to play a role in the induction 
of apoptosis signalling via other cell surface receptors. These include Fas-mediated 
apoptosis. Indeed, a recent study by Atsumi et. al. (118) presented data to suggest that 
Fas-mediated apoptosis in U937 cells was mediated by the generation of AA from 
iPLA2 activity. Interestingly, these studies also showed that CPLA2 activity was 
downregulated in these cells, which was shown to be due to the cleavage of the cPLAj 
protein by caspase-3. This is in agreement with other findings which have suggested a
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role for iPLA^ in the induction of late PLA^ activity during apoptosis, which was also 
shown to be secondary to caspase activity (26).
Additional factors which modulate the downstream effectors of cPLA^ activity 
include the localisation of cPLA^. The induction of apoptosis by TNFa-mediated 
activation of CPLA2 has previously been shown to interfere with the electron flow in the 
mitochondria (119) suggesting a direct link between the induction of apoptosis and the 
mitochondria. Recent work in our lab has shown that CPLA2 specifically translocates to 
the mitochondria after BCR-ligation. This results in the destabilisation of the 
mitochondrial membrane potential resulting death by apoptosis. Studies have also 
shown that this can be mimicked by exogenous treatment with AA, confirming a role 
for cPLAj in this process.
It is therefore clear that the location of AA generation by CPLA2 activity is a 
major determinant in the subsequent downstream effectors activated by this lipid second 
messenger.
5.4 Metabolism of Arachidonic Acid
5.4.1 The Lipoxygenase Pathway.
The metabolites of lipoxygenase action have been implicated in TNF responses 
such as TNF-induced cytotoxicity, induction of the transcription factor c-fos and the 
mitochondrial superoxide radieal scavenging enzyme manganous superoxide dismutase. 
They are produced by the enzymes 5-, 12- and 15-lipoxygenase which lead to the 
oxidation of AA, generating compounds such as HPETES, HETES, DHET, EET and 
leukotrienes. These compounds can subsequently be broken down into oxygen free 
radicals which are known to induce cell cytotoxicity (111).
5.4.2 The Cyclooxygenase Pathway.
Cyclooxygenase (COX) or prostaglandin H2 synthase was first purified 25 
years ago and subsequently cloned some 12 years later in the late 1980s. COX is the 
key enzyme in the synthesis of prostaglandins (PGs) from AA and catalyses the first 
two stages of primary prostanoid production (figure 41). Pharmacologically, COX is 
an important target of anti-inflammatory drugs. As early as the 1970s it was reported 
that non-steroidal anti-inflammatory drugs (NSAIDs) inhibited PG formation and that 
in vitro inhibition of PG formation correlated with their anti-inflammatory properties in 
vivo (120). Currently, two isoforms of COX are known to exist. They reflect both 
constituitively expressed, and inducible isoforms of COX and have been termed COX-1
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and COX-2 respectively. COX-2 is induced by a wide range of pro-inflammatory 
cytokines and microbial agents. However, its role as a purely pro-inflammatory 
enzyme is still unclear. Although selective COX-2 inhibitors have been shown to 
reduce murine air pouch and foot pad inflammation, selective inhibition of COX-2 has 
also been shown to delay healing of gastric ulcers in mice and exacerbate induced colitis 
in rat models (121). PG synthesis has also been proposed to play a role in the 
development of colorectal cancers with elevated levels of PGE^ and COX-2 both 
reported in human colorectal adenocarcinomas (122). Subsequent overexpression of 
COX-2 in intestinal epithelial cells has been shown to result in decreases in the number 
of cells undergoing apoptosis and is associated with rises in the anti-apoptotic protein 
Bcl-2. Studies have therefore suggested that COX-2 leads to decreases in apoptosis by 
regulating Bcl-2 expression via PGE2 production whilst also inducing the activation of 
mitogenic signals such as ERK-MAPKinase. This leads onto studies suggesting that 
COX-2, but not COX-1, can be located in perinuclear regions. Indeed PGJ2 derivatives 
have been shown to act as potent ligand for the nuclear peroxisome proliferator- 
activated receptor-y (PPAR-y) which acts as a transcription factor for genomic DNA 
(123).
Both COX isoforms share similar structural and catalytic activities, with both 
isoforms approximately 600 amino acids in length and sharing 63% sequence 
homology. They do however differ greatly at the gene level, reflecting their expression 
characteristics. Subsequently, COX-1 is known to be widely expresses in most 
mammalian organs, including the stomach and kidneys, whilst COX-2 is expressed 
constituitively in only a few organs including the brain (123). COX-1 originates from a 
22-kb gene in humans, whist the inducible COX-2 originates from a smaller 8.3-kb 
immediate early gene (123). Despite structural similarities, COX-1 and COX-2 can be 
distinguished by both substrate and inhibitor selectivity. For example, COX-2 will 
accept a wider range of fatty acids as substrates than COX-1 whilst aspirin-mediated 
acétylation of COX-1 will prevent its oxidisation of AA, although COX-2 is unaffected
(123).
The intracellular regulation of COX-2 expression and subsequent PGE2 
formation has been addressed in a range of cell types. Studies by Barry et a l (1999)
(124) provided evidence for the upregulation of COX-2 expression in platelets. Their 
studies highlighted that COX-2 expression was dependent on the activation of a 
membrane-linked signalling cascade, rather than the activation of nuclear receptors 
regulating gene expression. This signalling pathways was shown to be dependent on 
PKC-mediated activation of ERK-MAPKinase in a PI(3)K sensitive manner.
Additional studies, using human lung fibroblasts (125), have shown that CD40 ligation 
also leads to dramatic increases in PGEj levels which were accompanied by CD40-
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mediated increases in both COX-2 protein and mRNA levels. A role for CD40 in 
regulating PGE2 levels is not restricted to lung fibroblasts. Interestingly, PGEj, 
previously thought to act as an inhibitor of the immune response, has recently been 
shown to act in synergy with a number of cell surface receptors to enhance B 
lymphocyte proliferation. Studies by Garrone et, a l (1994) provided evidence to 
suggest that exogenous PGE2 treatment could greatly enhance DNA synthesis of anti- 
CD40-activated B cells, as well as proliferative responses from IL-4 and IL-10 treated 
cells. In addition, these authors also reported the ability of PGE2 to down-regulate IL- 
4-induced isotype switching, suggesting both positive and negative roles for PGE2 in B 
lymphocyte development. Reports have also suggested that PGE2 prevents BCR- 
mediated DNA synthesis in human B cells, suggesting that PGE2-mediated proliferative 
effects are very much receptor-specific and may indeed also reflect differential 
responses by different cell types. The role of PGE2 as a negative regulator of growth 
may reflect the ability of this prostanoid to stimulate receptor-mediated cAMP 
generation via the activation of the adenylate cyclase pathway (126).
5.5 Role of cPLAj and AA in B lymphocyte development.
A recent study by Gilbert et. a l (53) highlighted a key role for cPLAj activation 
and AA generation in the maturation of T and B lymphocytes. This study addressed the 
role of cPLAg activation in the transduction of proliferative signals via T and B 
lymphocyte antigen receptors. Briefly, they provide data to suggest that cPLAj is 
expressed and activated in immature B lymphocytes and thymoctyes following antigen 
receptor ligation only under conditions leading to growth-arrest and/or apoptosis. 
Ligation of antigen receptors in mature B and T lymphocytes, which undergo 
proliferation under such circumstances, was not found to be coupled to cPLAj 
activation. Indeed, the expression of cPLAj protein was shown to be limited to 
developmental stages of B and T lymphocyte maturation where antigen receptor ligation 
leads to apoptotic signals. In particular, this study suggests that A A generation in 
immature B lymphocytes plays a key role in the deletion of these cells. Recent work 
within our lab (Katz et. a l. Journal of Immunology, in press), as previously 
mentioned, has indicated a role for mitochondiral CPLA2 activity in the initiation of 
apoptosis in WEHI-231 cells following BCR-ligation. In addition, these results also 
show that exogenous treatment with AA can mimic the effects of BCR-ligation, 
corroborating a role for this lipid second messenger in mediating anti-proliferative 
responses in WEHI-231 cells.
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5.6 Aims and objectives of this investigation.
The objectives of this investigation were to investigate downstream signalling 
events from ERK-MAPKinase and cPLA^ and in particular:
1. to investigate the role of A A on ERK-MAPKinase activity in WEHI-231 cells.
2. to examine the biological role played by PGE^ in WEHI-231 cells,
3. to address the role of CD40 in modulating AA-mediated responses.
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5.7 Results.
5.7.1 Exogenous AA promotes WEHI-231 growth-arrest.
Studies by Gilbert et. al. (53) have shown that generation of AA may play a key 
role in mediating apoptotic responses in immature B lymphocytes. Indeed, AA 
generation only occurred when using anti-Ig concentrations favourable to growth- 
arrest/apoptosis, and anti-CD40 stimulation, which rescues WEHI-231 cells from anti- 
Ig-mediated growth-arrest does not induce AA generation. Indeed, we have previously 
shown that anti-CD40 co-stimulation is effective in reversing BCR-induced AA 
generation (figure 30). Additionally, we have also shown that U0126 inhibits BCR- 
induced apoptosis by inhibiting BCR-coupled ERK-MAPKinase activation, and 
presumably AA generation. In order to examine the downstream events of AA 
generation, WEHI-231 cells were treated with exogenous AA to mimic cPLAj 
activation via the BCR.
Exogenous treatment of WEHI-231 cells with AA (figure 42A) reduced DNA 
synthesis by approximately 36% whereas anti-Ig treatment, which has previously been 
shown to promote growth-arrest in WEHI-231 cells (figure ISA), reduced basal 
proliferation by as much as 60%. In addition, we have also shown that the ability of 
AA to induce growth arrest is concentration dependent (results not shown - 
concentrations used here after produce maximal growth arrest). The differences in the 
induction of growth arrest observed during anti-Ig or AA stimulation may also reflect 
differential effects of AA which is added to cells exogenously compared to AA 
generated intracellularly following BCR ligation. One interesting observation from 
these studies was the inability of CD40 ligation to rescue from AA-mediated growth 
arrest (figure 42A), suggesting that CD40-mediated rescue from BCR-induced 
growth-aiTest occurs upstream from AA. These results are consistent with previous 
findings (figure 28) which showed the inability of the ERK-MAPKinase inhibitors 
PD98059 or U0126 to reverse BCR-induced growth arrest, yet successfully inhibit 
BCR-induced apoptosis.
Previous studies in this report had revealed the ability of BCR ligation to abolish 
a basal ERK-MAPKinase signal essential for WEHI-231 cell proliferation (figures 
33 A and 42B). As exogenous A A was shown to also induce growth arrest, albeit 
less than BCR-ligation, it was examined whether it exerted this effect by also down- 
regulating this ERK-MAPKinase signal. AA treatment was shown to induce a 
substantial increase in ERK-MAPKinase activation 2 hours post-AA treatment (figure 
42C). This was also observed in cells treated with anti-Ig alone. However, in stark 
contrast to anti-Ig treated cells, ERK-MAPKinase activity was still present even after 4- 
8  hours post-treatment. Instead, ERK-MAPKinase activity was slowly down-regulated
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by AA, but was abolished 24-48 hours post-AA treatment. Therefore, the inability of 
AA to completely abolish long-term ERK-MAPKinase signals, as seen in anti-Ig treated 
cells, may account for its weaker induction of growth-arrest. Interestingly, although 
previous studies have indicated the inability of anti-CD40 co-simulation to reverse AA- 
induced growth arrest, figure 42C confirms the ability of CD40 co-stimulation to 
reverse the late down-regulation of ERK-MAPKinase activity induced by AA treatment. 
This suggests that another block in the cell cycle apparatus, induced by AA treatment, is 
still active, and is not reversed by anti-CD40 co-stimulation.
5.7.2 AA also induces apoptosis in WEHI-231 cells.
Previous studies within our group had reported the ability of AA to induce DNA 
fragmentation and hence apoptosis in WEHI-231 cells (figure 43A, Sandra 
Seatter, unpublished observation) confirming an important role for cPLA^ 
activation following apoptotic stimuli. These studies also indicate that exogenous AA 
treatment may bypass ERK-MAPKinase-cPLA^ activation, as observed following BCR 
ligation, and exerts its apoptotic mechanism by activation of downstream apoptotic 
effectors. Interestingly, unlike BCR-ligation, AA treatment did not induce activation of 
an early ERK-MAPKinase signal (figure 43B), but did appear to enhance ERK- 
MAPKinase activity approximately 2 hours post-stimulation (figure 42C). 
Additionally, studies in our group suggest A A stimulation may also activate a positive 
feedback mechanism promoting further AA generation (figure 44, Caroline Lord, 
unpublished observation). Together with the results obtained in figure 42C, these 
studies would appear to suggest that AA stimulation promotes the activation of a 
positive feedback mechanism resulting in further AA generation possibly through the 
activation of a ERK-MAPKinase/cPLA^ dependent pathway.
In addition, and similar to results obtained from cells treated with anti-Ig, AA 
did not induce activation of either p38 MAPKinase or INK over a similar time course 
(figure 43B) although a role for these MAPKinases in the induction of AA-induced 
apoptosis cannot be discounted and further studies must be carried out.
5.7.3 CD40 co-treatment reverses AA-induced apoptosis.
Having previously shown a important role for CD40 co-treatment in reversing 
BCR-mediated apoptosis and growth-arrest we investigated whether AA-induced 
apoptosis could also be reversed by CD40 treatment. Cells were treated with a range of 
A A concentrations with or without 10 pg/ml anti-CD40 co-stimulation for a 48 hour 
period and analysed by FACS as previously described to determine cells undergoing 
apoptosis or in G, arrest. Results obtained (figure 45) confirmed previous
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observations with BCR ligation driving cells into both apoptosis and growth-arrest. In 
addition, anti-CD40 treatment substantially blocked apoptosis as well as reducing cells 
in Gj arrest to below basal (untreated levels) indicating cells were now progressing 
through cell-cycle. Cells treated with increasing concentrations of AA (5-50 |xM) 
yielded a number of interesting observations. Cells treated with 5 (xM AA produced 
apoptotic/Gj arrest profiles similar to untreated cells. Cells treated with 25 jiM AA, 
compared to untreated cells, whilst seeing no induction of apoptosis, experienced a 
decrease in Gj arrest indicating that these cells were engaged in cell-cycle progression. 
In contrast, cells treated with 50 |xM, whilst also seeing a reduction in Gj arrest, were 
also shown to undergo apoptosis. These results indicate that whilst low AA 
concentrations promote cell-cycle progression higher concentrations of AA induce 
apoptosis in addition to cell-cycle progression in WEHI-231 cells. Indeed, examination 
of the cell cycle profiles of these cells confirmed earlier observations showing that 
whilst AA induces apoptosis at higher concentrations (50 jiM), the number of cells in 
Gj arrest compared to untreated cells was substantially decreased and a increase in cells 
in the S phase was also observed (table 2).
This may result from the non-synchronised nature of WEHI-231 cell 
populations, suggesting that AA treatment may induce differential biological responses 
depending on the stage of cell cycle when the stimulation was encountered, but is also 
suggestive of cells having to progress through the cell cycle before they die by 
apoptosis. Interestingly, co-treatment with anti-CD40 antibodies was shown to 
substantially reduce AA-mediated apoptosis at these higher concentrations, indicating 
that anti-CD40 treatment exerts one of its anti-apoptotic roles in WEHI-231 cells 
downstream of AA generation, possibly through the regulation of the anti-apoptotic 
protein, Bcl-x^. In addition, cells in Gj arrest were reduced, compared to 50 p,M AA 
alone, indicating CD40 treatment has an additional mitogenic signal alongside its anti- 
apoptotic role, results which would confirm earlier findings suggesting that CD40 co­
stimulation could enhance ERK-MAPKinase activity in AA treated cells (figure 42C).
The ability of anti-CD40 co-stimulation to reverse AA-induced apoptosis 
suggests that CD40 acts downstream of AA to reverse the induction of pro-apoptotic 
mechanisms, or may actually result from the metabolism of A A into an non-apoptotic 
intermediate. Studies within our lab, whilst not ruling out a role for the former, have 
provided some data to confirm the latter hypothesis. We have shown that CD40 co­
stimulation appears to be ineffective in reversing apoptosis mediated by AACOCF3, a 
AA derivative that cannot be further metabolised. Although these results are 
preliminary and require further study, they do suggest that CD40 co-stimulation may 
result in the conversion of A A into non-apoptotic intermediates.
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Another interesting finding was the apparent ability of the ERK-MAPKinase 
inhibitor U0126 to reduce AA-mediated apoptosis, albeit very weakly. This again 
suggests that AA stimulation may actually induce a positive feedback mechanism 
leading to the induction of ERK-MAPKinase and cPLA^ activities and hence generation 
of AA.
Taken together, these results provide evidence for the role of AA as a negative 
regulator of WEHI-231 cell fate, but also suggests that AA may play other quite distinct 
roles in determining cell proliferation.
5.7.4 Exogenous PGE^ treatment enhances BCR-mediated growth-arrest 
in WEHI-231 cells.
Previous reports by other groups have suggested that COX-2 can decrease 
apoptosis by regulating Bcl-2 expression via PGE^ production (122) whilst also 
inducing the activation of mitogenic signals such as ERK-MAPKinase. In addition, 
CD40 ligation has also been shown to enhance COX-2 expression in certain cell types 
(125). Taken together, these results suggest that CD40-mediated rescue from BCR- 
induced apoptosis, in addition to up-regulating Bcl-x^ expression and reversing BCR- 
mediated decreases in mitochondrial membrane potential, may also drive the production 
of PGs from AA generated following BCR ligation. Thus CD40 could mediate rescue 
signals by converting the negative regulator AA to a positive regulator, PGE^ of WEHI- 
23 1 cell fate.
In order to determine whether PGEj plays a role in regulating the fate of WEHI- 
231 cells, exogenous PGEg was added to the culture of anti-Ig stimulated cells or cells 
left otherwise untreated. Therefore, if PGE^ plays an important role in CD40-mediated 
rescue from growth-arrest, could PGEj treatment reverse anti-Ig-mediated growth- 
arrest. Results indicated that instead of a positive role in WEHI-231 cells fate, 
exogenous PGE^ treatment was actually inhibitory in nature (figure 46A). PGE^ 
treatment was shown to cause a dose-dependent increase in growth-arrest at higher 
concentrations, whilst also acting in synergy with anti-Ig to enhance growth-arrest.
Having shown that exogenous PGE^ treatment may inhibit cell proliferation in 
WEHI-231 cells, we examined the effect of exogenous PGE^ treatment in mature 
splenic B lymphocytes which are known to proliferate following BCR-ligation (figure 
46B). PGE^ treatment had no affect on the resting state of mature splenic B 
lymphocytes, however, cell activation and hence DNA synthesis activated by BCR- 
ligation was markedly reduced by co-culture with PGE^ in a dose-dependent manner. 
These results provide further evidence to suggest that exogenous PGE^ treatment plays 
a negative role in B lymphocyte function.
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The above studies suggest that exogenous PGE^ treatment activates anti­
proliferative signals in B lymphocytes. Interestingly, the EP2 receptor, one of three 
receptors for PGE^, is known to induce increase in intracellular cAMP (127), a negative 
regulator of B lymphocyte proliferation. It is therefore tempting to speculate that the 
negative effects observed in the above studies may be mediated by the binding of PGE^ 
to EP2, although the expression of this receptor on these cells has not been examined.
5.7.5 Intracellular production of PGEj is suppressed by BCR-ligation.
Although the above results suggest PGE2 treatment leads to the induction of 
anti-proliferative mechanisms in both immature and mature B lymphocytes, this may 
result from the activation of specific receptors on the cell surface by PGE^ and therefore 
may not truly mimic the biological effect of intracellular PGEj. Therefore we examined 
the ability of BCR-ligation with or without anti-CD40 co-stimulation to modulate 
intracellular PGEj levels (figure 47). Results obtained suggested that PGE^ levels in 
basal proliferating cells varied substantially with time, suggesting that PGE^ production 
was closely regulated during the cell-cycle. Perhaps more interesting was the ability of 
anti-Ig treatment to significantly reduce PGE^ levels over an 8-48 hour period relative to 
untreated cells, suggesting that BCR-ligation suppresses COX activity. Coupled to the 
ability of CD40 co-stimulation to restore anti-Ig-mediated decreases in PGE^ levels to 
almost basal (untreated) levels, these results suggest that receptor-mediated PGE^ 
production predominately occurs during proliferative responses. Although we were 
unable to control for cell death in this study, which may account for the reduction in 
PGE2 production by anti-Ig treated cells, it should be noted that the suppression of 
PGE2 production by anti-Ig, compared to untreated cells or those co-stimulated with 
anti-CD40, was most noticeable between 8-24 hours. Previous studies have shown 
that this time period precedes that of cell death, suggesting that decreases in intracellular 
PGE2 levels are the result of decreased production and not cell death. In addition, cell 
death by 24 h is of the order of 10-15% above basal levels, a value considerably less 
than % reduction in PGE2 observed here.
The results described in this chapter provide evidence to suggest both a positive 
and negative role for PGE2 in lymphocyte proliferation depending on whether it is intra- 
or extracellular. It was therefore important to investigate whether PGEj was actually 
secreted by WEHI-231 cells following cell stimulation. Cells were left untreated, or 
treated with anti-Ig, anti-CD40 or both anti-Ig and anti-CD40 for 1, 8 , 24 or 48 hours. 
At these time points a sample of cultured supernatant was removed and analysed for 
PGE2 levels. Results indicated that no PGE2 was present, or secreted into the culture 
media by WEHI-231 cells following any of the above treatments (results not 
shown). These results suggest that PGE2 plays no extracellular role in WEHI-231 cell
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physiology. Nevertheless, the results indicate that exogenous PGE^, possibly though 
receptor mediated activation of adenylate cyclase, can negatively regulate B lymphocyte 
proliferation.
5.7.6 Indomethacin inhibits basal and CD40-stimuIated proliferation, 
but does not affect CD40-mediated rescue from BCR-induced growth- 
arrest.
Our studies suggest a possible role for the intracellular production of PGE^ as a 
mechanism for CD40-mediated rescue from BCR ligation growth arrest. In addition, 
CD40 treatment has been shown to upregulate both the message and protein expression 
of COX-2 in human lung fibroblasts (125). We therefore wanted to address whether 
inhibition of both COX-1 and COX-2 using the chemical inhibitor indomethacin would 
block CD40-mediated rescue (figure 48). Treatment of WEHI-231 cells with 
indomethacin was shown to induce a marginal decrease in cell proliferation compared to 
untreated cells (vehicle studies confirmed no toxic effects from inhibitor vehicle). Co­
treatment with indomethacin was marginally effective in reducing anti-CD40 but not 
anti-IL-4 mediated increases in proliferation. In addition, indomethacin was ineffective 
in preventing anti-CD40-mediated rescue from BCR-induced growth arrest. Although 
indomethacin treatment did not prevent CD40-mediated rescue in these cells, this may 
reflect the availability of AA as a substrate for COX-1 and COX-2 and the inability of 
indomethacin to effectively block all COX activities possibly due to the instability of 
this inhibitor over long-term cultures as we have previously seen with the ERK- 
MAPKinase inhibitors PD98059 and U0126. It would therefore be favourable to repeat 
these experiments with prolonged treatment with indomethacin and perhaps try other, 
more specific COX inhibitors.
118
5.8 Discussion.
Although the activation of cPLA^ in the WEHI-231 cell line has been shown to 
play an important role in the induction of apoptotic signals following BCR-ligation and 
also as a key mediator in maturational state-dependent BCR responses, the role of key 
downstream effectors is still unclear. Arachidonic acid is the major product of cPLA^ 
activity and is produced following BCR, but not CD40 ligation in WEHI-231 cells 
confirming its role as a negative mediator. How AA mediates its biological effects are 
unclear. Recent work within our group (Katz et. a l. Journal of Immunology, in press) 
have highlighted the role of the BCR in mediating both the activation and translocation 
of cPLAg to the mitochondria, where it has been shown to induce disruption of the 
mitochondrial membrane potential, which is known to be pro-apoptotic. AA is also the 
major source for the production of prostaglandins, lipid mediators with a wide range of 
physiological roles. We therefore wanted to examine the role of AA in WEHI-231 cell 
responses and in jparticular, the role of the PGs under similar conditions.
Initial studies examining DNA fragmentation confirmed a role for AA in the 
induction of apoptosis in WEHI-231 cells. However, the use of FACS analysis to 
examine cell-cycle profiles by propidium iodide binding highlighted that AA may also 
play a role in cell proliferation in addition to apoptosis. These results could be 
interpreted in a number of ways. Firstly, although we know the BCR is coupled to AA 
generation under conditions of growth-arrest and apoptosis, the treatment of WEHI-231 
cells with exogenous AA is very different to that produced intracellularly by way of 
signalling cascades. This may explain why high concentrations of AA are required to 
induce apoptosis in these cells. Secondly, with respect to the reduction of cells stuck in 
Gj arrest, internalised AA may indeed be broken down by other intracellular 
mechanisms such as cyclooxygenase activity into growth-promoting lipid metabolites 
such as PGE^, this may also explain why the AA analogue, AACOCF3, which is 
resistant to enzymatic breakdown is so damaging the cells. Thirdly, the ability of high 
A A concentrations to induce both apoptosis and cell-cycle progression may reflect the 
non-synchronised nature of WEHI-231 cells. Consequently, cells already in G, arrest 
at time of A A treatment may be pre-disposed to undergo apoptosis, whilst other cells 
enter cell-cycle progression without blockages. However, it may also reflect the need 
for AA stimulated cells to progress through the cell cycle before committing to 
apoptosis.
Previous studies measuring cell proliferation by means of pHjthymidine 
incorporation indicated the ability of AA to induce growth-arrest in WEHI-231 cells, 
which unlike BCR-ligation, could not be reversed by co-treatment with anti-CD40. 
However, FACS profiles using propidium iodide suggested that CD40 treatment was 
capable of rescuing AA-induced apoptosis. As these plots also indicated that the
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percentage of cells stuck in G, arrest actually fell, in could be concluded that the 
growth-arrest induced by AA in the [^H]thymidine studies was actually due to apoptotic 
cells. The question therefore remains, if CD40-treatment is capable of reversing AA- 
induced apoptosis, why was theieno rescue in thymidine samples co-treated with 
anti-CD40. It was not due to cells rescued from apoptosis entering a state of Gj arrest, 
as G, arrest levels were less in samples treated with AA and anti-CD40, which also 
enhances mitogenic ERK-MAPKinase activity, than AA alone. Nevertheless, the 
ability of CD40 ligation to rescue from AA-induced apoptosis suggests that CD40 
ligation activates signalling cascades to block downstream effectors of AA signalling. 
Indeed, recent studies within our lab (Katz et.al., Journal of Immunology, in press) 
have confirmed the ability of anti-CD40 to rescue from AA-induced apoptosis by 
reversing AA-mediated decreases in the mitochondrial membrane potential. The ability 
of AA to drive cells through the cell-cycle, in addition to apoptosis is confirmed by time 
course studies investigating ERK-MAPKinase activation. Unlike BCR-ligation, AA 
treatment was incapable of completely abolishing basal ERK-MAPKinase signals which 
have previously been shown to be essential for WEHI-231 cell proliferation. A A 
treatment, therefore, may lead to the selective activation of apoptotic signals, although 
not all cells undergo this process, and unlike anti-Ig stimulated cells continue to 
proliferate, explaining the inability of AA stimulation to downregulate basal ERK- 
MAPKinase activity.
AA-induced apoptosis was also shown to possibly involve ERK-MAPKinase 
activation as the ERK-MAPKinase inhibitor U0126 was effective in reducing AA- 
induced apoptosis, albeit marginally. Previous data suggested that AA treatment was 
ineffective in inducing the activation of an early ERK-MAPKinase signal previously 
shown to be esseptial in BCR-induced apoptosis. However, AA stimulation did appear 
to enhance ERK-MAPKinase activation at a later time point (approximately 2 hours post 
stimulation) In addition, studies within our group have shown that AA treatment, 
possibly via a positive feedback mechanism, leads to an increase in the generation of 
intracellular AA. Therefore, AA, as part of a positive feedback loop, may induce the 
activation of ERK-MAPKinase/cPLA^ at time periods out with the 60 minute window 
investigated in figure 48B. This would account for the ability of U0126 to weakly 
inhibit AA-induced apoptosis in WEHI-231 cells.
One puzzling event uncovered when examining the effect of AA treatment on 
WEHI-231 cells was its apparent ability to induce both growth and apoptosis. As AA 
is the main substrate for COX activity leading to the generation of intracellular PGs and 
PGs have been shown to have mitogenic properties in certain cells types it is tempting 
to speculate that some of the exogenously added AA is broken down by basal COX 
activity into PGs. We therefore decided to examine the what role was played by PGs in 
WEHI-231 cell fate. Initial studies treating cells with exogenous PGE^ suggested a
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negative role for PGE^ in both immature and mature B lymphocyte proliferation. 
However, these results may not truly represent the role of PGE^ produced 
intracellularly via receptor-mediated activation of COX. Accordingly, we measured the 
levels of intracellular PGE^ produced under both normal (untreated), death (anti-Ig), 
and rescue (anti-CD40) conditions. These results showed that PGEj production was 
suppressed by BCR-ligation, either by inhibition of COX activity or perhaps activation 
of the lipoxygenase pathway, converting AA into anti-apoptotic second messengers. 
However, co-treatment with anti-CD40 could help restore PGE^ production to near 
basal levels. As CD40 activation has previously been shown to upregulate both COX-2 
protein expression and activation (125), it seems feasible to predict that BCR-ligation 
leads to the suppression of COX activity preventing breakdown of newly generated AA 
into PGEg. However, co-treatment with CD40 could feasibly re-establish COX activity 
allowing for the breakdown of BCR-mediated AA generation into PGE^.
In order to confirm a role for COX in WEHI-231 cell fate the non-selective 
COX inhibitor indomethacin was used to dissect the involvement of COX under both 
positive and negative conditions. These results suggested that indomethacin treatment 
was marginally effective in reducing basal proliferation in addition to receptor-mediated 
proliferation via CD40 or IL-4 treatment. However, no effect on CD40-mediated 
rescue from BCR-induced growth arrest was observed. Although these results suggest 
that COXs may play a role in normal WEHI-231 cell proliferation but no role in CD40- 
mediated rescue, the involvement of COX in the latter response cannot be directly ruled 
out. The ability of indomethacin to prevent all COX activity was not established in 
these studies. Therefore, even in the presence of indomethacin, a residual COX activity 
may still be present. This may account for the inability of indomethacin to block CD40- 
mediated rescue from BCR-induced growth-arrest. Indomethacin was capable of 
marginally reducing [^HJthymidine incorporation of basal WEHI-231 cells, however, 
cells treated under such conditions will have little or no intracellular AA. However, 
cells treated with anti-Ig will have elevated AA levels, therefore, any residual COX 
activity will presumably convert this into PGE2. The ability of indomethacin to induce 
growth-arrest under some stimuli, but not others, may be due to the availability of AA 
as a substrate for residual COX activity.
Taken together, these results suggest that A A plays a pivotal role in determining 
WEHI-231 cell fate (figures 49 and 50). It also highlights the ability of CD40- 
ligation to utilise lipid metabolites produced under negative, BCR-mediated responses, 
suggesting that the balance of positive and negative lipid metabolities plays a vital role 
in both the death and survival of the cell.
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Figure 41. Primary prostanoid production. Role of COX in the 
conversation of AA to PGE^. Cyclooxygenase (COX-1 (constitutive) and COX 
2  (inducible)) catalyses the first two steps of prostaglandin (PG) synthesis from the 
substrate, arachidonic acid (AA). The first step involves the oxidation of AA to the 
hydroperoxy endoperoxide PGG^ and then its subsequent reduction to the hydroxy 
endoperoxide, PGHj. PGH2 is then transformed by a range of enzymatic and 
nonenzymatic mechanisms into the primary prostanoids, PGE^. PGD^, PGF^, PGI^ 
and TXAj.
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Figure 42. AA induces moderate growth-arrest and down-regulation of 
ERK MAPKinase in WEHI-231 cells. A. WEHI-231 cells (lOVwell) were left 
untreated, or treated with anti-Ig (10 jig/ml) or anti-Ig plus anti-CD40 (both 10 |ig/ml). 
In addition, cells were also treated with AA (25 |LiM) or AA plus anti-CD40 (10 |ig/ml). 
Proliferation was assessed by measuring [^Hjthymidine uptake at 48 hours. Values 
shown are the means ± SD of quadruplicate wells. B. WEHI-231 cells (5 x lOVml) 
were stimulated as follows: lane 1, cells left untreated for 0 hours, lane 2, cells left 
untreated for 1 hour, lane 3, cells left untreated for 2 hours, lane 4, cells left 
untreated for 4 hours, lane 5, cells left untreated for 8 hours, lane 6, cells left 
untreated for 24 hours, lane 7, cells left untreated for 48 hours. Levels of 
pERK/wERK expression were determined by western blotting (30 jig/lane). Ç.
WEHI-231 cells (5 x lOVml) were stimulated as follows: lane 1, cells left untreated 
for 0 hours, lane 2, cells treated with AA (25 |iM) for 1 hour, lane 3, cells treated 
witli AA (25 | l iM )  for 2 hours, lane 4, cells treated with AA (25 |L iM ) for 4 hours, 
lane 5, cells treated with AA (25 jiiM) for 8 hours, lane 6, cells treated with AA (25 
|xM) for 24 hours, lane 7, cells treated with AA (25 fxM) for 48 hours, lane 8, cells 
treated with AA (25 p.M) plus anti-CD40 (10 jig/ml) for 1 hour, lane 9, cells treated 
with AA (25 fiM) plus anti-CD40 (10 |Xg/ml) for 2 hours, lane 10, cells treated with 
A A (25 p-M) plus anti-CD40 (10 pg/ml) for 4 hours, lane 11, cells treated with AA 
(25 pM) plus anti-CD40 (10 pg/ml) for 8 hours, lane 12, cells treated with AA (25 
pM) plus anti-CD40 (10 pg/ml) for 24 hours, lane 13, cells treated with AA (25 pM) 
plus anti-CD40 (10 pg/ml) for 48 hours, lane 14, cells left untreated for 48 hours. 
Levels of pERK/wERK expression were determined by Western blotting (30 pg/lane).
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Figure 43. AA treatment induces apoptosis, but not activation of the 
three members of the MAPkinase family in WEHI-231 cells. A. Cells 
were left untreated or treated with anti-Ig (10 pg/ml) or AA (25 pM ). Levels of 
apoptosis were measured by DNA laddering after 48 hours cell stimulation. B. WEHI- 
231 cells (IxlOVml) were stimulated as follows: lane 1, cells left untreated for 0 
minutes, lane 2, cells treated with A A (25 pM ) for 1 minute, lane 3, cells treated 
with A A (25 pM ) for 5 minutes, lane 4, cells treated with A A (25 pM ) for 10 
minutes, lane 5, cells treated with AA (25 pM ) for 30 minutes, lane 6, cells treated 
with AA (25 pM ) for 60 minutes, lane 7, cells left untreated for 60 minutes. Levels 
of pERK/wERK; pp38/wp38; pJNKYwJNK expression were determined by Western 
blotting (15 pg/lane).
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Figure 44. Exogenous AA stimulation promotes further generation of 
intracellular AA.
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Figure 45. AA treatment induces apoptosis in WEHI-231 cells that can 
be reversed by co-treatment with anti-CD40. WEHI-231 cells (5 x lOVml) 
were treated with the indicated stimuli (anti-Ig and anti-CD40 both 10 pg/ml). Levels 
of apoptosis were determined by PI staining and FACS analysis after 48 hours as 
described in Materials and Methods.
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Table 2. AA treatment induces apoptosis in WEHI-231 cells. W EHI-231 
cells (5 X lOVml) were treated as figure 45. Cell cycle progression was determined by 
PI staining and FACS analysis after 48 hours as described in Materials and Methods.
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Sam ple S ub-d ip lo id G l/G O S G2/M
(% ) (% ) (% ) (% )
none 15.2 51.1 18.1 14.9
anti-Ig 25.8 58.3 10 6.2
anti-Ig 20.7 41.8 20.4 14.3
+ anti-CD40
AA (5 |iM) 12.6 49.3 19.9 16.5
AA (25 jiiM) 10.6 40.7 24.3 22.6
AA (50 jLlM) 24.9 34.6 23.8 14.6
AA (5 |xM) 12.8 39.8 24.5 17.2
+ anti-CD40
AA (25 ixM) 10.7 37.7 31.6 19.7
+ anti-CD40
AA (50 |iM) 17 31.8 30.2 20.6
+ anti-CD40
AA (5 |liM) 13.7 49.5 19.2 16
vehicle
AA (25 juiM) 14.2 49.5 17 16.4
vehicle
AA (50 |IM) 13.5 51.6 18.4 15.4
vehicle
Table 2
Figure 46. Exogenous PGEj has negative effects on both immature and 
mature B lymphocyte proliferation, A. WEHI-231 cells (lOVwell) were left 
untreated, or treated with anti-Ig (10 pg/ml) with or without PGE^, or treated with 
PGEj alone. Proliferation was assessed by measuring [^H]thymidine uptake at 48 
hours. Values shown are the means ± SD of quadruplicate wells. B. Mature splenic 
B lymphocytes (5xlOVwell) were left untreated, or treated with anti-Ig (50 pg/ml) with 
or without PGE^, or treated with PGE^ alone.
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Figure 47. Intracellular production of PGEj in WEHI-231 under 
apoptotic or rescue conditions. WEHI-231 cells (5x10^) were left untreated, or 
treated with anti-Ig (1 pg/ml) or anti-Ig and anti-CD40 (10 pg/ml) for the times 
indicated. Intra- and extracellular PGE^ levels were measured by immuno-assay (R&D 
Systems) according to the manufacturers protocol (see Material and Methods).
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Figure 48. Indomethacin inhibits basal and CD40-stimulated 
proliferation, but does not affect CD40-mediated rescue from BCR- 
induced growth-arrest. WEHI-231 cells (lOVwell) were left untreated, or treated 
with anti-Ig (10 ]Xg/ml), anti-CD40 (10 pg/ml), IL-4 (1 pg/ml) or anti-Ig plus anti- 
CD40 with or without pre-treatment with indomethacin (15 pM). Proliferation was 
assessed by measuring thymidine uptake at 48 hours. Values shown are the means 
± SD of quadruplicate wells.
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Figure 49. Model for the role of intracellular A A generation in WEHI- 
231 cell apoptosis. BCR-ligation induces cPLA^ activation, AA generation and the 
induction of apoptosis. BCR ligation also downregulates PGE^ production, 
presumably through inhibition of COX activity. CD40 mediated rescue from apoptosis 
reduces AA generation and re-establishes COX activity.
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Figure 50. Exogenous AA stimulation induces both positive and 
negative responses in WEHI-231 cells. AA stimulation leads to the induction of 
both apoptotic and proliferative responses. AA-mediated apoptosis has been shown to 
result from the disruption of the mitochondrial membrane potential and subsequent 
cytochrome c release. However, AA stimulation also induces cell cycle progression, 
possibly via the conversion of AA into PGE^ by basal COX activity.
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CHAPTER 6 - Regulators o f  MAPKinase activity in WEHI-231 cells. 
6.0 Introduction.
The MAPKinases play crucial roles in determining cellular responses activated 
by a wide range of receptor types. Previous studies in this project have shown both 
proliferative and apoptotic responses to be modulated by ERK-MAPKinase in WEHI- 
231 cells. This chapter aims to address the mechanisms utilised by WEHI-231 cells to 
regulate ERK-MAPKinase activity, both positively and negatively, to help dissect the 
signalling mechanisms behind these differential biological responses.
As many signalling elements are known to regulate ERK-MAPKinase activity, 
this chapter shall be split into two sections. Section 6.1 will discuss the classical 
regulators of BCR mediated ERK-MAPKinase patterns, whilst section 6.2 investigates 
regulation of ERK-MAPKinase activity by cross-talk with other signalling pathways, 
including the roles played by lipid kinases.
6.1 Classical regulators of ERK-MAPKinase activity.
Negative feedback mechanisms leading to the inhibition of ERK-MAPKinase 
activities have been widely reported and encompass molecules that compete as upstream 
substrates of the Ras-Raf signalling cassette. These molecules include the recently 
described Raf-kinase inhibitor protein or RKIP, which prevents MEK activation by 
Raf-1 (128), Ras-GTPases such as pl20GAP or Rapl which inactivates Ras. In 
addition, a number of protein tyrosine phosphatases such as PAC-1, MKPl, MKP-2 
and PP2A have been shown to directly downregulate ERK-MAPKinase activity. These 
molecules may therefore play key roles in the mechanisms of BCR-mediated down- 
regulation of ERK-MAPKinase in WEHI-231 cells in addition to modulating other 
BCR-mediated responses.
6.1.1 Phosphatases.
Protein phosphorylation is central to almost all cellular events. However, in 
order to prevent aberrant signalling events this mechanism is tightly regulated. 
Abnormalities in these check-points can lead to severe physiological disorders, such as 
autoimmune diseases, immunodeficiency and neoplasia (129). Originally, protein 
tyrosine kinases were thought to be the major regulators of tyrosine phosphorylation. 
However, the discovery of a large number of protein tyrosine phosphatases (PTPs) has 
shown protein tyrosine de-phosphorylation to play a key role in determining protein 
phosphorylation levels within the cell.
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Presently, three families of PTPs have been classified:
1. Classical PTPs.
2. Dual specific PTPs.
3. Atypical PTPs.
Although all three families have similar tertiary structures and similar catalytic 
mechanisms, they differ greatly in their relative sequence homologies (129).
6.1.1.1 CD45
Classical PTPs can exist as transmembrane (receptor) and non-transmembrane 
forms, however, perhaps the most widely studied PTP is the transmembrane molecule 
CD45 which is expressed on all leukocytes. Early views suggested a positive role for 
CD45 in B and T lymphocyte signalling (reviewed in (130)). These studies suggested 
that C-terminal Src kinase (Csk) phosphorylated the C-terminal negative regulatory 
tyrosine residue of the src-family PTKs. But, upon antigen receptor ligation, CD45 
could dephosphorylate this negative regulatory site allowing the Src-PTKs to become 
activated. A number of studies have since challenged this view, including work using 
CD45-deficient WEHI-231 cells. These studies investigated the basal phosphorylation 
state of the Src family PTK Lyn, showing Lyn to be both constitutively active, and 
hyper-phosphorylated at regulatory tyrosine residues (130) suggesting that Src family 
PTKs can be activated even with phosphorylated C-terminal tyrosine residues. Other 
studies have addressed the importance of CD45 in B lymphocyte development/function 
(reviewed in (129)). CD45-/- mice have been shown to possess a mature B cell 
population, but normal B cell development is disturbed. This may reflect the potential 
role for CD45 in setting the threshold for BCR responsiveness. Indeed, recent studies 
have shown CD45-/- B lymphocytes have raised BCR thresholds for activation (131). 
Further evidence to support this comes from studies in which mice expressing 
transgenic, HEL-specific BCRs, were crossed onto a CD45-/- background. 
Subsequently, upon antigen (HEL) exposure, a marked decrease in HEL-induced 
deletion was observed, again suggesting a positive role for CD45 in setting BCR 
threshold levels for the deletion of auto-reactive B cells.
6.1.1.2 SH2 domain containing tyrosine PTP (SHP-1)
In addition to the transmembrane phosphatase CD45, other non-transmembrane 
PTPs are known to play key roles in B lymphocyte development and function. These 
include the two SH2 domain containing tyrosine PTPs (SHP-1 and SHP-2). The role 
of SHP-1 in B lymphocyte development/function is now more clearly understood due 
to studies on motheaten {me) and motheaten viable (mc‘') mice. These are natural
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mouse mutants which are SHP-1 null or express catalytically inactive SHP-1 
respectively (129). These mice have defects in nearly all hematopoietic cell lineages and 
physiologically, have high serum immunoglobulin and autoantibody levels suggesting 
defects in B lymphocyte development/function. An important role for SHP-1 in 
regulating BCR-mediated responses was shown in studies using purified splenic B 
lymphocytes from me and me'" mice. Stimulation of these cells with LPS induced 
normal proliferative responses, whereas anti-IgM stimulation induced proliferative 
responses comparable to wild-type cells at one-tenth the normal dose of anti-IgM (132). 
In addition, developing B cells from me"' mice crossed onto a HEL-transgenic 
background were shown to be hyperresponsive to anti-HEL mediated deletion, with 
noimally sub-lethal doses of anti-HEL sufficient to induce cell death. Taken together, 
these results suggest SHP-1 plays an important role in regulating both BCR-mediated 
proliferative and negative selection processes. Studies have addressed the signalling 
pathways targeted by SHP-1 in B lymphocytes under such conditions. Recent work by 
Dustin et. al., 1999 (133) showed that expression of catalytically inactive SHP-1 
increased Ca^  ^mobilisation, extracellular signal-regulated kinase activation, and 
homotypic adhesion after BCR engagement suggesting that SHP-1 regulates both early 
and late events in B lymphocyte activation.
How BCR-mediated signalling events are regulated by SHP-1 is still relatively 
unclear. However, SHP-1 has been shown to be recruited to the B lymphocyte- 
restricted surface molecule CD22 upon BCR-ligation by binding to an ITIM motif in its 
cytoplasmic tail (17, 60). CD22 has been shown to negatively regulate BCR-mediated 
responses, with B cells from CD22 -/- displaying enhanced intracellular Ca^  ^responses 
and characteristics of chronic BCR stimulation (134). Further evidence confirming a 
negative role for CD22 has emerged from studies suggesting that CD22 may remove 
SHP-1 from the BCR complex following BCR ligation (129). Further evidence to 
suggest such a theory comes from studies by Fujimoto et. al. (134) who have shown 
that CD 19, which is required for optimal CD22 phosphorylation after BCR-ligation, 
regulates SHP-1 binding to CD22. CD22 has also been shown to be a key regulator of 
BCR-mediated MAPKinase activation. Studies (reviewed in (17)) have shown that 
crosslinking of CD22 with the BCR reduce BCR-mediated activation of both ERK- 
MAPKinase and INK, but not p38 MAPKinase. These studies used biotinylated Fab 
fragments of anti-Ig and CD22 antibodies and crosslinking was induced by the addition 
of avidin. In contrast to these experiments, studies have shown that pre-treating cells 
with anti-CD22 antibodies prior to BCR ligation actually enhanced ERK-MAPKinase 
and JNK activation. This contradictory report has been attributed to the ability of the 
anti-CD22 antibody to sequester CD22 away from the BCR complex so removing any
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negative regulatory effect it might yield, in turn decreasing the threshold for BCR 
signalling.
SHP-1 has been shown to be constitutively associated with the BCR in resting 
B cells, but rapidly dissociates after BCR stimulation (132). However, additional roles 
for SHP-1 in modulating BCR-mediated responses have arisen from studies showing 
the inducible association of SHP-1 with other transmembrane molecules. The first of 
these processes involves the Fc receptor, FcyRIIB. Crosslinking of this inhibitory 
receptor with the BCR by immune complexes is known to abrogate BCR-mediated 
proliferative responses in mature splenic B lymphocytes. Early experiments showed 
the recruitment of SHP-1 (and SHP-2) to the cytoplasmic tail of phosphorylated (ITIM) 
FcyRIIB suggesting a role for SHP-1 in FcyRIIB-mediated inhibition of BCR 
stimulation (17). However, the absolute involvement of SHP-1 in FcyRIIB -mediated 
inhibitory responses is in doubt. Firstly, FcyRIIB-mediated suppression of BCR- 
induced calcium influxes remained even in SHP-1-/- DT40 cells. Secondly, under these 
circumstances the lipid phosphatase, SHIP, is still recruited by FcyRIIB. Only in 
studies where SHIP was also deficient, did FcyRIIB -mediated inhibition of BCR- 
induced calcium influxes become reversed (17). However, FcyRIIB-mediated 
inhibition of BCR-induced proliferation in mature B lymphocytes has been shown to be 
impaired in SHP-1 deficient motheaten mice (60) suggesting that SHP-1 is not 
redundant in all FcyRIIB mediated signalling events.
6.1.1.3 Specific MAPKinase phosphatases
In the last decade a number of MAPKinase specific, nuclear phosphatases have 
also been isolated, cloned and functional studies carried out. These include the 
MAPKinase phosphatases, MKP-1 and MKP2, and also PAC-1. All three 
phosphatases are dual-specific, that is, they all dephosphorylate ERK-MAPKinase on 
tyrosine and threonine residues. MKP-1 was the first MAPKinase phosphatase to be 
discovered, and is encoded by the human CL 100 and mouse 3CH134 immediate early 
genes and was shown to be activated following oxidative stress and mitogenic 
stimulation (135). PAC-1, a 32kDa nuclear PTPase, was originally discovered as a 
nuclear product of an early-response gene induced by T-cell activation, and has been 
subsequently shown to be predominantly expressed in hematopoietic tissue (136). 
Recombinant PAC-1 possesses strong substrate specificity for MAP kinase and has 
been shown to inhibit MAPKinase activity stimulated by epidermal growth factor, 
phorbol myristyl acetate, or T-cell receptor crosslinking (137). Recent studies have 
also indicated a role for PAC-1 in B lymphocyte biology. A paper by Grumont et. al. 
(138) has shown that PAC-1 mRNA expression is suppressed in resting mature B
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lymphocytes, however, mitogenic concentrations of anti-Ig, LPS and anti-CD40 were 
all shown to upregulate PAC-1 mRNA expression. These results suggest that PAC-1 
may be involved in the regulation of proliferative B lymphocyte responses.
The in vivo substrates of MKP-1, MKP-2 and PAC-1 are also distinct, with 
MKP-1 dephosphorylating ERK-MAPKinase and p38, MKP-2 dephosphorylating 
ERK-MAPKinase and JNK, whilst PAC-1 dephosphorylates ERK-MAPKinase, JNK 
and p38 MAPKinase respectively (139). This therefore allows for greater regulation of 
MAPKinase activation and cross-talk following cell stimulation.
6.1.2 Ras-like GTPases and GAPs.
The Ras-like GTPases belong to a family of proteins which contain a 
characteristic effector domain. This region undergoes a substantial conformational 
change during the conversion of a GDP-bound form into the active GTP-bound form 
which has been likened to a molecular switch. The Ras GTPase protein is the most 
widely studied member of this family as it frequently occurs in a mutated, 
constituitively active, form in human tumours (140). Ras activation has been shown to 
play key roles in antigen receptor signalling events in both B and T lymphocytes. 
Regulation of Ras activation occurs via two opposing pathways: activation by upstream 
Ras guanine nucleotide exchange factors (GEFs) and inhibition by GTPase-activating 
proteins (GAPs) (figure 51). A number of GAPs are known to be responsible for the 
downregulation of Ras, including pl20GAP and neurofibromin (140). pl20GAP is 
known to associate with the RasGAP-binding protein p62'’°’^ and this molecule has 
recently been shown to be a key mediator of inhibitory FcyRIIB signals in B 
lymphocytes (68). This study also highlighted the ability of SHIP to act as an adaptor 
molecule. Briefly, the study by Tamir et. al. (68) suggested BCR- FcyRIIB co­
aggregation led to phosphorylation of FcyRIIB on its ITIM motif which in turn led to 
the recruitment of SHIP. This in turn creates a binding site for and She whilst 
also bringing them in close proximity to the BCR. p62^ '^ '^  could then be phosphorylated 
and recruit RasGAP which in turn converts BCR-stimulated Ras into its GTP-bound 
inactive form (figure 52).
In addition to RasGAPs, the Ras-like GTPase, Rapl, has been shown to be 
responsible for negatively regulating Ras-MAPKinase activation. Rapl consists as two 
isoforms, Rap la  and Rap lb, differing in only a few amino-acids at the C-terminus 
(140). Rapl has been shown to have an intrinsic GTPase activity approximately 10- 
fold lower that Ras, and unlike Ras, does not transform cells (140). Rapl activity has 
not been extensively studied in B lymphocytes, however, its role as a negative regulator 
of T lymphocytes responses has been studied (96). The only known GEF for Rapl is
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C3G. A model of Rapl activation by the TCR is shown in figure 53. Rapl activity 
has been shown to negatively regulate the ERK-MAPKinase signalling cascade in 
lymphocytes due to the ability of Rapl to compete with Ras for Raf-1 binding. 
However, these studies have utilised Rapl mutants where Rapl is transiently 
overexpressed and it is not known whether normal cellular levels of Rapl are sufficient 
to induce such a response (96). It has been suggested however, that Rapl expression 
is upregulated during the induction of anergy in T lymphocytes (96) again confirming a 
role for this GTPase in negative T lymphocyte signalling events. In addition to the 
antagonistic effects of Rapl, it should also be noted that recent studies have indicated a 
positive role for Rapl in the activation of sustained ERK-MAPKinase signals. These 
studies highlighted the role of Rapl in the differentiation of PCI2 cells with nerve 
growth factor (NGF) which is associated with sustained ERK-MAPKinase activation. 
Subsequent investigation revealed that Rapl formed a stable complex with B-Raf 
leading to ERK-MAPKinase activation (42, 141, 142). Therefore, it appears Rapl can 
mediate both positive and negative signals by activating cAMP-dependent B-Raf, but 
inhibiting Raf-1 activity.
6.1.3 RKIP
Recent studies by Yeung et. a l, 1999 (128), have highlighted the role of a new 
protein-kinase-inhibitor protein to suppress the activity of the Raf/MEK/ERK signalling 
cascade. The technique of yeast two-hybrid screening, using the structural Raf-1 
kinase domain (BXB) as bait, was used to isolate scaffolding and regulatory proteins 
involved in regulating the Raf/MEK/ERK signalling cascade. One recovered clone was 
shown to bind to both kinase-active and kinase-negative BXB and was subsequently 
termed RKIP. RKIP, now known to be widely expressed in a range of cell types, was 
shown to suppress ERK-MAPKinase activity by disrupting the ERK-MAPKinase 
pathway primarily at the Raf/MEK interface both in vitro and in vivo (128) by directly 
disrupting the interaction between these two kinases.
6.1.4 Aim of studies.
The aim of th| s study is to investigate BCR-induced growth-arrest, and in 
particular, the mechanisms underlying the long-term down-regulation of ERK- 
MAPKinase.
In particular, we will focus on whether:
1. BCR-ligation uncouples elements of the Ras/Raf/MAPKinase pathway by 
recruitment of RasGAPs or other negative regulatory elements.
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2. known ERK-MAPKinase phosphatases, especially PAC-1 are regulated during 
BCR-mediated signalling cascades.
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6.1.5 Results.
6.1.5.1 BCR ligation increases the association of ERK-MAPKinase 
with the nuclear phosphatase PAC-1.
In order to determine a possible mechanism by which BCR ligation down­
regulates ERK-MAPKinase activation, we decided to investigate whether PAC-1 played 
any role in this process. PAC-1 is an inducible nuclear phosphatase which has been 
shown to possess strong substrate specificity towards ERK-MAPKinase. To 
investigate a possible association between ERK-MAPKinase and PAC-1, whole cell 
lysates were immuno-precipitated with an antibody recognising ERK-MAPKinase. 
Samples were then subjected to SDS-PAGE and probed with an antibody recognising 
PAC-1. Western-blot analysis revealed an association with ERK-MAPKinase and 
PAC-1 which increased with time following BCR ligation (Bgure 54A). This 
suggests that BCR ligation leads to an increase in the association of these two enzymes 
which may result in the dephosphorylation of ERK-MAPKinase. Interestingly, co­
treatment with CD40 prevents this increase in association, suggesting that CD40 
treatment reverses BCR-mediated growth arrest by re-establishing a proliferative ERK- 
MAPKinase by suppressing the association of PAC-1 with ERK-MAPKinase. In order 
to rule out the possibility of BCR-mediated increases in PAC-1 protein expression, 
whole cell lysates were probed with anti-PAC-1 antibody and compared to wERK 
expression used as a loading control for whole protein levels (figure 54B). 
Interestingly western blot analysis showed that PAC-1 protein levels varied with time 
(0-48 hours) by both anti-Ig and anti-Ig plus anti-CD40 treatment. However, the most 
pronounced effect on PAC-1 protein expression resulted from co-stimulation with anti- 
Ig and anti-CD40. This observation is in agreement with other studies which observed 
increases in PAC-1 mRNA levels following CD40 stimulation in mature B lymphocytes 
(138). However, together, these observations suggest that although PAC-1 protein 
expression is upregulated by anti-CD40 stimulation, the association with ERK- 
MAPKinase is decreased.
Additional studies have examined whether ERK-MAPKinase associates with the 
phosphatase PP2A. Initial experiments suggest that ERK-MAPKinase and PP2A are 
constituitively associated with each other, and this association remains unchanged 
regardless of cell stimulation. Whether PP2A activity is modulated by BCR-ligation 
has not yet been addressed in immature B cells and warrants further study.
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6.1.5.2 Role of GAPs in WEHI-231 ceil signalling.
Having shown that early, BCR-mediated ERK-MAPKinase signals correlated 
with Ras activation in WEHI-231 cells (figure 25C), similar studies were carried out 
to examine whether long-term ERK-MAPKinase signals (0-48 hours) were also 
activated in a Ras-dependent manner (figure 55A). WEHI-231 cells left untreated 
were shown to express a basal Ras activity. Ras activity, unlike ERK-MAPKinase 
(figure 55B), was also observed over the whole 48 hour time course in anti-Ig treated 
cells suggesting that BCR-induced suppression of ERK-MAPKinase occurs 
downstream of Ras. Cells treated with anti-Ig and anti-CD40 were shown to have 
substantial elevations in Ras activity, suggesting that CD40 mediated rescue from BCR- 
induced growth arrest involves the enhanced activation of Ras.
In addition, as Rapl has previously been shown to uncouple TCR signalling 
through the Ras/Raf-1/MAPKinase, the activity of Rapl was measured following BCR 
ligation. Due to the specific nature of Raf-RBD (Ras) and Ral-RBD (Rapl) substrates, 
activated Ras and Rapl could be immunoprecipitated from the same source, allowing 
for the direct comparison of their relative activities. As previously shown, untreated 
WEHI-231 cells express a basal level of Ras activity which appears to be cyclic in 
nature and is probably linked to basal proliferation of this cell line (figure 55A and 
56A). Interestingly, untreated cells also expressed a high amount of activated Rapl 
protein (figure 56A). This may reflect a negative feedback mechanism utilised by 
WEHI-231 to prevent excessive ERK-MAPKinase activation during normal, 
unstimulated, proliferation. However, basal Rapl activity could also represent an 
additional model of basal Raf/ERK-MAPKinase activation which results in the 
activation of B-Raf by Rapl (42, 141, 142).
Previous studies had demonstrated that long-term BCR-ligation led to the down­
regulation of a basal, proliferative, ERK-MAPKinase signal which is presumably 
central to BCR-mediated growth-arrest in WEHI-231 cells. However, long-term BCR- 
ligation was ineffective in down-regulating Ras activity in these cells (figures 55A 
and 56A). Therefore, some other mechanism must be activated upon BCR-ligation to 
uncouple Ras-activity from ERK-MAPKinase activation. We therefore examined 
whether Rapl activity was induced by BCR ligation and hence down-regulate ERK- 
MAPKinase activity. Initial studies (figure 56A) indicated that BCR ligation did not 
induce Rapl activation suggesting that this pathway is not utilised in the down­
regulation of ERK-MAPKinase activity following BCR ligation.
Earlier findings had determined a role for CD40 in both re-establishing and 
strengthening ERK-MAPKinase activity in cells co-stimulated with anti-Ig to ligate the 
BCR. This was also seen to induce a late, but large increase in Ras activity compared
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to untreated cells (figures 55A and 56A). Studies also indicated that Rapl activity 
was not upregulated in these samples (figure 56A).
These results suggest that BCR ligation does not utilise Rapl activity in the 
down-regulation of ERK-MAPKinase activity in WEHI-231 cells. However, these 
results do suggest that Rapl activity may be important for the basal proliferation of 
these cells. In addition, the results indicate that co-stimulation with CD40, whilst 
substantially enhancing Ras activity compared to untreated cells, down-regulates the 
basal Rapl activity present in untreated cells.
6.1.5.3 BCR-ligation uncouples ERK-MAPKinase from its upstream  
m ediators.
In order to address the possibility that BCR ligation physically uncouples Ras 
from the Raf/ERK-MAPKinase signalling cassette, Raf-RBD pull down samples from 
figure 56A were stripped and re-probed with an antibody recognising whole ERK- 
MAPKinase (figure 56B) Cells left untreated, or co-treated with both anti-Ig plus 
anti-CD40, both proliferative signals, were shown to express wERK over the whole 
time range which followed the cyclic nature of Ras activation. However, cells 
stimulated with anti-Ig alone, although Ras activation could be detected (figure 56A), 
ERK-MAPKinase protein expression was markedly decreased indicating that BCR- 
ligation, in addition to regulating ERK-MAPKinase activity, promotes the dissociation 
of the Ras/Raf/MAPKinase signalling cascade. These results are therefore suggestive 
of a possible role for RKIP in the uncoupling of the Ras/ERK-MAPKinase signalling 
cascade.
6.1.5.4 RKIP-mediated suppression of ERK-MAPKinase by BCR- 
ligation is yet undetermined in WEHI-231 cells.
In order to determine whether RKIP could be responsible for BCR-mediated 
suppression of ERK-MAPKinase in WEHI-231 cells we examined whether RKTP/Raf- 
1 association was modulated by BCR, or indeed CD40 ligation. Whole cell lysates of 
WEHI-231 cells left untreated or treated with anti-Ig or anti-Ig and anti-CD40 over a 48 
hour period were immuno-precipitated with Raf-1 and subjected to SDS-PAGE. 
Membranes were then probed with RKIP (kindly provided by W. Kolch, Beatson 
Institute for Cancer Research, Glasgow). Unfortunately, the results indicated that the 
antisera to RKIP recognised multiple, non-specific, proteins and no accurate analysis of 
RKIP/Raf-1 association could be determined. However, these results do not rule out a 
role for RKIP in modulating ERK-MAPKinase activities in B lymphocytes.
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6.1.6 Discussion.
The results in this section aimed to address the role of a number of classical 
regulators of ERK-MAPKinase activation in order to dissect the signalling mechanisms 
involved in the downregulation of ERK-MAPKinase activities following BCR-ligation. 
This phenomenon is likely to result from the activation of a wide range of signalling 
molecules following BCR-ligation and not solely one particular signalling element.
This is likely because ERK-MAPKinase is known to act as both a cytoplasmic protein 
kinase, but also translocates to the nucleus upon activation where it acts as a nuclear 
protein kinase activating transcription factors. Therefore termination of this signal 
probably involves the activation of both nuclear and cytoplasmic regulators of ERK- 
MAPKinase.
Initial studies examined the role of the nuclear phosphatase PAC-1 in the 
regulation of ERR-MAPKinase activity following BCR ligation. These results suggest 
that BCR ligation promotes the association of PAC-1 with ERK-MAPKinase 
suggesting that PAC-1 may be involved in the dephosphorylation, and hence 
inactivation, of this kinase. Interestingly, the co-association between PAC-1 and ERK- 
MAPKinase appeared to be enhanced approximately 4-8 hours post anti-Ig treatment, 
however, it remains to be determined whether these interactions are localised to the 
nucleus. This fits the kinetics of previous experiments which showed the down­
regulation of basal, proliferative ERK-MAPKinase signals at approximately the same 
time. Interestingly, this co-association was reversed by co-treatment with anti-CD40 
indicating that CD40 ligation leads to the regulation of nuclear- aswell as cytoplasmic- 
signalling events. Additional experiments have suggested that co-stimulation of anti-Ig 
treated cells with anti-CD40 results in upregulated PAC-1 protein expression. This is in 
agreement with other studies (138) which described increased expression of PAC-1 
mRNA in resting splenic B lymphocyte following mitogenic stimulation, including anti- 
CD40. However, why PAC-1 expression should increase during the rescue of WEHI- 
231 cells from BCR-induced growth-arrest is unclear, but suggests that PAC-1 may 
regulate ERK-MAPKinase responses during cell proliferation.
In addition to studying the role of PAC-1 in WEHI-231 cell signalling we 
examined the ability of BCR ligation to regulate Ras activity and hence down-regulate 
ERK-MAPKinase activity. Earlier studies in this section had described the inability of 
BCR ligation to down-regulate Ras activation. We therefore decided to examine Rapl 
GTPase activity as the effector binding domain of this can compete with Ras-GTP for 
downstream effectors such as Ras. A previous study by McLeod et. al., 1998 (44) had 
confirmed the ability of BCR-ligation to activate Rapl in WEHI-231 cells. However, 
these studies used extremely high levels of anti-Ig over relatively a short time course.
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We therefore wanted to examine whether BCR-ligation activated Rapl at lower anti-Ig 
concentrations and whether its activity was also modulated by CD40-ligation.
Our results indicated that BCR-ligation does not induce Rapl activation under 
conditions favourable to the induction of growth arrest and apoptosis in WEHI-231 
cells. In comparison, and initially rather surprising, untreated cells were shown to 
express high levels of active Rapl in a cyclic pattern. However, recent studies have 
suggested a role for Rapl in the sustained activation of ERK-MAPKinase by B-Raf. 
This suggests that basal ERK-MAPKinase activity, which is vital for cell cycle 
progression, may be activated via a Rapl/B-Raf dependent mechanism (figure 57), 
however, basal Ras activity suggests that it is not the sole pathway leading to ERK- 
MAPKinase activation. The loss of Rapl activity in anti-Ig stimulated cells may 
therefore be due to the uncoupling of this mechanism, resulting in the loss of basal 
ERK-MAPKinase activity and hence growth arrest, all of which we have observed 
following BCR-ligation. Interestingly, co-stimulation of anti-Ig treated cells with anti- 
CD40 did not restore basal Rapl activity, but has previously been shown to restore 
ERK-MAPKinase activity, in addition to enhancing Ras activation.
In order to investigate whether BCR-ligation lead to the dissociation of the 
Ras/Raf/ERK signalling cascade, Ras assay blots (figure 56A) were stripped and re­
probed with an antibody to ERK-MAPKinase. Surprisingly, these results indicated that 
that GTP-bound Ras was complexed to ERK-MAPKinase in cells left untreated, or 
stimulated with anti-Ig plus anti-CD40 (both proliferative in nature). In contrast to this, 
ERK-MAPKinase was not complexed with GTP-bound Ras in cells treated with anti- 
Ig. These results indicate that the Ras/Raf/MEK/ERK signalling cascade may exist as a 
pre-formed complex in WEHI-231 cells and that BCR ligation promotes the 
dissociation of this complex and inhibition of ERK-MAPKinase signalling. The 
recently described Raf binding protein, RKIP (128), has been shown to suppress ERK- 
MAPKinase activity by competitively disrupting Raf/MEK interactions. We therefore 
examined whether this molecule was involved in the disruption of the Ras/Raf/ERK 
cascade following BCR ligation. Unfortunately, initial studies have been unable to 
address this hypothesis.
144
6.2 Cross-talk regulation of ERK-MAPKinase activity by BCR- 
activated signalling pathways.
In addition to the mechanisms discussed in section 5.1, other signalling 
pathways are known to directly regulate ERK-MAPKinase activity. Unlike the 
regulatory processes described above, many of these pathways are initiated upon 
receptor ligation and regulate ERK-MAPKinase activity through the activation of cross­
talk mechanisms. This section will concentrate on three known signalling elements 
which are known to regulate ERK-MAPKinase activity. These include cAMP and the 
lipid kinases, PI(3)K and sphingosine kinase.
6.2.1 cAMP and the phosphodiesterases.
Adenosine-3’, 5’-cyclic monophosphate (cAMP) is known to a play central role 
in many biological responses. However, its role as a negative regulator of cell growth 
is perhaps the most widely documented of these functions. Elevation of intracellular 
cAMP levels has been shown to promote growth arrest in growth-factor stimulated 
fibroblasts (including rat-1 and NIH 3T3 cells), smooth muscle cells and adipocytes
(142). In addition, cAMP has also been shown to play a key role as a negative 
regulator of proliferation in lymphocytes (143). Indeed, early studies indicated that 
cAMP generating agents such as cholera toxin, forskolin and prostaglandin E ,^ were 
able to inhibit BCR-mediated proliferation of both human and murine lymphocytes 
(144).
cAMP is generated by the membrane bound adenylyl cyclases which catalyse 
the generation of cAMP from ATP. Presently, there are more than eight isoforms of 
adenylyl cyclase, each genetically unique, being encoded from separate genes (143). A 
wealth of literature has arisen examining the downstream effectors of cAMP generation, 
where subsequently, the cAMP-dependent protein kinase, PKA, has been shown to 
play a key role. PKA is a holoenzyme consisting of two regulatory and two catalytic 
sub-units. cAMP binding to the regulatory subunits causes the release and subsequent 
activation of the two catalytic subunits. The catalytic subunits act as serine/threonine 
kinases with both cytoplasmic and nuclear substrates (143, 145). The nuclear targets of 
PKA are transcription factors, consisting of members of the cAMP responsive element- 
binding factor (CREB) family, whilst cytoplasmic targets include PKC activation and 
the inhibition of PIP^ breakdown by PLCy. In addition, the role of cAMP/PKA as a 
negative regulator of ERK-MAPKinase activity has been reviewed in T lymphocytes
(143) where PKA activity has been shown to suppress Raf-1 activity stimulated 
through the TCR/CD3 receptor complex.
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Intracellular cAMP levels are tightly regulated to help maintain the normal 
homeostasis of the cell. This process is achieved by both the regulation of cAMP 
generation, but also by cAMP degradation by the cyclic nucleotide phosphodiesterases 
(PDEs). The PDEs form part of a multigene family and have been shown to have roles 
in vascular relaxation, cardiac muscle contraction and inflammation (143). They can be 
separated into at least seven functional classes, depending on their substrate specificity, 
inhibitor sensitivity and molecular sequence (146). Catalytically, the PDEs promote the 
hydrolysis of cAMP and cGMP to their respective 5’ nucleoside monophosphates. In 
recent years, the mechanisms underlying PDE activity and expression have been studied 
extensively. Reports suggest that anti-CD3 or TCR-mAbs induce a slow, but sustained 
activation of PDE4. In addition, this was shown to be PKC-dependent as selective 
inhibitors of PKC could block this effect, but could be mimicked by phorbol ester 
treatment (143). More recent reports have suggested roles for both ERK-MAPKinase 
and PKA itself in regulating PDE activity and expression. Studies by Lui and 
Maurice, 1999 (146), provided evidence suggesting that PKA caused the 
phosphorylation and activation of the PDE4D3 and PDE4D5 isoforms in vascular 
smooth muscle. PDE4D3 was also activated by PKC-mediated ERK-MAPKinase 
activity in the same cells, whilst, co-activation of both PKA and ERK-MAPKinase 
allowed for both the activation, but also translocation of PDE4D3 from the particulate to 
the cytosolic fraction of the same cells.
The role played by cAMP/PKA in lymphocyte signalling remains controversial. 
However, a number of lines of evidence exist to suggest that cAMP my play role in 
lymphocyte responses. A range of stimuli regulating B lymphocyte function including 
anti-Ig, IL-4 and IL-10, which induce DNA synthesis and differentiation, have been 
shown to be tightly influenced by cAMP (144). An emerging area of cAMP/PKA 
signalling in B lymphocytes is via CD40 ligation, although evidence for this is remains 
controversial. A number of studies have observed CD40-mediated increases in cAMP 
levels in both human tonsillar B cells activated with anti-CD40 antibodies and also 
murine splenic B cells treated with activated T cell clones or membranes (145). 
However, reports also suggest that cAMP/PKA signalling events regulate, but are not 
activated by, CD40-ligation. For example, studies by Goldstein et. a l (145) provided 
evidence for the role of cAMP/PKA in CD40 signalling by using a tetracycline- 
repressible dominant-negative form of PKA in the B lymphoma line M12. Expression 
of a dominant-negative form of PKA inhibited cAMP mediated growth arrest which 
was reversed upon tetracycline treatment. However, expression of the dominant- 
negative PKA had no effect on CD40-mediated growth arrest suggesting that CD40- 
mediated growth arrest in M12 cells is cAMP/PKA independent. Other studies 
examining a role for PKA in CD40 mediated signalling events have shown that unlike 
BCR-ligation, CD40-mediated activation of ERK-MAPKinase uses an unidentified
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PKA-insensitive MEKK (ie. other than Raf-1) to regulate ERK-MAPKinase activation 
(97).
6.2.2 Lipid kinases
Important roles for sphingophospholipid- and glycerophospholipid-derived 
second messengers in determining cell fate have been shown in a wide range of studies 
over many years. Perhaps the most intensely studied of all lipid second messengers are 
ceramide and 1,2-diacylglycerol (DAG). Not only do these second messengers act as 
signalling intermediates, but that also have key structural roles as they form the 
backbone of all phospholipids, existing as bound or free forms making up 1-2% of total 
phospholipid levels in mammalian cells (147).
The structural roles of the glycerophospholipid-derived second messenger DAG 
are well established. However, its generation and ability to activate protein kinase C 
(PKC) remain less well understood. DAG is produced from the hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP^) by the activation of phospholipase C 
(PLC) (148). Currently, three PLC isoforms have been discovered and include PLCP, 
PLCy and PLCÔ. All three PLC isoforms share similarities in their structure. 
Subsequently, each isoform is known to contain two regions of high homology, 
preceded by a lipid-binding pleckstrin homology (PH) domain. To-date a number of 
mechanisms exist explaining the activation of PLC. These include the activation of 
PLC-p by hetertrimeric G-proteins, whilst PLC-y is recruited to the cell membrane by 
binding to receptor tyrosine kinases via its SH2 domains and is activated by subsequent 
phosphorylation (147).
In addition to the above mentioned sphingophospholipid and glycero- 
phospholipid lipid pathways, other phospholipid generating pathways have been shown 
to play keys roles in a wide range of cellular responses. Perhaps the most important of 
these was the discovery of phosphoinositide-3-OH kinase (PI(3)K) over a decade ago.
6.2.2.1 Structure, function of PI(3)K.
PI(3)K was originally discovered due to its association with the polyoma middle 
T antigen, ppôO'"'*'' and pp68'"’'”®, and with anti-phosphotyrosine immunoprecipitates 
from PDGF-stimulated fibroblasts (149). These studies also suggested a potential role 
for PI(3)K in mitogenic responses. The kinase activity of PI(3)K is known to 
phosphorylate the D3-hydroxy-group of the inositol headgroup of phosphoinositides 
(figure 58A). Subsequently, PI(3)K has been shown to phosphorylate PtdIns(4)P 
and PtdIns(4,5)P2 to produce PtdIns(3,4)P2 and PtdIns(3,4,5)P3 respectively (150).
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Use of modem molecular biology techniques has identified PI(3)K to consist of a 
number of family members. Subsequently, three sub-families of PI(3)K have been 
described, each based on its specific in vitro substrate specificity (149). These sub­
families can be summarised as follows:
• Class I PI(3)Ks - heterodimers of approximately 200kDa (110-120kDa 
catalytic subunit and a 50-100kDa adaptor subunit) that phosphorylate Ptdlns 
and Ptdins(4,5)P2 (preferred substrate).
• Class II PI(3)Ks - 170-210kDa proteins with no identified adaptor 
molecules that phosphorylate Ptdlns and Ptdlns 4-P.
• Class III PI(3)Ks - exclusively phosphorylate Ptdlns.
Class I PI(3)Ks can be divided further into class lA and class IB (151). Class 
lA PI(3)Ks (consisting of p i 10a, p i lOp or p i lOy catalytic subunits) associate with a 
p85 adaptor protein essential for interaction with receptor tyrosine kinases. Class IB 
PI(3)K is activated by heterotrimeric G-protein sub-units and associates via its N- 
terminus with a plOl adaptor subunit which is believed to confer GPy sensitivity to 
PI(3)Ky (149).
The structure of class lA PI(3)Ks has been extensively studied by many groups 
and has produced many insights into its activation process. The p85 prototype adaptor 
(or regulatory) sub-unit associated with the class lA PI(3)Ks is a multi-domain 
molecule consisting of N-terminal SH3 domains, a BH domain flanked by two proline 
rich regions and two C-terminal SH2 domains and also a inter-SH2 domain that 
mediates the association of p85 with the catalytic sub-unit (149) (figure 58B).
This structural information has helped in the understanding of the mechanisms 
underlying class lA PI(3)K activation. In quiescent cells, class I PI(3)K is inactive, but 
in the presence of extracellular stimuli, is rapidly activated. Although the precise 
mechanisms for both maintaining PI(3)K in an inactive state and subsequent activation 
are still under much investigation some theories have come to light (reviewed in 
Wymann et. al., 1998 (149)). It has been suggested that class I PI(3)K is kept inactive 
due to the intrinsic protein serine kinase activity of its associated catalytic subunit. This 
allows regulatory subunits to become phosphorylated on Ser residues (Ser^^^of p85a) 
which in turn reduces lipid kinase activity.
Mechanisms of class I PI(3)K activation have been suggested that involve 
binding of different molecules to the different domains in the structure of PI(3)K. One 
such model has suggested that class lA PI(3)Ks can be activated by four co-operating 
processes:
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1. PI(3)K translocation to the plasma membrane by targeting the SH2 domains 
of p85 subunits to pYXXM motives of receptor protein tyrosine kinases or 
their substrates.
2. Binding of GTP-loaded Ras to a Ras-binding domain (RBD) in the catalytic 
subunit.
3. Binding of proline-rich regions of She, Cbl and dynamin to p85 SH3 
domains.
4. Binding of Lyn, Fyn, Grb2, v-Src, Abl and Lck SH3 domains to p85 
proline rich regions.
Downstream targets of PI(3)K include a wide range of protein kinases leading 
to physiological responses such as actin rearrangement, vesicular trafficking, cell 
adhesion, growth or survival (figure 59). The protein Ser/Thr kinase Akt/PKB has 
received much attention as a major downstream substrate of PI(3)K activity. Much of 
this attention is attributable to the survival signal provided by Akt/PKB in many cell 
systems. Akt/PKB was first discovered in the early 1990s as a retroviral oncogene 
which was amplified in many human tumours (152). Further analysis of the cellular 
function of Akt has revealed that it acts as a strong mediator of growth-factor-induced 
survival and has been shown to suppress apoptosis induced by a wide range of stimuli 
(32). Akt is activated both upon membrane localisation and phosphorylation of Ser'^ ’  ^
and Thr^ °® residues. PI(3)K is known to be crucial for these events because membrane 
localisation of Akt is dependent upon binding to PtdIns(3 ,4 )P2/ PtdIns(3 ,4 ,5 )P3 and 
phosphorylation on Thr^°  ^and Ser'^ ^^  requires the activity of PtdIns(3 ,4 ,5 )P3-dependent 
protein kinases (PDKs). PDK-1, known to be directly activated by PtdIns(3 ,4 )P2 and 
PtdIns(3 ,4 ,5 )P3 (150) phosphorylates Akt on Thr °^  ^only. Therefore, additional 
protein kinases are required for full activation of Akt, and these may also be under the 
control of PI(3)K lipid products. PI(3)K activation, and in particular PIP3 generation, 
has also been shown to be important for the activation of both PLCy and Btk in 
lymphocytes. Under these circumstances PIP3 accumulation at the plasma membrane 
acts as a specific membrane binding site for the PH domains of both PLCy and Btk. 
This allows these enzymes to then come into contact with membrane associated tyrosine 
kinases that are required for their full activation (36). In addition, PI(3)K has been 
shown to exert its anti-apoptotic response by suppressing ceramide generation in TNF- 
a  treated MCF-7 cells suggesting cross-talk between PI(3)K and SMase pathways 
(153).
149
6.2.2.2 A dual role for PI(3)K as both a lipid and a protein kinase.
An emerging area of PI(3)K interest lies in its role as both a lipid and a protein 
kinase. Mutations to the catalytic core of PI(3)Ka and PI(3)Ky corresponding to a 
region of the activation loop in protein kinases have allowed the generation of protein 
kinase-active, but lipid kinase-inactive mutant enzymes (149). Studies by Lopez- 
Ilasaca et al. (154) have shown that lipid-kinase inactive PI(3)Ky mutants are still able 
to activate ERK-MAPKinase in a G-protein dependent manner. In addition, studies by 
Bonde va et al. (155) have shown that PI(3)Ky lipid kinase-inactive mutants are as 
effective as wild-type PI(3)Ky in LPA-mediated ERK-MAPKinase activation. These 
studies highlight a new area for PI(3)K signalling.
6.2 2.3 Role of PI(3)K in B lymphocyte signalling.
PI(3)K activation is also known to play key roles in BCR mediated signalling 
pathways leading to B lymphocyte differentiation (156) and survival (36). Indeed, 
ablation of PI(3)K signalling in B lymphocytes by targeted disruption of the p85a 
regulatory subunit has been shown to lead to impaired B cell development at the pro-B 
cell stage and reduced numbers of mature B cells with decreased proliferative responses 
to BCR-ligation, LPS and anti-CD40 stimulation, a phenotype similar to that of xid 
(Btk)-deficient mice (157). This similarity in phenotypes between p85a -/- and xid 
mice is due to the involvement of PI(3)K activity in Btk activation. Studies have shown 
that the PH domain of Btk binds to PtdIns(3,4,5)P3 (generated by PI(3)K) in the 
plasma membrane, and that this membrane recruitment is required for the enzymatic 
activation of Btk. Therefore in the case of p85a -/- mice, the reduced generation of 
PtdIns(3,4,5)P3 results in decreased Btk activity. In addition, the mutation to Btk in 
xid mice is known to be located in the PH domain, which also results in decreased Btk 
activation, but this time due to the defective binding of Btk to membrane 
PtdIns(3,4,5)P3.
BCR-mediated activation of PI(3)K has been shown to occur via Ras-dependent 
mechanisms, where active GTP-bound Ras binds the catalytic sub-unit of PI(3)K. In 
addition, the activation of PI(3)K has been shown to result from the phosphorylation of 
CD 19 following BCR ligation. This mediates the association and activation of PI(3)K 
due to SH2 domains in its p85 regulatory sub-unit which bind pTyr residues on the 
cytoplasmic tail of CD19 (7, 38, 156). In addition, the binding of PI(3)K to CD19 
following BCR-ligation also serves to localise PI(3)K to the plasma membrane where 
its phosphoinositide substrates are located.
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Although PI(3)K activity and PIP3 generation are crucial for normal B 
lymphocyte development, PIP3 levels generated through BCR ligation are attenuated 
through coaggregation of the BCR with the low affinity Fc receptor, FcyRIIB. This 
inhibition is due to the recruitment of the Src homology 2 domain-containing 5’ inositol 
phosphatase (SHIP) which hydrolyses the 5’ phosphate from PtdIns(3 ,4 ,5 )P3 to 
produce PtdIns(3 ,4 )P2- This in turn leads to the disruption of BCR-mediated PLCy 
and Btk signalling as both these molecules preferentially bind PtdIns(3 ,4 ,5 )P3 (67). 
Physiologically, this leads to decreases in BCR-mediated proliferative signalling in 
mature B lymphocytes due to decreased calcium influx resulting from impaired PLCy 
signalling (69) and impaired B lymphocyte development (16).
6.2.2.4 Sphingolipid signalling pathways.
Although sphingolipid-derived second messengers have been shown to play key 
roles in mediating both proliferative and apoptotic responses they still remain relatively 
unstudied. Perhaps the best known of the sphingolipid-derived second messengers is 
ceramide, which is generated through the sphingomyelin pathway and has been shown 
to have key roles in the induction of apoptosis by agents such as TNF-a or FasL (158). 
Sphingomyelin is preferentially located on the outer leaflet of the plasma membrane and 
is hydrolysed by the activation of a phospholipase C (PLC)-like enzyme, 
sphingomyelinase (SMase). Three classes of SMase are currently known, classified 
according to their pH optima and Mg^  ^-dependence. As well as the production of 
ceramide, the immediate product of SMase activity, other metabolities of sphingomyelin 
are known to function as second messengers. These include sphingosine (formed by 
the ceramidase-catalysed déacylation of ceramide), and sphingosine-1-phosphate (SPP) 
(formed by the sphingosine kinase-catalysed phosphorylation of sphingosine) (159). 
Interestingly, although ceramide is believed to be a negative regulator of cell fate by 
inducing apoptosis in a wide range of cell types, other sphingolipid-derived second 
messengers such as SPP have been shown to be mitogenic (147).
6.2.2.5 Structure and function of sphingosine kinase and its metabolite 
sph ingosine-l-phosphate.
Sphingosine-1-phosphate (SPP) is a highly polar lipid second messenger 
metabolised from sphingosine by the activation of sphingosine kinase (figure 60) and 
like many lipid messengers, has been shown to possess both intra- and extra-cellular 
actions (160). Evidence as an intracellular messenger is wide-spread with suggested 
roles in a wide range of cell types, from T lymphocytes to monocytes (159). SPP is
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believed to play a key role in many mitogenic responses including those activated via 
platelet-derived growth factor or fetal calf serum (161). It has also been shown to play 
a key role in anti-apoptotic responses by rescuing HL60 promyelocytic cells, U937 
monoblastic leukaemia cells and Fas-expressing Jurkat T lymphocytes from apoptosis 
induced by dimethylsphingosine, TNF-a, ceramide, sphingomyelinase, PKC inhibitors 
and Fas (159). The mechanisms behind these anti-apoptotic mechanisms are still 
poorly understood. Suggestions have been put forward suggesting that the balance of 
sphingosine to SPP may play key roles in determining cell fate. In addition, PKC may 
play a role in the suppression of ceramide-mediated apoptosis by the activation of 
sphingosine kinase. Studies by Cuviller et a l (162) provided evidence suggesting that 
not only could activation of PKC reverse ceramide induced apoptosis in HL-60 cells, 
but PKC mediated rescue was prevented using the competitive inhibitor of sphingosine 
kinase, N,N-dimethylsphingosine.
SPP, secreted by activated platelets (163), is also known to signal 
extracellularly through a group of orphan G-protein coupled receptors called Edg-1, 
Edg-3 and H218 (SPPRl, SPPR3 and SPPR2 respectively) (164).
G-protein coupled receptors comprise of seven membrane spanning domains, of 
which one interacts with the G-protein. G-proteins exist as trimers, consisting of ap  
and y subunits, although it is the a  subunit which possess GTPase activity. In the 
resting state, GDP is associated with the a  subunit, however, when the receptor 
becomes occupied by an agonist molecule a number of conformational changes occur 
resulting in the activation of target proteins (figure 61). Firstly, upon agonist 
binding, the aPy trimer associates with the receptor which causes the GDP bound to 
the a  subunit to dissociate and become replaced with GTP which in turn causes the 
dissociation of a-GTP from the py subunits. a-GTP, now in its active form now acts 
as an effector activating downstream signalling elements. However, it should be noted 
that Py subunits have also been implicated in the activation of downstream effectors. 
G-proteins can be divided into 4 families; G ,^ G^ ,^ G^  and Gj. The G-proteins G^  and 
Gj have been shown to stimulate or inhibit adenylyl cyclase activity respectively and are 
perhaps the most widely studied of all G-protein families. This is perhaps due to the 
ability of cholera toxin and pertussis toxin to inhibit signalling through G^  and G; 
coupled receptors respectively, enabling the investigation of the G-proteins involved in 
a number of biological systems to be explored.
The signals activated by SPP following the ligation of G.-coupled Edg-receptors 
have been shown to include the activation of PLD, leading to Ca^  ^mobilisation (163), 
the activation of ERK-MAPKinase via a pertussis toxin-sensitive pathway (164) and 
also the inhibition of forskolin induced cAMP generation (165). Studies have also 
suggested that SPP-mediated protection of T lymphocytes from apoptosis may involve
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signalling through distinct Edg receptors leading to the suppression of the pro-apoptotic 
molecule, Bax (166).
The cloning and characterisation of the first mammalian sphingosine kinase was 
carried out by the work of Kohama et. al. (160). In this study they reported on the 
structure of the murine sphingosine kinase. Their studies indicated that murine 
sphingosine kinase consisted of two isoforms with a reported molecular mass of only 
49 kDa. The authors also discussed that sequence analysis of these enzymes suggested 
that murine sphingosine kinases (SPHKl and SPHK2) belonged to a novel family of 
kinases, but did show evolutionary conserved regions common to other kinases.
6.2.3 Aims of study.
The aims of this investigation are:
1. To examine the role of cAMP in immature B lymphocyte responses to BCR and 
CD40 ligation.
2. To investigate the coupling of the BCR to PI(3)K activation under conditions of 
apoptosis and to examine the effect of co-stimulation with anti-CD40 on PI(3)K 
responses.
3. To investigate the coupling of the BCR to SPP production under apoptotic and 
proliferative conditions.
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6.2.4 Results.
Previous reports have suggested a negative role for cAMP in lymphocyte signalling. In 
addition, cAMP has been shown to negatively regulate key enzymes involved in 
signalling cascades, including ERK-MAPKinase by suppressing Raf-1 activity (143). 
Due to these results, and additional studies suggesting that cAMP levels could modulate 
BCR signals (144) we hypothesised that cAMP may play a role in BCR-mediated 
growth-arrest/apoptosis in WEHI-231 cells and may indeed mediate these signals by 
regulating ERK-MAPKinase activity.
6.2.4.1 Pharmacological increases in cAMP levels correlate with the 
induction of growth-arrest in WEHI-231 cells.
Initial studies were carried out to examine the role of increasing cAMP levels on 
basal WEHI-231 cell proliferation (figure 62). Cells treated with forskolin, a direct 
activator of adenyl cyclase, showed a dose-dependent increase in growth arrest 
indicating a potential negative role for cAMP in WEHI-231 cell growth. Additional 
studies indicated that increased cAMP levels could act in synergy with anti-Ig to 
increase growth-arrest, whilst anti-CD40 or anti-Ig plus anti-CD40 treated cells also 
witnessed a dose-dependent increase in growth-arrest with forskolin treatment (figure 
62).
6.2.4.2 Inhibition of PDE activity promotes growth-arrest in WEHI-231 
c e lls .
In order to investigate a role for cAMP in the regulation anti-Ig mediated WEHI- 
23 1 cell growth arrest, cells were treated with a range of PDE inhibitors which act 
intracellularly to prevent cAMP breakdown and therefore enhance intracellular cAMP 
levels. Previous studies from other groups have suggested that specific PDE isoforms 
are differentially activated under different conditions. For example, PDE4 has been 
shown to play an important role in the regulation of cAMP degradation in CD4^CD8^ 
thymocytes, whereas the role of PDE3 was redundant (143). In this study we therefore 
utilised the specific PDE inhibitors Rolipram (PDE4) and Cilostamide (PDE3) and the 
non-specific PDE inhibitor IB MX to study the role of the PDEs in WEHI-231 cell 
growth. Rolipram treatment (figure 63A) appeared to induce a concentration- 
dependent increase in growth-arrest. However, at low concentrations, thymidine 
uptake appeared to be enhanced, compared to basal, untreated cells. Thymidine 
incorporation levels from vehicle studies however, suggested that these increases may 
be due to cell stimulation from the vehicle used (DMSO). Treatment of WEHI-231 cells
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with the PDE3 specific inhibitor cilostamide (figure 63B) also induced growth-arrest 
in a concentration-dependent manner. Additional studies using the non-specific PDE 
inhibitor IBMX (figure 63C), also caused a concentration dependent increase in 
growth arrest. Once again, increased thymidine incorporation shown at lower IBMX 
concentrations may be attributable to the apparent stimulation of cell proliferation shown 
in vehicle controls. Taken together, these results suggest, but do not definitively 
confirm, that cAMP can negatively regulate basal proliferation of WEHI-231 cells.
6.2.4.3 BCR ligation suppresses PDE4 activity in WEHI-231 cells.
As previous studies (figures 62 and 63) addressed the role of cAMP in 
WEHI-231 cells by pharmacological enhancement of cAMP levels, additional 
investigations were carried out to address whether the BCR was coupled to pathways 
regulating cAMP levels/PDE activity under conditions of growth-arrest/apoptosis. 
Subsequent studies (figure 64; unpublished data by Sandra Seatter) compared 
the effect of BCR ligation or EPS treatment on PDE4 activity with time. PDE4 activity 
was maintained at a basal level in untreated (control) cells over a 24 hour period. 
However, BCR ligation was shown to cause an early, sustained decrease in PDE4 
activity, which recovered back to basal levels after approximately 7 hours. In contrast, 
EPS treatment, a mitogenic signal for WEHI-231 cells, enhanced PDE4 activity over 
the same time scale in which it was suppressed by BCR-ligation. These results confirm 
that the BCR is coupled to a pathway capable of suppressing PDE activity. In addition, 
the ability of EPS to enhance PDE4 activity suggests that other, proliferative pathways 
such as CD40, may be positively coupled to PDE activity.
6.2.4.4 Anti-CD40 co-stimulation can rescue from IB MX-induced 
growth arrest.
Previous studies in this thesis had postulated that BCR-mediated suppression of 
growth was due to the down-regulation of a vital ERK-MAPKinase signal. Anti-CD40 
treatment is known not only to restore growth, but also restore ERK-MAPKinase 
activity. Since cAMP is known to downregulate ERK-MAPKinase activity by 
suppression of Raf-1 activity in other systems, and the BCR is known to down-regulate 
PDE activity in WEHI-231 cells, does CD40-mediate some of its rescue signals by 
reversing cAMP-mediated effects? In order to investigate this hypothesis, the ability of 
the non-selective PDE inhibitor, IBMX, to block CD40-mediated effects was examined.
Treatment of WEHI-231 cells with IBMX induced growth-arrest, and also low 
levels of apoptosis (figures 65A and 65B). These correlate with previous findings 
suggesting a role for cAMP as a negative regulator of WEHI-231 cell growth. In
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addition, the effect of IBMX pre-treatment on BCR-mediated Ras and ERK- 
MAPKinase activation was also examined (figure 66A and 66B). These results 
indicated, that although IBMX at 10 p,M caused a small decrease in Ras activation it 
was relatively ineffective in modulating BCR-mediated ERK-MAPKinase activation. In 
contrast, treatment of cells with 20 |iM IBMX, previously shown to induce apoptosis, 
enhanced BCR-mediated ERK-MAPKinase activation.
Interestingly, co-treatment of cells with anti-CD40 antibodies could reverse 
IBMX-induced growth arrest (figure 65A). In addition, anti-CD40-mediated rescue 
of BCR-induced growth-arrest was unaffected by co-treatment with IBMX. This latter 
point would be consistent with ideas put forward by Purkerson et. al., 1998 (97) who, 
as previously mentioned, suggested that CD40-mediated ERK-MAPKinase activation 
was cAMP/PKA-independent/insensitive. It would therefore be interesting to examine 
whether cAMP generation downregulated basal ERK-MAPKinase activity in long-term 
(0-48 hour) samples during the induction of growth arrest and whether CD40 
costimulation could override this signal and re-establish ERK-MAPKinase activity.
6.2.4.5 Pharmacological inhibition of PKA does not reverse BCR- 
mediated grovrth arrest.
In order to examine the role of cAMP/PKA in WEHI-231 signalling, we 
investigated the effect of PKA inhibition in WEHI-231 cells treated under both negative 
and positive conditions. Figure 67 shows the effect of PKA inhibition using the 
pharmacological inhibitor H-89. Perhaps as expected, PKA inhibition did not inhibit 
the basal proliferation of WEHI-231 cells. Additionally, PKA inhibition did not reverse 
BCR-mediated growth arrest, suggesting that PKA is not involved in BCR-induced 
growth arrest. In addition, CD40-mediated rescue from BCR induced growth-arrest 
was unaffected by PKA inhibition.
These results would appear to suggest that BCR-induced growth arrest and the 
suppression of basal ERK-MAPKinase activities does not involve PKA activity.
6.2.4.6 BCR ligation leads to PtdIns(3,4,5)P^ generation in WEHI-231 
ce lls .
In order to determine if the BCR is coupled to PI(3)K activation, levels of 
PtdIns(3,4,5)P3 generation were measured following anti-Ig treatment over a time 
period of 60 minutes (figure 68A). The results show that anti-Ig stimulation induces 
a rapid increase in PtdIns(3,4,5)Pg production, peaking at 60 minutes. Interestingly, 
co-stimulation with anti-CD40 antibodies was shown to alter the kinetics of anti-Ig-
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induced PtdIns(3,4,5)P3 production, inducing an early enhanced, yet transient rise in 
PtdIns(3,4,5)P3 production, peaking at 5 minutes, which was downregulated with time 
there after. In addition, cells treated with only anti-CD40 produced PtdIns(3,4,5)P3 
generation profiles similar to those treated with anti-Ig plus anti-CD40. These results 
suggest that the BCR is coupled to PI(3)K activation and that late (30-60 minute) 
increases in PtdIns(3,4,5)P3 generation may play a role in BCR-mediated growth-arrest 
and apoptosis. Indeed, the kinetics of PtdIns(3,4,5)P3 production mirror that of BCR- 
induced ERK-MAPKinase activation, and its subsequent down-regulation by co­
stimulation with anti-CD40. Figure 68B shows the percentage of PtdIns(3,4,5)P3 
generation following anti-Ig and anti-CD40 co-stimulation relative to the levels obtained 
by anti-Ig treatment alone in a repeat experiment confirming that BCR-ligation induces a 
late (60 minute) PtdIns(3,4,5)P3 signal which is suppressed following co-treatment 
with anti-CD40.
6.2.4.7 PI(3)K inhibition prevents BCR-mediated activation of ERK- 
M APKinase.
Although Ras is known to lie upstream of PI(3)K in a wide range of signalling 
cascades, evidence is also emerging for a role of PI(3)K in the activation of ERK- 
MAPKinase. Due to the similarity in terms of kinetics of ERK-MAPKinase activation 
and PtdIns(3,4,5)P3 generation following anti-Ig and/or anti-CD40 treatment the ability 
of specific PI(3)K inhibitors to modulate BCR-mediated ERK-MAPKinase activation 
was examined (figure 69). Cells were pre-treated with either wortmannin (Wm) or 
Ly294002 (Ly) for different time periods and at different concentrations prior to anti-Ig 
stimulation for 30 minutes, which has previously been shown to induce a strong ERK- 
MAPKinase signal. Interestingly, both the Wm and Ly compounds were partially 
effective in reducing BCR-mediated ERK-MAPKinase activation. This suggests that 
PI(3)K activity lies upstream of ERK-MAPKinase activation following BCR ligation 
and that PI(3)K may play some role in BCR-mediated responses such as apoptosis. 
These results are consistent with other findings in which wortmannin blocked acute 
PDGF-dependent activation of Raf in CHO cells and also the inhibition of Raf kinase 
activation by nerve growth factor (167). However, wortmannin-mediated inhibition of 
MAPKinase is not universal and appears to be both cell- and stimuli-specific.
6.2 4.8 PI(3)K plays a non-essential role in BCR mediated apoptosis.
In order to address the hypothesis that PI(3)K may play a role in transducing 
negative BCR-mediated signalling events the ability of the PI(3)K inhibitors 
wortmannin (Wm) and Ly294002 (Ly) to prevent BCR-mediated apoptosis was
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examined. Therefore, following pre-incubation with either Wm or Ly, cells were 
treated with anti-Ig and the level of apoptosis measured by PI staining and measurement 
of DNA content. Anti-Ig treatment was shown to increase basal apoptosis levels from 
25.7% to 47.3% and this was partially reversed with co-treatment with anti-CD40 
antibodies, reducing apoptosis levels to 36.3% (figure 70). However, pre-incubation 
with either Wm or Ly, previously shown to partially block BCR-mediated ERK- 
MAPKinase activation, was ineffective in blocking BCR-induced apoptosis. Although 
this would appear to suggest that PI(3)K plays no role in the induction of apoptosis 
following BCR ligation in WEHI-231 cells, this may be explained due to the inability of 
PI(3)K inhibition to completely block BCR-induced ERK-MAPKinase activation. It 
could also suggest that other apoptotic mechanisms are activated following BCR- 
ligation and that PI(3)K mediated ERK-MAPKinase activation is not essential for the 
induction of cPLA^ activity or indeed other apoptotic signals. It would therefore be of 
interest to examine whether Wm or Ly treatment modulates BCR-mediated cPLA2 
activity.
6.2.4.9 Long-term BCR-ligation down-reguiates p85a-subunit protein  
expression .
Having ruled out an essential role for PI(3)K in early, BCR-mediated apoptotic 
responses, it still remained to be determined whether PI(3)K played a role in the long­
term rescue of WEHI-231 cells from growth-arrest by anti-CD40 stimulation. Western 
blot analysis of whole cell lysates suggested that protein levels of the p85a-regulatory 
subunit of PI(3)K were affected by BCR ligation (figure 71). These results 
suggested that long-term BCR ligation down-regulates p85 a  protein expression, which 
would in turn reduce PI(3)K activation due to disruption of the adaptor (regulatory) and 
catalytic sub-unit association required for PI(3)K activation (personal communication, 
Lewis Cantley). p85 a  protein levels were restored in samples co-stimulated with anti- 
CD40 antibodies indicating a role for CD40 in regulating BCR-mediated changes in 
PI(3)K signalling. These studies examined protein expression, it would also be 
interesting to examine whether p85a mRNA expression is modulated under similar 
conditions. What mechanisms the BCR activates in order to down-regulate p85 a  
protein expression are unclear, indeed, no reports exist suggesting the regulation of 
PI(3)K activity by modulating p85 a  protein levels.
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6.2.4.10 PI(3)K plays no apparent role in CD40-mediated rescue from 
BCR-mediated growth-arrest.
As the above study suggests a positive, possibly proliferative role for PI(3)K in 
WEHI-231 cells, we wanted to determine whether PI(3)K played a role in the 
regulation of basal ERK-MAPKinase activity and in CD40-mediated rescue of WEHI- 
23 1 cells. Cells were therefore pre-treated with either Wm or Ly and levels of 
proliferation/growth-anest measured by thymidine uptake and subsequent DNA 
synthesis. Pre-incubation with either inhibitor (figure 72A and 72B) had no effect 
on either anti-CD40 treated cells or cells treated with anti-Ig plus anti-CD40 suggesting 
that PI(3)K does not play an essential role in CD40 mediated rescue from anti-Ig- 
induced growth-arrest. Due to previous observations (results not shown) 
suggesting that the ERK-MAPKinase inhibitors PD98059 and U0126 had relatively 
short half-lives in WEHI-231 cells, additional studies were carried out in which both 
Wm and Ly were added at 1 hour pre-stimuli and then at the following time intervals; 1, 
2, 4, 8 , 12, 16, 20, 24 and 28 hours post-stimuli to maintain PI(3)K inhibition over a 
long time period. Prolonged additions of both Wm and Ly were effective in inducing 
substantial growth arrest of unstimulated cells indicating that PI(3)K activity may be 
important for the basal proliferation of WEHI-231 cells (figure 73). Prolonged 
additions also reversed CD40-mediated rescue, although this may be purely be due to 
the ability of Wm and Ly to inhibit basal proliferation in WEHI-231 cells.
6.2.4.11 Anti-CD40 mediated rescue from growth-arrest does not 
involve long-term PtdIns(3,4,5)Pg production.
The above results in this section have suggested roles for PI(3)K activity in the 
basal proliferation of WEHI-231 cells and possibly in CD40-mediated rescue from 
growth arrest. Therefore, long-term studies were carried out to examine the profiles of 
the PtdIns(3 ,4 ,5 )P3 generation in WEHI-231 cells during these responses and also 
during BCR-stimulation. Unlike ERK-MAPKinase, which has previously been shown 
to possess a cyclic pattern of activation in untreated (basal) cells, PtdIns(3 ,4 ,5 )P3 levels 
were maintained at a steady-state with very little fluctuation over time (figure 74) 
suggesting tight regulation of PtdIns(3 ,4 ,5 )P3 generation. In contrast, anti-Ig 
stimulated cells appeared to increase PtdIns(3,4,5)Pj levels with time, whilst cells 
treated with anti-Ig and anti-CD40 suppressed PtdIns(3 ,4 ,5 )P3 profiles similar to 
untreated cells. The finding suggesting that long-term BCR ligation, but not other 
stimuli, increases PtdIns(3 ,4 ,5 )P3 levels appears contradictory to earlier studies as 
similar treatment has also been shown to cause substantial down-regulation of p85a 
protein expression. However, reports (personal communication, Lewis Cantley)
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suggest that other regulatory sub-units such as p85p or p55y may be recruited under 
such circumstances restoring PI(3)K activity. These studies also indicate that BCR- 
stimulated PtdIns(3 ,4 ,5 )P3 generation may be involved in the promotion of growth 
arrest in WEHI-231 cells.
Although these results suggest that BCR-induced PtdIns(3 ,4 ,5 )P3 generation 
may play a role in the induction of growth arrest, results similar to those described in 
the human RL B cell line (17), they do not rule out positive roles for PI(3)K in both the 
basal proliferation, as indicated in previous studies, and in CD40-mediated rescue. It 
would be interesting to examine the generation or suppression of other PI(3)K 
generated phosphoinositides such as PtdIns(3 ,4 )P2, but also the role of other PI(3)K 
isoforms such as the G-protein sensitive pi 10yPI(3)K in the basal proliferation of 
WEHI-231 cells.
6.2.4.12 Akt is weakly activated by apoptotic and proliferative signals 
in WEHI-231 cells.
One major downstream effector of PI(3)K activity is the anti-apoptotic protein 
kinase PKB/Akt which has been shown to suppress apoptosis induced by growth- 
factor withdrawal, cell-cycle discordance, loss of cell adhesion and DNA damage (32).
As Akt requires dual phosphorylation on both Thr^ ^® and Ser"^ ^^  residues for full 
activation (168) we utilised antibodies recognising p-Thr or p-Ser residues to establish 
the relative activation state of Akt under both apoptotic and rescue conditions. Figure 
75A presents the data obtained from these studies. In addition to pThr and pSer 
antibodies, the membrane was also probed with pThr^°^-Akt and a antibody recognising 
the whole form of Akt to confirm the identity of observed bands as Akt. The phospho- 
specific (Thr^^ )^ Akt antibody indicated that Akt was weakly phosphorylated in 
untreated cells. Cells treated with anti-Ig plus anti-CD40 also expressed weak Thr 
phosphorylation which decreased with time. In contrast, anti-Ig treatment enhanced 
Thr phosphorylation of Akt becoming maximal after 30 minutes. Interestingly, an 
antibody specific to p-Thr residues produced a different pattern of pThr-Akt expression 
than the pThr^ °® specific Akt antibody. Under these conditions, untreated cells 
expressed low, but detectable levels of Thr-phosphorylation. Treatment with anti-Ig, 
enhanced Thr-phosphorylation relative to untreated (basal) cells after 30 minutes, but 
was suppressed to below basal after 60 minutes. Perhaps most striking was anti-Ig 
plus anti-CD40 mediated increases in Thr phosphorylation which were previously 
undetected by the pThr^ °® specific antibody suggesting that anti-Ig plus anti-CD40 
treatment phosphorylates a Thr residue other than 308 on Akt. Levels of Ser- 
phosphorylation were also examined and indicated that both anti-Ig and anti-Ig plus
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anti-CD40 treatments lead to similar levels of Ser-phosphorylation with similar kinetics. 
Taken together, these results suggest that anti-Ig treatment appears to be the only stimuli 
leading to dual Thr/Ser phosphorylation in WEHI-231 cells, occurring approximately 
30 minutes post-BCR ligation.
Further studies to investigate the long-term kinetics of Akt activation were also 
examined. Results shown in figure 75B suggested that long-term (1-48 hours) anti- 
Ig, anti-CD40 and most interestingly anti-Ig plus anti-CD40 treatment were all in­
effective in promoting Akt Thr-phosphorylation suggesting that Akt is not involved in 
CD40-mediated rescue from BCR-mediated growth arrest and apoptosis. These results 
are compatible with previous findings which suggested anti-Ig plus anti-CD40 co­
stimulation were ineffective in induced PtdIns(3 ,4 ,5 )P3 production. However, they 
also suggest that the late generation of PtdIns(3 ,4 ,5 )P3 following BCR-ligation is 
unlikely to be involved in the regulation of Akt activity.
Taken together, these results provide weak evidence to suggest that Akt may 
play a role in modulating early, BCR-mediated signalling events, but does not play a 
role in late survival signals induced by CD40 treatment. BCR-induced apoptosis may 
therefore result, at least in part, from the inability of BCR-ligation to sustain Akt 
activity, therefore preventing cell survival. Further studies examining Akt enzyme 
activity using the specific Akt substrate, crosstide, would more accurately determine the 
activation state of Akt following cell stimulation and would help confirm whether or not 
Akt is involved in CD40-mediated rescue of WEHI-231 cells.
6.2.4.13 BCR-ligation is coupled to sphingosine-kinase in WEHI-231 
B cells.
Sphingosine kinase activity has been shown to play a positive, mitogenic role in 
a number of cell types. In addition, a wide range of cell surface receptors have been 
shown to be coupled to sphingosine-kinase including FcyRI (169). Currently, no 
evidence is available suggesting a role for SPP as a lipid second messenger in B 
lymphocytes . In this study, we aimed to identify whether signalling events activated 
through BCR-ligation in WEHI-231 cells were coupled to sphingosine kinase activation 
and whether SPP could signal via extracellular mechanisms.
In order to determine if there was differential receptor coupling of sphingosine 
kinase under apoptotic or proliferative signals, WEHI-231 cells were treated with either 
anti-Ig or both anti-Ig and anti-CD40 (figure 76). Anti-Ig treatment caused a rapid 
rise in SPP levels, however, by 10 minutes this was suppressed to below basal levels. 
In contrast, co-treatment of anti-Ig treated cells with anti-CD40 antibodies maintained 
SPP levels above basal over the 10 minute time course. These results suggest that BCR
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ligation uncouples activation of a sphingosine kinase pathway and that CD40 mediated 
rescue from growth-arrest/apoptosis may involve the maintenance of this signal.
In order to determine whether BCR-mediated suppression of SPP levels after 10 
minutes of stimulation was maintained over longer time periods further time course 
studies were carried out (figure 77A). Anti-Ig stimulation over a 60 minute time 
period induced a rapid increase in SPP levels, maximal at 15 minutes, which then 
rapidly dropped back to basal levels where it remained after 30 minutes. Although 
these results do not show suppression of SPP levels to below basal as seen in figure 
76, they confirm that BCR ligation induces an early, transient, activation of 
sphingosine kinase.
Previous studies in this investigation have shown the ability of anti-CD40 co­
stimulation to uncouple the BCR from the induction of apoptotic signals via ERK- 
MAPKinase and cPLA^. We therefore investigated the effect of anti-CD40 co­
stimulation on BCR-mediated SPP generation. Our results indicated that CD40 co­
stimulation lead to an elevated and sustained generation of SPP (figures 76 and 
77B) suggesting that CD40 mediated rescue was positively coupled to sustained SPP 
generation.
6.2.4.14 The BCR of mature splenic B lymphocytes is also coupled to 
sphingosine kinase activation.
In order to determine if the coupling of the BCR to sphingosine kinase 
activation was a maturation state-dependent phenomenon, mature splenic B 
lymphocytes were stimulated with anti-Ig and SPP levels determined. Unlike WEHI- 
231 cells, mature splenic B lymphocytes undergo an activation process following BCR 
ligation, with concurrent increases in cell proliferation measured by tritiated thymidine 
uptake. As for WEHI-231 cells, splenic B lymphocytes were incubated with [^H]serine 
to label phospholipid pools. Cells were then stimulated with a mitogenic dose (50 
|ig/ml) of anti-Ig and a time course study examined changes in SPP generation (figure 
78). These results indicated that BCR-ligation induces an early rise in sphingosine 
kinase activity after 30 minutes, which then drops back to basal. Results recorded from 
1 hour post anti-Ig treatment suggested that untreated splenic B lymphocytes have the 
ability to regulate SPP levels, although this is as yet unconfirmed. Sphingosine kinase 
activation therefore also appears to be coupled to BCR-ligation in mature B 
lymphocytes. Our results also indicated that the BCR of WEHI-231 cells was also 
coupled to sphingosine kinase activation. However, the kinetics of SPP generation 
between these two developmental stages of B lymphocytes were shown to differ, yet 
were still transient in nature.
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BCR-induced SPP generation may therefore represent a primary signal in both 
immature and mature B lymphocytes which requires costimulation for sustained 
generation. These costimulatory signals may include CD40 stimulation or additional 
activation signals generated in mature B lymphocytes following BCR-ligation. This 
may explain the rapid suppression of SPP generation, following its initial activation, in 
immature B lymphocytes following BCR-ligation.
6.2.4.15 Exogenous Sphingosine-l-phosphate (SPP) has no 
extracellular role in determining WEHI-231 cell fate.
Having determined that both BCR- and CD40-ligation can regulate intracellular 
SPP levels in WEHI-231 cells, its role as an extracellular lipid second messenger was 
examined. SPP is known to signal through Edg-receptor family members with 
important roles in the activation of multiple signalling cascades such as the ERK- 
MAPKinase family. In order to examine an extracellular role two separate approaches 
were made. Firstly, supernatant from stimulated cells was examined for the presence of 
SPP and secondly, exogenous SPP was added to cells in culture and subsequent affects 
on growth-arrest/proliferation were examined. Studies revealed (figure 79A) that no 
SPP could be detected in the supernatant under any of the experimental conditions over 
a 60 minute time range, indicating that SPP was not secreted by WEHI-231 cells 
following stimulation. In addition, exogenously added SPP caused little change in 
DNA synthesis of otherwise untreated cells, and in particular, was ineffective in 
rescuing WEHI-231 cells from anti-Ig mediated growth arrest (figure 79B). Taken 
together, these results suggest that SPP is acting purely as a intracellular second 
messenger and appears to play no extracellular role in regulating WEHI-231 cell fate.
6.2.4.16 CD40 treatment restores long-term suppression of SPP levels 
following BCR-ligation.
Previous studies in this investigation had examined the regulation of SPP levels 
over a one hour period. As previous studies have shown SPP to be a downstream 
mediator of proliferative responses by fetal calf serum, studies were extended to further 
examine any correlation between growth arrest/proliferation and SPP levels in WEHI- 
23 1 cells (figure 80). Untreated cells, over a 48 hour time course, produced peak 
SPP levels between 8-24 hours, suggesting a potential role for SPP in the basal 
proliferation of WEHI-231 cells. Interestingly, long-term anti-Ig treatment of WEHI- 
23 1 cells, suppressed SPP levels well below that of untreated cells although SPP levels 
still peaked at 8-24 hours. BCR ligation may therefore promote growth arrest by 
uncoupling of a sphingosine kinase dependent mitogenic signal or regulate SPP levels
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directly via lipid phosphate phosphatase activity (163). In addition, co-treatment with 
anti-CD40 induced a slight elevation of SPP levels relative to anti-Ig alone, especially at 
later time points (24-48 hours) where anti-Ig mediated suppression of SPP levels was at 
its greatest. These results indicate that SPP levels are tightly controlled by cell stimuli 
and removal of such signals may have a negative effect on WEHI-231 cell growth. 
Indeed, it has been suggested the balance between SPP and ceramide may determine the 
physiological fate of a cell (165). Therefore removal of SPP may tip the balance in the 
favour of ceramide and lead to the induction of apoptosis. It would therefore be 
interesting to examine whether WEHI-231 cell death results in the accumulation of 
intracellular ceramide that mirrors decreases in SPP levels.
6.2.4.17 Sphingosine kinase inhibition promotes growth-arrest and 
apoptosis.
In order to substantiate the hypothesis that SPP is an essential proliferative 
signal for WEHI-231 cells, we utilised the potent sphingosine kinase inhibitor N,N- 
dimethylsphingosine (DMS) which has been shown to inhibit sphingosine kinase with 
few non-specific toxic effects (170). Thymidine incorporation studies confirmed that 
blockage of SPP production induced complete growth-arrest in WEHI-231 cells 
(figure 81). In addition, DMS was shown to act in synergy with anti-Ig to promote 
increased growth-arrest and apoptosis over cells treated with anti-Ig alone.
In order to determine whether the growth-arrest induced by sphingosine kinase 
inhibition was due to the induction of apoptosis, additional studies were carried out to 
measure DNA content (figure 82). Cells treated with DMS were shown to be 
strongly driven into apoptosis. In addition, DMS appeared to act in synergy to enhance 
BCR-induced apoptosis. DMS treatment also prevented CD40-mediated rescue from 
BCR-induced apoptosis, although the addition of anti-CD40 to cells treated with DMS 
and anti-Ig did reduce the number of apoptotic cells compared to those treated with 
DMS and anti-Ig only. This suggests that CD40 ligation may be able to restore some 
sphingosine kinase activity abolished by DMS treatment, data consistent with earlier 
studies examining SPP production.
164
6.2.5 Discussion.
A wide range of signalling cascades are activated upon receptor ligation, which 
through cross-talk mechanisms, regulate the activity of other signalling elements such 
as ERK-MAPKinase. This section aimed to address the roles of three signalling 
pathways all of which are known to regulate ERK-MAPKinase activities.
Firstly, we examined the role of cAMP which has been shown to suppress Raf- 
1 activity and hence ERK-MAPKinase activity. In order to determine whether 
modulation of intracellular cAMP could affect WEHI-231 cell growth a number of 
pharmacological agents were used to artificially enhance cAMP levels. Both forskolin, 
a potent activator of adenylyl cyclase, and a number of PDE inhibitors were effective in 
promoting WEHI-231 cell growth-arrest. Interestingly , BCR-ligation was also shown 
to be capable of suppressing PDE activity over a 1-7 hour period of time. These results 
suggested that cAMP elevation could play important roles BCR-mediated growth- 
arrest, possibly due to PKA-mediated suppression of Raf-1.
Therefore, in addition to examining the role of cAMP in WEHI-231 cell 
signalling, the cAMP-dependent enzyme, PK-A, was also examined. Inhibition of PK- 
A with H-89 was ineffective in inhibiting basal proliferation or inducing apoptosis in 
WEHI-231 cells. These results confirmed, as expected, that PK-A plays no role in 
basal WEHI-231 proliferation, or indeed, is not activated during basal proliferation 
possibly due to low cAMP levels. However, PK-A inhibition had no effect on BCR- 
mediated growth-arrest, apparently ruling out a role for PK-A mediated suppression of 
Raf-1 during BCR-induced growth arrest.
As LPS treatment, a proliferative signal in WEHI-231 cells, was shown to 
enhance PDE activity, we hypothesised that CD40-mediated rescue of WEHI-231 cells 
may involve the recovery of PDE activity. Consequently, we examined the ability of 
CD40 treatment to rescue IBMX-induced growth-arrest. CD40 treatment was effective 
in reversing IBMX-induced growth-arrest suggesting that CD40 acts independently, or 
downstream, of PDE activity to restore cell proliferation. IBMX treatment was also 
shown to be ineffective in preventing CD40-mediated rescue of BCR-induced growth- 
arrest again suggesting that CD40 acts independently of, or acts below, PDE activity. 
As previously mentioned this data is consistent with recent data by Purkerson et. a l 
(97) suggesting that CD40 activated ERK-MAPKinase in a PKA-insensitive manner at 
the level of MEK. Although previous studies in this report suggest that both BCR- and 
CD40- mediated ERK-MAPKinase activation are Ras-dependent, Ras is known to 
activate MEK kinases other than Raf-1 (97). Our results are therefore not inconsistent 
with the model proposed by Purkerson et. a l in which they suggest CD40 may be 
coupled to a Ras-dependent, PKA insensitive MEKK other than Raf-1 (figure 83). It
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would therefore be of interest to examine the kinase activity of MEK and Raf-1 in 
WEHI-231 cells under conditions of growth-arrest/rescue to examine possible 
differences in their activation.
In addition to cAMP pathways which have been shown to down-regulate ERK- 
MAPKinase activity, a number of pathways have been implicated in positively 
regulating ERK-MAPKinase, including PI(3)K which is a known intermediate in the 
signal transduction of growth factor signals in a wide range of cell types. In addition, a 
number of newly emerging lipid second messengers including SPP are emerging as key 
regulators of cell fate and regulators of ERK-MAPKinase activity.
PI(3)K activity has been reported to be activated in both immature and mature B 
lymphocytes, with important roles in determining the rate of positive selection of 
immature B lymphocytes (16) as SHIP-/- B lymphocyte were shown to develop in an 
accelerated manner. However, its role in the transduction, or prevention, of apoptotic 
signalling pathways is unclear. In addition, although the coupling of numerous growth 
factor receptors to sphingosine kinase is well documented, the coupling of the BCR to 
sphingosine kinase has never been shown. The results in this study therefore indicate a 
novel signalling mechanism activated by BCR ligation on both immature, and mature B 
lymphocytes.
Initial data (figure 68) suggested that PI(3)K may play an role in mediating 
BCR-induced apoptosis by coupling proximal-BCR signalling events to the activation 
of an early, ERK-MAPKinase signal in WEHI-231 cells (figure 84). Evidence for 
this was obtained from studies investigating the generation of Ptdlns (3 ,4 ,5 )P3 
following BCR-ligation which appeared to closely mirror the known kinetics of BCR- 
induced ERK-MAPKinase activation (figure 25A). In addition, studies have shown 
that the PI(3)K inhibitors Wm and Ly can block BCR-mediated ERK-MAPKinase 
activation (figure 69). However, these inhibitors were ineffective in preventing BCR- 
mediated apoptosis (figure 70). These results suggest that early PI(3)K signals 
generated through BCR-ligation are not essential for the induction of apoptosis in 
WEHI-231 cells suggesting that other apoptotic pathways are activated by BCR-ligation 
which may or may not be ERK-MAPKinase dependent. However, the generation of 
Ptdlns (3 ,4 ,5 )P3 following BCR-ligation may play additional roles in WEHI-231 
signalling events by recruiting signalling elements containing lipid binding PH domains 
such as Btk or PLCy to the cell membrane. Indeed PI(3)K mediated activation of 
PLCy may play a role in the generation of Ca^ '*' influx required for cPLA^ activation 
following BCR-ligation (figure 84). Additional studies aimed to address the effect of 
long-term BCR-ligation and CD40-mediated rescue on PI(3)K activity. These studies 
indicated that PI(3)K inhibition could block basal proliferation of WEHI-231 cells. 
However, additional studies have revealed that Ptdlns (3 ,4 ,5 )P3 levels remain constant
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during basal proliferation of WEHI-231 cells. The ability of prolonged PI(3)K 
inhibition to block basal proliferation may therefore result from the decrease in 
generation of other lipid species regulated by PI(3)K activity such as PtdIns(3 ,4 )P2. 
Interestingly, PtdIns(3 ,4 )P2 is known to activate ERK-MAPKinase via a PKC-sensitive 
pathway (150), suggesting this may play a role in the basal proliferation of WEHI-231 
cells.
The ability of BCR-ligation to induce PtdIns(3,4,5)P3 generation suggests that 
PI(3)K activity may be involved in the induction of growth arrest. Indeed, it has been 
suggested that PI(3)K mediates INK activation through a 
Rac/PAK/MEKK/MKK4/JNK pathway (149). Previous data has suggested the 
possible induction of INK activity 1-2 hours after BCR-ligation in WEHI-231 cells.
We were, however, unable to measure any Rac activity in BCR-stimulated cells. 
Interestingly, a recent review article (171) has described the ability of sphingo- and 
phospho-lipid species to activate PAK, and hence INK, in a Rac-independent manner 
suggesting that BCR-stimulated PtdIns(3 ,4 ,5 )P3 generation may mediate the induction 
of growth arrest through the activation of INK.
In summary, it would appear that basal PI(3)K activity, possibly through the 
generation of lipid species other that PtdIns(3 ,4 ,5 )P3 may play positive roles in 
regulating WEHI-231 cell proliferation. However, our results also indicate that BCR- 
stimulated PtdIns(3 ,4 ,5 )P3 generation has an opposite effect and may promote growth 
arrest. These differential effects may result from the activation of different downstream 
signalling elements from PI(3)K but may also result from the activation of different 
PI(3)K pools.
Interestingly, Ptdlns (3 ,4 ,5 )p3 generation was only observed in anti-Ig treated 
samples. These results confirm that PtdIns(3 ,4 ,5 )P3 plays no, or a minor, role in the 
rescue of WEHI-231 cells from BCR-induced apoptosis by anti-CD40 co-stimulation. 
This may therefore be linked to the inability to observe any Akt signals under such 
rescue conditions. Ironically, studies in this chapter and other published results
GroW eV 0^   ^ have suggested that BCR-ligation induces Akt activation.
Although this would seem immediately contradictory, the induction of apoptotic signals 
is undoubtedly a balance between both positive and negative signals. The activation of 
Akt following BCR-ligation in immature B lymphocyte may therefore form part of the 
proposed “rescue window” (50) which allows Ag-stimulated cells to undergo RAG 
gene reactivation and receptor editing. However, what is clear from our studies in this 
section, is that Akt appears to play a minor role, if any, in CD40-mediated rescue of 
WEHI-231 cells from BCR-induced apoptosis.
However, our results do not rule out a role for PI(3)K in the survival of WEHI- 
231 cells. As previously discussed, PI(3)K has been shown to exert both lipid and 
protein kinase functions. PI(3)K may therefore play a role in the long-term re-
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establishment of ERK-MAPKinase activity by CD40 ligation. Mutant studies utilising 
lipid- or protein kinase inactive PI(3)K would help address this hypothesis.
PI(3)K and Akt have been shown to induce key survival signals in a number of 
cells types. However, data in this study suggests that its role, if any, in CD40- 
mediated survival signals is limited. We therefore examined whether other known 
survival signals were activated in WEHI-231 cells by CD40 ligation. One emerging 
lipid metabolite with roles in cell survival is SPP. However, there are no reports as to 
whether SPP generation is coupled to BCR, or CD40 ligation. Previous studies within 
our group and others (54) have highlighted the ability of BCR-ligation to induce 
increases in intracellular ceramide levels under apoptotic conditions. Interestingly, the 
balance between cellular concentrations of ceramide and SPP have been proposed to 
determine cell fate in what has been termed the ceramide/SPP rheostat (165). Our 
results indicate that not only is the BCR directly linked to the suppression of SPP 
generation, but co-treatment with anti-CD40 antibodies may reverse this. This result 
indicates that SPP levels may play a key role in determining cell fate in WEHI-231 cells 
with a shift in the balance towards ceramide levels promoting the activation of apoptotic 
mechanisms within the cell. In contrast, elevation of SPP levels by CD40 treatment 
may prevent this shift, keeping the balance of ceramide:SPP levels more equal, or even 
reducing ceramide levels. Longer term studies examining the effect of both BCR- 
ligation and CD40:.-mediated rescue indicated that SPP may also play an important role 
in determining growth-arrest levels. Cells left untreated over a 48 hour period did not 
maintain SPP levels at a constant level, instead, SPP levels were shown to peak after 8 
hours, falling back to lower levels after 24 hours. As SPP has been linked to the intra­
cellular activation of ERK-MAPKinase, sphingosine kinase may represent a route for 
the basal ERK-MAPKinase signal expressed in WEHI-231 cells. In contrast, BCR- 
ligation partially reduced levels of SPP over the 4-48 hour period. Co-treatment with 
anti-CD40 however, appeared to reverse some of the BCR-mediated suppression of 
SPP generation, albeit at later time points (24-48 hours). These results suggest that 
long-term BCR-ligation acts to suppress sphingosine kinase activity. As SPP has been 
proposed regulate the ERK-MAPKinase pathway, suppression of this pathway may 
account for the ability of BCR-ligation to suppress basal ERK-MAPKinase signals. 
Indeed, inhibition of sphingosine kinase activity with DMS was shown to promote both 
growth-arrest and apoptosis, confirming its role as a mitogenic signal in WEHI-231 
cells. In addition SPP has been shown to negatively regulate both INK and caspase 
activities and cAMP generation (165). Early (0-60 minute) increases in SPP levels 
induced by CD40 ligation may therefore play a role in the suppression of these key 
apoptotic signals although our data currently suggests that INK activity is not activated 
under apoptotic conditions, but does not rule out a role for SPP in downregulating 
BCR-mediated increases in cAMP.
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In order to determine if the coupling of the BCR to sphingosine kinase activity 
was a maturation-state dependent phenomenon, similar studies were carried out on 
mature splenic B lymphocytes. These results indicated that sphingosine kinase activity, 
as observed in WEHI-231 cells, was also coupled to the BCR in mature B 
lymphocytes. Why sphingosine kinase activation is coupled to BCR-ligation in both 
WEHI-231 cells and mature B cells at first seems strange. BCR-ligation initiates 
negative signalling in WEHI-231-231 cells, yet activation in mature B cells. However, 
although the BCR was coupled to transient sphingosine kinase activity in both these 
cells, the kinetics of SPP generation differed. BCR-ligation induced an early, yet short­
lived activation of sphingosine kinase which was suppressed by about 10-15 minutes. 
In contrast, BCR-ligation of mature B lymphocytes activated a later sphingosine kinase 
signal, peaking at 30 minutes. BCR-induced sphingosine kinase activation may 
therefore represent a primary signal activated at both immature and mature 
developmental stages. The later, and slightly more sustained nature of sphingosine 
kinase activation in mature B cells may result from additional costimulatory signals 
activated during BCR-ligation. The failure to activate these additional costimulatory 
signals following BCR-ligation in WEHI-231 cells may account for the short, transient 
activation of sphingosine kinase in these cells. However, co-stimulation of WEHI-231 
cells with anti-CD40 was shown to elevate and maintain sphingosine kinase activity, 
again suggesting that costimulation may be required for sustained activation of this 
enzyme. Why the BCR is coupled to a short, transient increase in sphingosine kinase 
activity in WEHI-231 cells is still unclear. However, this may relate to the ability of 
SPP to induce Ca^  ^influxes which may be required for cPLA^ activity which is known 
to occur following BCR-ligation. Another interesting factor observed in these studies 
was the evidence suggesting that SPP acted intracellularly and not extracellularly as 
observed in some systems.
These results suggest that lipid metabolities play important roles in the 
regulation of WEHI-231 cell fate. They also highlight the emergence of a new, but 
potentially important, signalling pathway coupled to BCR-ligation which may have key 
roles in B lymphocyte maturation.
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Figure 51. Regulation of Ras activation by upstream Ras guanine 
nucleotide exchange factors (GEFs) and inhibition by GTPase-activating 
proteins (GAPs).
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Figure 52. Role of SHIP as an adaptor molecule. BCR- FcyRIIB co­
aggregation leads to phosphoiylation of F c y R I I B  on its ITIM motif which in turn leads 
to the recruitment of SHIP. This in turn creates a binding site for p62"’°‘' and She whilst 
also bringing them in close proximity to the BCR. p62‘*®^ can then be phosphorylated 
and recruit RasGAP which in turn converts BCR-stimulated Ras into its GDP-bound 
inactive form.
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Figure 53. Mechanisms involved in Rapl activation in T lymphocytes.
TCR“induced Lyn activation promotes formation of a Cbl-CrkL-C3G complex. This 
leads to increased interactions between the GEF C3G and its downstream target Rapl 
leading to GTPase activity and hence Rapl activation. Active Rapl then competes with 
Ras for Raf-1 downregulating the activity of the Ras/Raf/MEK/ERK-MAPKinase 
pathway.
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Figure 54. BCR-ligation promotes PAC-1 association with ERK- 
MAPKinase but does not induce new PAC-1 protein synthesis. A.
WEHI-231 whole cell lysates were immunoprecipitated with wERK antibody as 
described in Materials and Methods. Immunoprecipitates were subjected to SDS-PAGE 
and immuno-blotted with an anti-Pacl antibody. Densitometry shows relative band 
density analysed on Gel-Pro software. Lanes were loaded as follows: : lane 1, cells 
left untreated for 0 hours, lane 2, cells treated with anti-Ig (1 jig/ml) for 1 hour, lane 
3, cells treated with anti-Ig (1 jXg/ml) for 4 hours, lane 4, cells treated with anti-Ig (1 
pg/ml) for 8 hours, lane 5, cells treated with anti-Ig (1 pg/ml) for 24 hours, lane 6, 
cells treated with anti-Ig (1 pg/ml) plus anti-CD40 (10 pg/ml) for 1 hour, lane 7, cells 
treated with anti-Ig (1 |lg/ml) plus anti-CD40 (10 flg/ml) for 4 hours, lane 8, cells
treated with anti-Ig (1 |Llg/ml) plus anti-CD40 (10 pg/ml) for 8 hours, lane 9, cells
treated with anti-Ig (1 |lg/ml) plus anti-CD40 (10 pg/ml) for 24 hours, Levels of PAC- 
1 expression were determined by western blotting. B. WEHI-231 cells (5 x lOVml) 
were stimulated as follows: lane 1, cells left untreated for 0 hours, lane 2, cells 
treated with anti-Ig (1 pg/ml) for 1 hour, lane 3, cells treated with anti-Ig (1 |ig/ml) 
for 2 hours, lane 4, cells treated with anti-Ig (1 pg/ml) for 4 hours, lane 5, cells 
treated with anti-Ig (1 |ig/ml) for 8 hours, lane 6, cells treated with anti-Ig (1 pg/ml) 
for 24 hours, lane 7, cells treated with anti-Ig (1 pg/ml) for 48 hours, lane 8, cells 
treated with anti-Ig (1 jitg/ml) plus anti-CD40 (10 pg/ml) for 1 hour, lane 9, cells
treated with anti-Ig (1 |lg/ml) plus anti-CD40 (10 flg/ml) for 2 hours, lane 10, cells
treated with anti-Ig (1 |ig/ml) plus anti-CD40 (10 jiXg/ml) for 4 hours, lane 11, cells
treated with anti-Ig (1 |Lig/ml) plus anti-CD40 (10 jag/ml) for 8 hours, lane 12, cells
treated with anti-Ig (1 pg/ml) plus anti-CD40 (10 pg/ml) for 24 hours, lane 13, cells
treated with anti-Ig (1 |ig/ml) plus anti-CD40 (10 flg/ml) for 48 hours, lane 14, cells
left untreated for 48 hours. Levels of PAC-1 and wERK expression were determined 
by Western blotting (30 |ig/lane).
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Figure 55. Ras activity is present in both resting and apoptotic 
conditions, but is enhanced in the rescue of WEHI-231 cells by anti- 
CD40. A. WEHI-231 cells (5 x lOVml) were stimulated as follows, lane 1, cells 
stimulated as indicated for 1 hour, lane 2, cells stimulated as indicated for 2 hours, 
lane 3, cells stimulated as indicated for 4 hours, lane 4, cells stimulated as indicated 
for 8 hours, lane 5, cells stimulated as indicated for 24 hours, lane 6, cells stimulated 
as indicated for 48 hours. GTP-bound Ras was then immunoprecipitated using Raf-1- 
RBD as bait. Ras activation was then determined by Western blotting using a anti-Ras 
antibody to equal levels of cell sample. Densitometry shows relative band density 
measured on Gel-Pro Analysis software. B. WEHI-231 cells (5 x lOVml) were 
stimulated as follows, lane 1, cells left untreated for 0 hours, lane 2, cells stimulated 
as indicated for 1 hour, lane 3, cells left untreated for 2 hours, lane 4, cells stimulated 
as indicated for 4 hours, lane 5, cells stimulated as indicated for 8 hours, lane 6, cells 
stimulated as indicated for 24 hours, lane 7, cells stimulated as indicated for 48 hours. 
Levels of pERK/wERK expression were determined by western blotting (30 pg/lane).
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Figure 56. Basal R apl activity is suppressed by anti-Ig and anti-CD40 
treatment. A. WEHI-231 cells (5 x lOVml) were stimulated as follows, lane 1, cells 
stimulated as indicated for 5 minutes, lane 2, cells stimulated as indicated for 30 
minutes, lane 3, cells stimulated as indicated for 1 hour, lane 4, cells stimulated as 
indicated for 2 hours, lane 5, cells stimulated as indicated for 4 hours, lane 6, cells 
stimulated as indicated for 8 hours, lane 7, cells stimulated as indicated for 18 hours, 
lane 8, cells stimulated as indicated for 24 hours, lane 9, cells stimulated as indicated 
for 32 hours, lane 9, cells stimulated as indicated for 48 hours. GTP-bound Ras and 
GTP-bound Rapl were then immunoprecipitated using Raf-l-RBD or Ral-RBD, 
respectively, as bait. Ras or Rapl activity was then determined by Western blotting 
using a anti-Ras or anti-Rapl antibody to equal volumes of cell sample. B. Ras 
activity membranes from figure 56A were stripped of bound antibody and re-probed 
with an antibody recognising wERK.
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Figure 57. Model for basal ERK-MAPKinase activity in WEHI-231 
cells mediated by Rapl activity. GTP-bound Rapl is known to induce the long- 
teiTn activation of ERK-MAPKinase through stimulation of B-Raf. BCR-ligation in 
WEHI-231 cells downregulates basal Rapl activity suggesting Rapl may be involved 
in the maintenance of basal ERK-MAPKinase activity in proliferating WEHI-231 cells.
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Figure 58. A. Structure of Phosphatidylinositol. B. Structure of p85a regulatory 
sub-unit of PI(3)K.
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Figure 59. Downstream targets of PI(3)K activity. Figure taken from 
(150).
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Figure 60. Ceramide/SPP rheostat. Pathways showing the generation of 
ceramide and SPP.
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Figure 61. Model of G-protein activation following receptor-agonist 
binding. Receptor agonist binding leads to the association of the apy  trimer with the 
receptor which causes the GDP bound to the a  subunit to dissociate and become 
replaced with GTP, This in turn, causes the dissociation of a-GTP from the py 
subunits. a-GTP, now in its active form now acts as an effector activating downstream 
signalling elements. However, it should be noted that the dissociated py subunits are 
also known to activate downstream signalling elements.
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Figure 62. Pharmacological increases in cAMP levels by forskolin 
correlate with induction of growth-arrest in WEHI-231 cells. W E H I-231 
cells (lOVwell) were left untreated or treated with anti-Ig (10 jag/ml), anti-CD40 (10 
ixg/ml) or anti-Ig plus anti-CD40 (both 10 jLig/ml). In addition, cells were treated with 
increasing concentrations of forskolin (as indicated) either alone, or in the presence of 
anti-Ig (10 fig/ml), anti-CD40 (10 |ig/ml) or anti-Ig plus anti-CD40 (both 10 jiig/ml). 
Proliferation was assessed by measuring cell measuring DNA synthesis as indicated by 
pH]thymidine uptake at 48 hours. Values shown are means ± SD of quadruplicate 
wells.
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Figure 63. Inhibition of PDE activity promotes growth-arrest in WEHI- 
231 cells. A. WEHI-231 cells (lOVwell) were left untreated, treated with anti-Ig (10 
pg/ml) or with increasing concentrations with rolipram (0.01 pM-lOO pM) or vehicle 
controls. Proliferation was assessed by measuring DNA synthesis as indicated by 
pH]thymidine uptake at 48 hours. Values shown are means ± SD of quadruplicate 
wells. B. WEHI-231 cells (lOVwell) were left untreated, treated with anti-Ig (10 
jLig/ml) or with increasing concentrations with cilostamide (0.001 jiM-10 jiM) or 
vehicle controls. Proliferation was assessed by measuring DNA synthesis as indicated 
by [^HJthymidine uptake at 48 hours. Values shown are means ± SD of quadruplicate 
wells. C. WEHI-231 cells (lOVwell) were left untreated, treated with anti-Ig (10 
pg/ml) or with increasing concentrations with IB MX (0.2 pM-lOO pM) or vehicle 
controls. Proliferation was assessed by measuring pH]thymidine uptake at 48 hours. 
Values shown are means ± SD of quadmplicate wells.
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Figure 64. BCR-ligation suppresses PDE activity in immature B 
lymphocytes. Anti-Ig stimulation of WEHI-231 cells was shown to transiently 
downregulate basal PDE activity. In contrast, LPS stimulation, which induces cell 
proliferation, was shown to enhance PDE activity over the same time period.
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Figure 65. Anti-CD40 mediated rescue from growth-arrest/apoptosis is 
independent of PDE activity, but can rescue from IBMX mediated 
growth arrest. A. WEHI-231 cells (lOVwell) were left untreated or treated with 
increasing concentrations of anti-Ig (0.001-10 pg/ml). In addition, cells were treated 
with IBMX (20 pM) with or without anti-Ig (10 pg/ml), anti-CD40 (10 pg/ml) or anti- 
Ig plus anti-CD40 (both 10 pg/ml). Proliferation was assessed by measuring 
pH]thymidine uptake at 48 hours. Values shown are means ± SD of quadruplicate 
wells. B. WEHI-231 cells (SxlOVml) were left untreated, or treated with anti-Ig (10 
pg/ml), anti-CD40 (10 pg/ml), IBMX (20 pM) and anti-Ig plus anti-CD40 (both 10 
pg/ml) with or without IBMX (20 pM). Levels of apoptosis were determined by PI 
staining and FACS analysis after 48 hours as described in Materials and Methods.
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Figure 66. IBMX treatment reduces BCR-mediated Ras activation, but 
enhances BCR-mediated ERK-MAPKinase activity. A. WEHI-231 cells 
(IxlOVml) were stimulated as follows: lane 1, cells left untreated for 5 minutes, lane 
2, cells stimulated with anti-Ig (10 pg/ml) for 5 minutes, lane 3, cells pre-treated with 
IB MX (10 pM) for 60 minutes and then stimulated with anti-Ig (10 pg/ml) for 5 
minutes. GTP-bound Ras was then immunoprecipitated using Raf-l-RBD as bait. Ras 
activation was then detemiined by Western blotting using an anti-Ras antibody. 
Densitometry shows relative band density measured on Gel-Pro Analysis software. B. 
WEHI-231 cells (5 x lOVml) were stimulated as follows: lane 1, cells left untreated 
for 30 minutes, lane 2, cells left untreated for 60 minutes and then stimulated with 
anti-Ig (10 pg/ml) for 30 minutes, lane 3, cells were pre-incubated with IBMX (10 
pM) for 1 hour and then stimulated for 30 min with anti-Ig (10 pg/ml), lane 4, cells 
were pre-incubated with IBMX (20 pM) for 1 hour and then stimulated for 30 min with 
anti-Ig (10 pg/ml) were indicated. Levels of pERK/wERK expression were determined 
by Western blotting (15 pg/lane). Densitometry shows relative band density measured 
on Gel-Pro Analysis software.
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Figure 67. Pharmacological inhibition of PKA hy H-89 does not reverse 
BCR-mediated growth arrest. WEHI-231 cells (lOVwell) were left untreated or 
treated with anti-Ig (10 |Xg/ml) with or without H-89 (0.005-1 )iM), anti-CD40 (10 
jig/ml) with or without H-89 (0.005-1 |iM) or anti-Ig plus anti-CD40 (both 10 jUg/ml) 
with or without H-89 (0.005-1 jiiM). Proliferation was assessed by measuring DNA 
synthesis as indicated by [^H]thymidine uptake at 48 hours. Values shown are means ± 
SD of quadruplicate wells.
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Figure 68. BCR-ligation induces PtdIns(3,4,5)P3 generation in WEHI- 
231 cells. A. WEHI-231 cells (5xlOVml) were left untreated or treated with anti-Ig 
(10 jig/ml), anti-CD40 (10 |ig/ml) or anti-Ig plus anti-CD40 (both 10 |ig/ml) for the 
times indicated. Reactions were stopped and lipids extracted as described in materials 
and methods. Lipid samples were dried under vacuum-centrifugation and subject to 
TLC analysis. The band corresponding to PtdIns(3,4,5)Pg was scraped and levels 
determined by liquid scintillation counting. B. Repeat experiment of figure 57B. 
Values are % PtdIns(3,4,5)P^ production compared to anti-Ig stimulated cells in anti-Ig 
plus anti-CD40 stimulated samples ± SD from triplicate samples.
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Figure 69. PI(3)K inhibitors wortmannin (Wm) and Ly294002 (Ly) 
inhibit BCR-mediated ERK-MAPKlnase activation. WEHI-231 cells (5 x 
lOVml) were stimulated as follows: lane 1, cells left untreated for 0 minutes, lane 2, 
cells left untreated for 210 minutes, lane 3, cells treated with anti-Ig (10 |Lig/ml) for 30 
minutes, lane 4, cells treated for 1 hour with 0.5 nM Wm and then anti-Ig (10 jLig/ml) 
for 30 minutes, lane 5, cells treated with 50 nM Wm for 1 hour and then anti-Ig (10 
jig/ml) for 30 minutes, lane 6, cells treated with 5 nM Wm for 2 hours and then anti- 
Ig (10 |ag/ml) for 30 minutes , lane 7, cells treated with 50 nM Wm for 2 hours and 
then anti-Ig (10 |Ug/ml) for 30 minutes, lane 8, cells treated with 1 |xM Ly for 1 hour 
and then anti-Ig (10 (ig/ml) for 30 minutes, lane 9, cells treated with 10 |LiM Ly for 1 
hour and then anti-Ig (10 jig/ml) for 30 minutes, lane 10, cells treated with 1 fxM Ly 
for 2 hours and then anti-Ig (10 fig/ml) for 30 minutes, lane 11, cells treated with 10 
|iM Ly for 2 hours and then anti-Ig (10 |ig/ml) for 30 minutes. Levels of 
pERK/wERK expression were determined by Western blotting (15 pg/lane).
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Figure 70. PI(3)K plays no role in BCR-induced apoptosis. WEHI-231 
cells (SxlOVml) were stimulated as indicated (anti-Ig and anti-CD40 both at 10 |ag/ml). 
Cells treated with Wm or Ly294002 were pre-incubated in the presence of the indicated 
concentration of inhibitor for 75 minutes prior to further cell stimulation (if indicated). 
Levels of apoptosis were determined by PI staining and FACS analysis after 48 hours 
as described in materials and Methods.
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Figure 71. BCR-ligation downregulates p85a PI(3)K protein 
expression. WEHI-231 cells (SxlOVml) were stimulated as follows: lane 1, cells left 
unstimulated for 1 hour, lane 2, cells stimulated with anti-Ig (1 jig/ml) for 1 hour, 
lane 3, cells stimulated with anti-Ig (1 jig/ml) for 4 hours, lane 4, cells stimulated 
with anti-Ig (1 |Lig/ml) for 24 hours, lane 5, cells stimulated with anti-Ig (1 jig/ml) for 
48 hours, lane 6, cells stimulated with anti-CD40 (10 jiig/ml) for 1 hour, lane 7, cells 
stimulated with anti-CD40 (10 |ig/ml) for 4 hours, lane 8, cells stimulated with anti- 
CD40 (10 fLg/ml) for 24 hours, lane 9, cells stimulated with anti-CD40 (10 jig/ml) for 
48 hours, lane 10, cells stimulated with anti-Ig plus anti-CD40 for 1 hour, lane 11, 
cells stimulated with anti-Ig plus anti-CD40 for 4 hours, lane 12, cells stimulated with 
anti-Ig plus anti-CD40 for 24 hours, lane 13, cells stimulated with anti-Ig plus anti- 
CD40 for 48 hours, lane 14, cells left unstimulated for 48 hours. Levels of PI(3)K 
p85a expression were determined by Western blotting (30 p.g/lane).
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Figure 72. PI(3)K activity is not involved in CD40-mediated rescue 
from growth arrest. A. WEHI-231 cells (10^ cells/well) were left untreated or pre- 
incubated for 1 hour in wortmannin (5 or 50 nM) prior to stimulation with anti-Ig (10 
pg/ml); anti-CD40 (10 pg/ml) or a combination of both. Proliferation was assessed by 
measuring DNA synthesis as indicated by thymidine uptake at 48 hours. Values 
shown are the means ± SD of quadruplicate wells. B. WEHI-231 cells (10"* cells/well) 
were left untreated or pre-incubated for 1 hour in Ly294002 (0.1 or 1 pM) prior to 
stimulation with anti-Ig (10 pg/ml); anti-CD40 (10 pg/ml) or a combination of both. 
Proliferation was assessed by measuring DNA synthesis as indicated by [^H]thymidine 
uptake at 48 hours. Values shown are the means ± SD of quadruplicate wells.
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Figure 73. Sustained PI(3)K inhibition does not prevent anti-CD40 
mediated rescue from BCR-induced growth arrest in WEHI-231 cells.
WEHI-231 cells (10  ^cells/well) were left untreated or pre-treated for 1 hour with either 
5 or 50 nM wortmannin or 1 or 10 |aM Ly294002. Cells were then left otherwise 
untreated or treated with anti-Ig (10 pg/ml) or anti-Ig plus anti-CD40 (both at 10 pg/ml) 
where indicated. All cell samples that had previously received either Wm or Ly294002 
pre-incubation were treated with additional doses (similar concentrations) after 1 ,2 ,4 , 
8, 12, 16, 20, 24 and 28 hours. Proliferation was assessed by measuring DNA 
synthesis as indicated by [^Hjthymidine uptake at 48 hours. Values shown are the 
means ± SD of quadruplicate wells.
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Figure 74. Long-term BCR-ligation, but not anti-CD40 treatment 
induces PtdIns(3,4,5)P3 generation in WEHI-231 cells. WEHI-231 cells 
(5xlOVml) were left untreated or treated with anti-Ig (1 |Lig/ml), anti-CD40 (10 pg/ml) 
or anti-Ig plus anti-CD40 for the times indicated. Reactions were stopped and lipids 
extracted as described in Materials and Methods. Lipid samples were dried under 
vacuum-centrifugation and subject to TLC analysis. The band corresponding to 
Ptdlns(3,4,5)?3 was scrapped and ^^ P levels determined by liquid scintillation 
counting. Values shown are the means ± SEM of triplicate samples.
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Figure 75. Akt is not activated during CD40-mediated rescue of WEHI- 
231 cells from BCR-induced growth-arrest/apoptosis. A. WEHI-231 cells 
(5 X lOVml) were left untreated or stimulated with anti-Ig (1 jag/ml) or anti-Ig (1 |ig/ml) 
plus anti-CD40 (10 |Xg/ml) for the time periods indicated. Levels of pThr^^^-Akt, wAkt, 
pThr or pSer expression were determined by Western blotting (70 jig/lane). B. 
WEHI-231 cells (5 x lOVml) were stimulated as follows, lane 1, cells left 
unstimulated for 0 hours, lane 2, cells stimulated with anti-Ig (1 jilg/ml) for 1 hour, 
lane 3, cells stimulated with anti-Ig (1 |ig/ml) for 8 hours, lane 4, cells stimulated 
with anti-Ig (1 pg/ml) for 24 hours, lane 5, cells stimulated with anti-CD40 (10 
pg/mi) for 1 hour, lane 6, cells stimulated with anti-CD40 (10 pg/ml) for 8 hours, 
lane 7, cells stimulated with anti-CD40 (10 pg/ml) for 24 hours, lane 8, cells 
stimulated with anti-Ig (1 pg/ml) and anti-CD40 (10 pg/ml) for 1 hour, lane 9, cells 
stimulated with anti-Ig (1 pg/ml) and anti-CD40 (10 pg/ml) for 8 hours, lane 10, cells 
stimulated with anti-Ig (1 pg/ml) and anti-CD40 (10 pg/ml) for 24 hours, lane 11, 
cells left un stimulated for 24 hours. Levels of pThr^°®-Akt or wAkt expression were 
determined by Western blotting (15 pg/lane).
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Figure 76. BCR-ligation is coupled to sphingosine-kinase in WEHI- 
231 B cells. WEHI-231 cells (IxlOVml) were left untreated or treated with anti-Ig 
(10 pg/ml) or anti-Ig plus anti-CD40 (both 10 pg/ml) for the time periods indicated. 
Reactions were stopped and lipids extracted as described in Materials and Methods. 
Lipid samples were dried under vacuum-centrifugation and subject to TLC analysis.
The band coiiesponding to SPP was scraped and [^Hjserine levels determined by liquid 
scintillation counting.
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Figure 77. BCR and CD40 are both coupled to sphingosine kinase in 
WEHI-231 cells. A. WEHI-231 cells (IxlOVml) were left untreated or treated with 
anti-Ig (10 pg/ml) or anti-Ig plus anti-CD40 (both 10 pg/ml) for the time periods 
indicated. Reactions were stopped and lipids extracted as described in Materials and 
Methods. Lipid samples were dried under vacuum-centrifugation and subject to TLC 
analysis. The band corresponding to SPP was scraped and [^H]serine levels 
determined by liquid scintillation counting. B. WEHI-231 cells (IxlOVml) were left 
untreated, or treated with anti-Ig plus anti-CD40 (both 10 pg/ml) for the time periods 
indicated. Reactions were stopped and lipids extracted as described in Materials and 
Methods. Lipid samples were dried under vacuum-centrifugation and subject to TLC 
analysis. The band corresponding to SPP was scraped and [^H]serine levels 
determined by liquid scintillation counting.
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Figure 78. The BCR of mature splenic B lymphocytes is coupled to 
sphingosine kinase activation. Freshly isolated mature splenic B lymphocytes 
(2xlOVml) were left untreated or treated with anti-Ig (50 fig/ml) for the time periods 
indicated. Reactions were stopped and lipids extracted as described in Materials and 
Methods. Lipid samples were dried under vacuum-centrifugation and subject to TLC 
analysis. The band corresponding to SPP was scraped and serine levels 
determined by liquid scintillation counting.
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Figure 79. SPP is not secreted by WEHI-231 cells under apoptotic or 
proliferative conditions and exogenous SPP treatment does not affect 
WEHI-231 cell grovyth. A. WEHI-231 cells (IxlOVml) were left untreated or 
treated with anti-Ig (10 jig/ml), anti-CD40 (10 |ig/ml) or anti-Ig plus anti-CD40 (both 
10 jag/ml) for the time periods indicated. Supernatants were collected and lipids 
extracted as described in Materials and Methods. Lipid samples were dried under 
vacuum-centrifugation and subject to TLC analysis. The band corresponding to SPP 
was scraped and [^H]serine levels determined by liquid scintillation counting. B. 
WEHI-231 cells (10"^  cells/well) were left untreated or treated with anti-Ig (10 p,g/ml), 
anti-CD40 (10 p.g/ml) or anti-Ig plus anti-CD40 (both 10 |Lig/ml). Additional samples 
were treated with SPP (100 nM, 1 p,M or 10 p,M) with or without anti-Ig (10 |JLg/ml) or 
vehicle controls for SPP. Proliferation was assessed by measuring DNA synthesis as 
indicated by [^H]thymidine uptake at 48 hours. Values shown are the means ± SD of 
quadruplicate wells.
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Figure 80. Long-term BCR-Iigation suppresses basal SPP production 
which is restored with anti-CD40 co-treatment. WEHI-231 cells (5x10^) 
were left untreated or treated with anti-Ig (1 jLlg/ml) or anti-Ig plus anti-CD40 (10 
pg/ml) for the time periods indicated. Reactions were stopped and lipids extracted as 
described in Materials and Methods. Lipid samples were dried under vacuum- 
centrifugation and subject to TLC analysis. The band corresponding to SPP was 
scraped and [^H]serine levels determined by liquid scintillation counting. Values 
shown are means ± SEM of triplicate samples.
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Figure 81. Inhibition of sphingosine kinase induces growth-arrest in 
WEHI-231 ceils. WEHI-231 cells (lO'^  cells/well) were left untreated or treated 
with anti-Ig (10 pg/ml), anti-CD40 (10 pg/ml) or anti-Ig plus anti-CD40 (both 10 
pg/ml). Additional samples were treated with SPP (0.1, 1,5, 10, 25 jiM) with or 
without anti-Ig (lOpg/ml) or anti-Ig plus anti-CD40 (lOpg/ml) or vehicle controls for 
SPP. Proliferation was assessed by measuring DNA synthesis as indicated by 
[^H]thymidine uptake at 48 hours. Values shown are the means ± SD of quadruplicate 
wells.
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Figure 82. Inhibition of sphingosine kinase induces apoptosis in WEHI- 
231 cells. WEHI-231 cells (SxlOVml) were stimulated as indicated (anti-Ig and anti- 
CD40 both at 10 jxg/ml). Cells treated with DMS were pre-incubated in the presence of 
the indicated concentration of inhibitor for 60 minutes prior to further cell stimulation (if 
indicated). Levels of apoptosis were determined by PI staining and FACS analysis after 
48 hours as described in Materials and Methods.
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Figure 83. Model for the differential activation of ERK-MAPKinase by 
BCR or CD40 ligation. Taken from Purkerson et. al. (97).
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Figure 84. Model for the role of Ptdlns(3,4,5)p3 in the induction of 
apoptosis in WEHI-231 cells.
203
BCR
\//
Ras
Raf
MEK
ERK-MAPKinase PEG
CPLA2
I?
C a 2 +
apoptosis
figure 84
CHAPTER 7 - GENERAL DISCUSSION.
The deletion of immature B lymphocytes with self-reactive BCRs is a 
recognised phenomenon of B lymphocyte maturation and development. However, the 
molecular and biochemical mechanisms responsible for this are still unclear. This 
investigation has focused on the signalling mechanisms activated during the induction 
of growth arrest and apoptosis following BCR ligation in the WEHI-231 cell line, 
which acts as a model for immature B lymphocytes. In addition, the signalling 
pathways activated by CD40 stimulation, which reverses BCR-induced apoptosis, were 
also examined to determine whether this rescue signal mediates its affect by inducing 
anti-apoptotic signals or modulating the pro-apoptotic signals generated via BCR 
ligation.
Previous studies within our lab (53) highlighted a role for the phospholipase, 
cPLA^, in the maturation of B lymphocytes and the induction of apoptotic mechanisms 
in immature B lymphocytes. The investigation of the signalling mechanisms involved 
in the activation of this enzyme therefore represented a good starting point in the 
determination of BCR-induced signalling events.
Initial studies investigated the kinetics of BCR-induced growth arrest in order to 
determine whether short exposures to antigen (anti-Ig) were sufficient to induce the 
activation of growth inhibitory signalling cascades, or whether prolonged exposure to 
antigen was required. Interestingly, our data suggests that early BCR-mediated 
signalling events are capable of committing approximately 30% of cells to undergo 
growth arrest, whereas 100% commitment requires exposure to antigen for 8 or more 
hours. Our studies also showed that CD40 co-stimulation can reverse BCR-induced 
growth arrest even when added to culture after anti-Ig. However, our results also 
indicate that the ability of CD40 co-stimulation to rescue WEHI-231 cells from the 
negative signalling events activated via BCR stimulation is ineffectual once cells have 
fully committed to growth arrest. These results are in agreement with other studies, 
including work by John Monroe (8) who suggests that self-reactive immature B 
lymphocyte are “primed” for deletion during early BCR-mediated signalling events, but 
then enter a “temporal-window” in which external factors can redirect the intrinsic 
apoptotic signal allowing for cellular activation or receptor editing.
Due to the ability of short-term BCR-ligation to induce growth arrest we 
investigated the signalling molecules activated during early BCR-mediated responses. 
As cPLA^ has previously been implicated in the induction of BCR-mediated negative 
signalling events, initial studies investigated whether BCR-ligation induced the 
activation of the MAPKinase family of enzymes, as these have been implicated, along 
with calcium, in the activation cPLA^.
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BCR-ligation induced the activation of an early ERK-MAPKinase signal, but 
not the other members of the MAPKinase family. Studies using the ERK-MAPKinase 
inhibitors confirmed that this early ERK-MAPKinase signal was coupled to BCR- 
mediated apoptotic signals. Preliminary data also suggests that this ERK-MAPKinase 
lies upstream of cPLA^. Additionally, anti-CD40 stimulation, which has previously 
been shown to reverse BCR-induced cPLA2 activation was also shown to 
downregulate this early ERK-MAPKinase signal. These results are in agreement with 
another study (40) which together confirm a role for ERK-MAPKinase in the induction 
of BCR-induced apoptosis. These results are potentially very interesting because they 
suggest that ERK-MAPKinase, which is more often than not described as a mitogenic 
signal, can also initiate negative signalling events.
The mechanisms coupling the BCR to ERK-MAPKinase activation were also 
examined in order .to determine if early ERK-MAPKinase signals were activated 
through classical or cross-talk signalling pathways. Results indicated that Ras and 
PI(3)K activities were activated by BCR-ligation with similar kinetics to ERK- 
MAPKinase. Indeed, inhibition of PI(3)K was shown to abolish BCR-induced ERK- 
MAPKinase activation. This is suggestive of an upstream role for PI(3)K in the 
activation of ERK-MAPKinase. Interestingly, a recent study has highlighted an 
important role for PI(3)K and Grb2 in the activation of ERK-MAPKinase in airway 
smooth muscle cells following stimulation with SPP. Coupled to our preliminary data 
which shows that the BCR is coupled to an early sphingosine kinase signal (with 
kinetics of activation which precede that of both PI(3)K and ERK-MAPKinase, it is 
tempting to speculate that the BCR may activate a SPP/PI(3)K/Ras/ERK-MAPKinase 
signal cascade (figure 85). Further evidence to support this hypothesis comes from 
our studies examining the effect of the sphingosine kinase inhibitor, DMS, on BCR- 
induced Ras and ERK-MAPKinase activation. These studies indicated that DMS was 
effective in downregulating BCR-mediated Ras activation, and at higher concentrations, 
downregulation of ERK-MAPKinase. Inhibition of this early BCR-induced 
sphingosine kinase signal with DMS did not prevent BCR-induced apoptosis. This is 
probably due to our suggested role for sphingosine kinase and SPP generation in the 
basal proliferation of WEHI-231 cells and the induction of apoptosis should we remove 
this signal. However, if SPP and PI(3)K form part of a signalling pathway which is 
coupled to ERK-MAPKinase activation following BCR-ligation why does our data 
suggest that PI(3)K inhibition, unlike ERK-MAPKinase inhibition, is insufficient to 
block BCR-induced apoptosis? This is suggestive of the activation of multiple ERK- 
MAPKinase activating pathways following BCR-ligation, such as the classical 
Ras/Raf/ERK-MAPKinase pathway or activation via PKC (figure 85). Indeed, 
studies have already indicated that PKC inhibition can block BCR-induced ERK- 
MAPKinase activation in WEHI-231 cells (38). It would be interesting to further
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investigate the potential role of multiple ERK-MAPKinase activating pathways 
following BCR-ligation. In particular it would be interesting to examine whether 
inhibition of sphingosine kinase blocks the early, BCR-induced, generation of 
PtdIns(3,4,5)Pg to examine whether sphingosine kinase lies upstream of PI(3)K to 
provide further evidence to confirm the above hypothesis.
The ability of CD40 co-stimulation to almost completely block BCR-induced 
apoptosis suggests that CD40 recruits signalling elements which block BCR-mediated 
ERK-MAPKinase activation either at ERK-MAPKinase itself or immediately upstream, 
probably at the level of Ras, the latter of which we have confirmed in earlier studies in 
this investigation. However, what signalling elements are involved in this process are 
still unclear. Early studies (results not shown) indicated that the Rapl protein, a 
competitor for Raf from Ras is not involved. However, the role of other GTPases have 
not been examined and warrant further study. In addition, CD40 is known to rescue 
WEHI-231 cells from BCR-induced apoptosis by increasing the expression of the anti- 
apoptotic protein Bcl-x^ suggesting that in addition to uncoupling the BCR from the 
induction of apoptotic signalling pathways, CD40 co-stimulation also directly activates 
anti-apoptotic signals (83). Indeed, work by our group and others (54) have shown 
that overexpression of Bc1-Xl in WEHI-231 cells renders these cells resistant to BCR- 
induced apoptosis. Another recognised anti-apoptotic signal is PKB or Akt, a protein 
kinase originally discovered as a product of a retrovirus-encoded oncogene that 
transforms lymphoid cells that is known to lie downstream of PI(3)K activity. 
Unfortunately, our studies have been unable to either confirm or deny a role for this 
protein in the rescue of WEHI-231 cells from BCR-induced apoptosis. Although our 
results suggest CD40 co-stimulation does not induce PtdIns(3,4,5)P3 generation, Akt is 
known to bind with higher affinity to another product of PI(3)K activity, namely 
Ptdlns(3,4)P^ ( 172). It would therefore be interesting to assay for the generation of this 
phosphoinositide following CD40 stimulation. In addition, the commercial antibodies 
Akt, both in our hands and others, are still very non-specific. Therefore the use of 
new, Akt specific substrates such as cross-tide, may be useful to measure the activity of 
Akt and help resolve some of the issues surrounding its role in the rescue of immature 
B lymphocyte from BCR-induced apoptosis.
In addition to examining the early signalling mechanisms initiated following 
BCR-ligation, we were interested in studying the long-term effects of BCR-ligation, 
especially with respect to the induction of growth arrest. Early studies indicated that 
although we could abolish BCR-induced apoptosis by inhibiting the early, BCR- 
induced ERK-MAPKinase signal, BCR-induced growth arrest remained. This is 
suggestive of the BCR signalling to two distinct signalling cascades, one linked to the 
induction of apoptotic programmes and the other linked to the induction of growth 
arrest (figure 86).
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Our first observation from long-term studies was the appearance of a basal 
ERK-MAPKinase activity, which appeared cyclic in nature suggesting that it was 
intrinsically linked to cell cycle progression. Further studies confirmed that the 
inhibition of this signal via prolonged exposure to inhibitors of ERK-MAPKinase 
induced apoptosis. Interestingly, we also observed that BCR-ligation was also 
effective in the downregulation of this proliferative ERK-MAPKinase signal.
Therefore, it became apparent that BCR ligation induces apoptosis via an early, ERK- 
MAPKinase dependent signal, but also promotes the inhibition of proliferative, basal, 
ERK-MAPKinase signals. Although this is interesting in its own right, suggesting a 
differential role for ERK-MAPKinase in immature B lymphocyte biology, the ability of 
CD40 co-stimulation to modulate both of these responses confirmed this hypothesis. 
Thus, our studies have shown that CD40 co-stimulation can downregulate the early, 
BCR-induced ERK-MAPKinase signal (and hence abolish apoptosis) and also re­
establish basal ERK-MAPKinase signals downregulated by BCR-ligation (and hence 
rescue from growth arrest).
The molecular and biochemical mechanisms which regulate the downregulation 
of ERK-MAPKinase following BCR-ligation were examined. In addition, the 
pathways which regulate basal ERK-MAPKinase activity were also examined as these 
signals may give clues as to the mechanisms utilised by BCR-ligation in the induction 
of growth arrest.
The observation of Ras activity in untreated cells suggested that ERK- 
MAPKinase activity may be under the control of conventional Ras/Raf/ERK- 
MAPKinase pathways. However, when compared to the strength of Ras signal 
generated following CD40 stimulation and also the kinetics of basal ERK-MAPKinase 
activity, it would appear that other Ras-independent signals are generated which induce 
ERK-MAPKinase activation.
Our results suggest that sphingosine kinase may play a key role in the basal 
proliferation of WEHI-231 cells. Not only does sphingosine kinase inhibition induce 
apoptosis in these cells, but studies have shown that SPP levels, like ERK- 
MAPKinase, are regulated in a cyclic nature. Indeed, we have shown that the induction 
of growth arrest following BCR-ligation suppresses long-term basal sphingosine kinase 
signals. The ability of SPP to activate ERK-MAPKinase is well documented.
However, the signalling mechanisms induced by this process are not. Further work to 
characterise the activation of ERK-MAPKinase by sphingosine kinase must therefore be 
addressed, especially to determine whether this mechanism is Ras dependent.
We have additional evidence to suggest that PI(3)K may also be involved in the 
basal proliferation of WEHI-231 cells. Although studies have shown that 
PtdIns(3,4,5)P3 generation in untreated WEHI-231 cells does not vary with time, our 
studies indicate that inhibition of PI(3)K does block basal proliferation. The role of
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PI(3)K in the basal proliferation of these cells may therefore result from the generation 
of PtdIns(3,4)P2. Generation of this phosphoinositide is known to activate ERK- 
MAPKinase (150) in a PKC/Raf dependent manner. In addition, recent reports (149, 
155) suggest a protein kinase only function for PI(3)K with the ability to activate ERK- 
MAPKinase. Our results therefore suggest a role for PI(3)K in both BCR-mediated 
responses and in the basal proliferation of WEHI-231 cells. Subsequently, it appears 
that BCR stimulated PI(3)K activity is anti-proliferative, whilst basal PI(3)K activity is 
proliferative in nature. This may reflect differential activation of PI(3)K isoforms. 
Previously, we have described how PI(3)K may couple the BCR to an early ERK- 
MAPKinase, apoptotic, signal. As the BCR has previously been shown to be G- 
protein coupled, it is tempting to speculate that BCR-induced PtdIns(3,4,5)Pg 
generation could be coupled to the G-protein sensitive pi lOy PI(3)K isoform. Basal 
PI(3)K activity resulting in PtdIns(3,4,5)P3 generation may therefore result from p85a 
dependent PI(3)K activity, as we have shown that BCR-ligation and the induction of 
growth arrest downregulates p85a protein expression, which is restored with co­
stimulation with anti-CD40. Although basal WEHI-231 cells maintained constant 
levels of PtdIns(3,4,5)Pg, ERK-MAPKinase activity was shown to cycle. This may be 
coupled the to generation of PtdIns(3,4)P2 which is known to activate ERK- 
MAPKinase. This would explain the ability of PI(3)K to inhibit the basal proliferation 
of WEHI-231 cells, it would therefore be of interest to measure PtdIns(3,4)P2 
generation in basal and anti-Ig stimulated WEHI-231 cells.
Our studies have also indicated that the GTPase, Rapl, was extremely active in 
basal WEHI-231 cells. Although this would appear to be contradictory, as Rapl is a 
known suppressor of Raf-1 activation, recent reports suggest that Rapl is involved in 
the long-term activation of ERK-MAPKinase by a B-Raf dependent manner (44, 141). 
This pathway may therefore play a key role in the proliferative nature of WEHI-231 
cells.
In conclusion, our studies suggest that basal ERK-MAPKinase activity in 
WEHI-231 cells, which is vital for cellular proliferation, may result from multiple 
signalling cascades, which appear to be both Ras dependent and Ras independent.
Having discovered that both PI(3)K and sphingosine kinase may play key roles 
in the activation of proliferative, basal, ERK-MAPKinase signals we investigated 
possible routes employed by BCR-ligation in the suppression of these signals. Firstly, 
initial studies examining Ras activity confirmed that whilst BCR-ligation abolished 
ERK-MAPKinase activity, Ras activity was unaffected. Indeed, other studies (results 
not shown) have shown that Grb2 phosphorylation is also unaffected by BCR- 
ligation. We therefore wanted to examine pathways which inhibit ERK-MAPKinase 
activity at, or below Raf.
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Initial studies ruled out the involvement of Rapl, so we investigated other 
known suppressors of ERK-MAPKinase activities. However, because evidence 
provided by ourselves and others (108) have confirmed that ERK-MAPKinase activity 
can be both cytoplasmic or nuclear in origin in WEHI-231, we have to be aware that 
these different pools may be coupled to different biological responses. We examined 
whether the nuclear phosphatase, PAC-1, was involved in the suppression of ERK- 
MAPKinase by BCR-signalling. Our results suggested that BCR-ligation increased the 
association of PAC-1 with ERK-MAPKinase. Further studies to confirm that both 
these molecules were nuclear in location would confirm a role for PAC-1 in BCR- 
mediated responses. This suggests that basal ERK-MAPKinase activity may be 
involved the activation of transcription factors and it would therefore be interesting to 
examine which transcription factors are activated during the basal proliferation of 
WEHI-231 cells with the previously described ERK-MAPKinase targets of Elk-1 and 
c-Myc (93) being possible candidates.
Our studies have indicated that BCR-ligation leads to the inhibition of PDE 
activity. In addition, pharmacological inhibition of PDE activity and elevation of cAMP 
levels with forskolin appeared to induce moderate levels of growth arrest in WEHI-231 
cells. These studies appeared to suggest a role for cAMP and PDE activity in the 
induction of growth arrest. Additionally, these results appeared to confirm earlier 
studies which indicated that Ras activity was unaffected by BCR-ligation. This is 
because cAMP mediated activation of PKA is known to inhibit Raf-1 activity.
However, subsequent studies using the PKA inhibitor, H-89, were unsuccessful in 
reversing BCR-induced growth arrest suggesting that cAMP/PKA pathways were not 
utilised following BCR-ligation in the suppression of basal ERK-MAPKinase activity. 
However, in order to rule out the involvement of this pathway it would be interesting to 
measure cAMP generation and PKA activity following BCR-ligation.
Interestingly, sphingosine kinase activity is known to downregulate cAMP 
generation (165). Our studies indicate that CD40 co-stimulation can moderately restore 
long-term decreases in SPP generation (24-48 hours). This could be suggestive of 
CD40 co-stimulation downregulating cAMP signals through the re-establishment of 
sphingosine kinase activity, although this requires further study. However, a study by 
McKenzie el a l (173) has suggested that cAMP mediated growth arrest in fibroblasts 
is due to the modulation of an intracellular target other than ERK-MAPKinase which 
results in reduced entry of cells into the S phase of the cell cycle. It would therefore be 
interesting to examine whether a similar model occurred in WEHI-231 cells.
In addition to examining the signalling events activated by BCR-ligation, studies 
in this investigation have also explored the role of AA in the induction of apoptosis.
AA is generated by the hydrolysis of phospholipids by CPLA2 and previous studies 
within our group have shown this enzyme to play a role in the induction of apoptosis.
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Additionally, we have previously shown that CD40 co-stimulation can reduce BCR- 
induced A A generation, which has been shown to be due to the uncoupling of the BCR 
from CPLA2 activity. However, studies in this investigation also suggest that CD40 
mediated suppression of AA may also be due to the conversion of AA into PGE2 which 
may play a role in the induction of proliferative responses in WEHI-231 cells.
Previous studies within our group have measured AA-induced apoptosis by 
DNA fragmentation. However, experiments within this investigation have suggested 
that AA treatment, unlike BCR-ligation, is relatively ineffective in downregulating basal 
ERK-MAPKinase activity. Subsequent studies therefore examined the DNA content of 
WEHI-231 cells to examine the affect of AA stimulation on cell cycle progression. 
These studies indicated increased numbers of cell in both sub-diploid and S-phase 
pools, results which would appear to confirm earlier observations involving ERK- 
MAPKinase. It is therefore possible that whilst some of the AA is utilised in the 
induction of apoptosis, some of the AA may also be metabolised into proliferative lipid 
second messengers such as PGEj by basal cyclooxygenase (COX) activity (figure 
87). It would therefore be interesting to examine whether cyclooxygenase inhibitors 
such as indomethacin enhance AA-mediated apoptosis.
The role of PGEj in the biology of WEHI-231 cells was also examined. PGE2 
has previously been shown to prevent apoptosis and increase the expression of anti- 
apoptotic proteins such as Bcl-x^ (122) in human colon cancer cells. In addition, CD40 
stimulation has been shown increase COX-2 expression and activity (125). Subsequent 
studies within this investigation have shown that PGE2 production is suppressed 
following BCR-ligation in WEHI-231 cells, but is recovered by co-stimulation with 
anti-CD40 (figure 87). These results suggest a role for COXs in regulating WEHI- 
23 1 cell fate and indicate that in addition to suppressing BCR-induced signalling 
cascades, CD40 co-stimulation mediates some of its protective effects by utilising 
products of BCR-ligation.
This investigation has highlighted a number of interesting observations in the 
regulation of immature B lymphocyte cell fate. In particular, it has highlighted the role 
of the BCR in the induction of apoptosis and growth arrest as quite distinct signalling 
programmes (figure 88). It has also highlighted the role of ERK-MAPKinase as both 
an inducer of apoptosis and mediator of cell growth which reflects both differences in 
its mode of activation, but also its intracellular location.
Additionally this study is this first to describe the coupling of the BCR to 
sphingosine kinase activation, highlighting a role for this lipid kinase in the modulation 
of immature B lymphocyte cell fate.
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Figure 85. BCR-induced apoptosis may involve the activation of ERK-MAPKinase 
by different routes including a SPP/PI(3)K/Ras/ERK-MAPKinase signal cascade, a 
PKC-dependent mechanism and perhaps the classical Shc(BLNK)/Ras/Raf/ERK- 
MAPKinase pathway.
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Figure 86. BCR-ligation activates distinct signalling cascades involved in growth 
arrest and apoptosis.
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Figure 87. Role of AA and PGE2 in the induction of apoptosis and proliferative 
responses in WEHI-231 cells.
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Figure 88. Integrated signalling mechanisms responsible for the induction of 
apoptosis and growth arrest in WEHI-231 cells.
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